Biochemical and regulatory aspects of DNA double-strand break repair by Godau, Julia Eileen
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Biochemical and regulatory aspects of DNA double-strand break repair
Godau, Julia Eileen
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-170542
Dissertation
Published Version
Originally published at:
Godau, Julia Eileen. Biochemical and regulatory aspects of DNA double-strand break repair. 2018,
University of Zurich, Faculty of Science.
Biochemical and Regulatory Aspects of DNA
Double-Strand Break Repair
Dissertation
zur Erlangung der naturwissenschaftlichen Doktorwürde
(Dr. sc. nat.)
vorgelegt der
Mathematisch-naturwissenschaftlichen Fakultät
der
Universität Zürich
von
Julia Eileen Godau
aus
Deutschland
Promotionskommission
Prof. Dr. Alessandro A. Sartori (Vorsitz und Leitung der Dissertation)
Prof. Dr. Joao Matos
PD. Dr. Pavel Janscak
Prof. Dr. Matthias Altmeyer
Zürich, 2018



Contents
Abbreviations v
Summary vii
Zusammenfassung ix
1 Introduction 1
1.1 Genome instability - A hallmark of cancer . . . . . . . . . . . . . . . . . . . 1
1.2 DNA damage response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 DNA repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3.1 DSB repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3.2 Meiotic recombination . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.3.3 Fanconi anemia pathway of ICL repair . . . . . . . . . . . . . . . . . 7
1.4 Post-translational modifications . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.5 CtIP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.5.1 Sae2/Ctp1/CtIP protein family . . . . . . . . . . . . . . . . . . . . . . 11
1.5.2 CtIP promotes DNA-end resection . . . . . . . . . . . . . . . . . . . 13
1.5.3 Regulation of CtIP by PTMs . . . . . . . . . . . . . . . . . . . . . . . 15
1.5.4 CtIP and its connection to cancer development and therapy . . . . . 18
1.6 SLX4 - A nuclease scaffold . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.7 PIN1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.7.1 PIN1 - A molecular switch regulating diverse pathways . . . . . . . . 22
1.7.2 PIN1 and its role in tumorigenesis . . . . . . . . . . . . . . . . . . . 25
1.8 P. tetraurelia as a model organism to study DSB repair . . . . . . . . . . . . 27
2 Aims 31
3 Material and Methods 33
4 Results 41
4.1 Investigating the biochemical function of CtIP in DSB repair . . . . . . . . . 41
4.1.1 Identification of a miniature Sae2/Ctp1/CtIP ortholog from Paramecium
tetraurelia required for sexual reproduction and DNA double-strand
break repair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Supplementary Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
i
4.1.2 Paramecium CtIP stimulates MRE11 nuclease activity . . . . . . . . 85
4.2 Deciphering the potential regulation of SLX4 by PIN1-
mediated isomerization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
4.2.1 Validation of the PIN1-SLX4 interaction . . . . . . . . . . . . . . . . 89
4.2.2 Identification of the PIN1-interaction motif in SLX4 . . . . . . . . . . 89
4.2.3 Establishing a phospho-SLX4 (T1315) antibody . . . . . . . . . . . . 97
4.2.4 Investigating the potential role of PIN1 in regulating SLX4 function . 98
5 Discussion and Outlook 109
5.1 Investigating the biochemical function of CtIP in DSB repair . . . . . . . . . 109
5.2 Deciphering the potential regulation of SLX4 by PIN1-
mediated isomerization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Bibliography 119
Acknowledgments 147
Appendix 149
Curriculum Vitae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Publication: A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51
Function and Confers Hypersensitivity toward PARP Inhibition. . . . . . . . 152
ii


Abbreviations
ALT alternative lengthening of telomeres
AML acute myeloid leukemia
Aph aphidicolin
ATM ataxia-telangiectasia mutated
ATR ataxia-telangiectasia and Rad3-related
BER base excision repair
CDC25 cell division cycle 25 family members
CDK cyclin-dependent kinase
CFS common fragile sites
CO crossover
CPT camptothecin
CTD C-terminal domain
CtIP CtBP-interacting protein
DDR DNA damage response
dHJ double Holliday junction
DNA deoxyribonucleic acid
DNA-PKcs DNA-dependent protein kinase catalytic subunit
ds double-stranded
DSB double-strand break
Ess1 essential in yeast 1
FA fanconi anemia
FAAP24 FA-associated protein 24 kDa
GSK3 glycogen synthase kinase 3
HJ Holliday junction
HR homologous recombination
ICL interstrand crosslink
IES internal eliminated sequences
IP immunoprecipitation
IR Ionizing radiation
JNK Jun-N-terminal protein kinase
LE long exposure
MAC macronucleus
MAPK mitogen-activated protein kinases
MEF mouse embryonic fibroblasts
MIC micronucleus
MMC mitomycin C
MMR mismatch repair
v
MRE11 meiotic recombination 11 homolog A
MRN MRE11-RAD50-NBS1
NBS1 nijmegen breakage syndrome 1
NER nucleotide excision repair
NHEJ non-homologous end joining
NIMA never in mitosis A
NTD N-terminal domain
PARP poly(ADP-ribose) polymerase
PD pulldown
PIKK phosphatidylinositol 3-kinase-like protein kinase
PLK1 polo-like kinase 1
PPase protein phosphatase
PPIase peptidyl-prolyl cis/trans isomerase
PTMs posttranslational modifications
RB retinoblastoma
RBBP8 retinoblastoma binding protein 8
Rtt107 regulator of Ty1 transposition
ROS reactive-oxygen species
RPA replication protein A
Sae2 sporulation in the absence of Spo11 protein 2 homolog
SC synaptonemal complex
SE short exposure
SIM SUMO interaction motif
SLX synthetic lethal of unknown function
Spo11 sporulation-specific protein 11
ss single-stranded
SSB single-strand breaks
ssc single-stranded circular
S/T-P serine/threonine-proline
SUMO small ubiquitin-related modifiers
TLS translesion synthesis
UV ultraviolet light
wt wild type
vi
Summary
Faithful transmission of genetic information to daughter cells is fundamental for all living
cells. DNA lesions resulting from exogenous or endogenous sources are potent driving
forces of genomic instability and tumorigenesis. To maintain genome integrity, cells have
evolved a complex network of DNA damage signaling and repair pathways, referred to as
the DNA damage response (DDR). CtIP and SLX4 are key DDR factors, contributing to
the error-free survival of cells in response to genotoxic stress. However, our mechanistic
understanding about how these DNA repair proteins operate at the molecular level and
how their activities are regulated during the cell cycle is very limited.
Human CtIP is crucial for the resection and repair of DNA double-strand breaks (DSBs),
one of the most cytotoxic lesions a cell can encounter. At the molecular level, the func-
tion of CtIP in DSB repair is not fully understood and the lack of high-resolution structures
precludes any detailed insights into its biochemical features. Recently, our lab identified
two open reading frames in the ciliate Paramecium tetraurelia, representing the short-
est known orthologs of CtIP in evolution. In the course of our studies, we investigated
the DNA binding properties of recombinant PtCtIP and its functional interplay with the
MRE11-RAD50 nuclease complex. Specifically, we find that PtCtIP binds with high affin-
ity to replication fork-like DNA structures but lacks any detectable intrinsic nuclease ac-
tivity. Moreover, DNA binding, but not MRE11-RAD50 interaction, strongly depends on
a highly conserved RHR motif located in the evolutionarily conserved C-terminus. Addi-
tionally, using genetically engineered cells stably expressing a CtIP DNA binding mutant,
we provide evidence that the RHR motif mediates recruitment of CtIP to sites of DNA
damage, thereby ensuring efficient DNA-end resection and homology-directed repair of
DSBs. In collaboration with the lab of Dr. Mireille Bétermier, we further unveiled that
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PtCtIP is required for the processing of Spo11-dependent meiotic DSBs in P. tetraurelia.
Together, these results establish that PtCtIP is a true homolog of CtIP and that a short
DNA-interaction motif is crucial for its function in DSB repair.
In the second part of my Ph.D. thesis, we sought to decipher the potential regulation of
SLX4 by PIN1-mediated prolyl isomerization. PIN1 catalyzes the isomerization of pro-
line peptide bounds adjacent to phosphorylated serines or threonines (pS/T-P) to either
cis or trans configuration, thereby controlling protein function. We previously discovered
various DDR factors in a proteomic screen for potential PIN1 targets, including the DNA
repair endonuclease scaffold SLX4. Human SLX4 is involved in the cleavage of DNA
interstrand-crosslinks (ICL) and resolution of Holliday junctions (HJs) as well as in the
trimming of telomeric loops. Our results hitherto suggest that PIN1 binds to SLX4 in
a direct and phosphorylation-dependent manner. Moreover, fine-mapping of the PIN1
interaction motif in SLX4 points towards multiple pS/T-P sites as critical sites for PIN1
recognition. However, overexpression or knockdown of PIN1 does neither alter estab-
lished SLX4 protein-protein interactions required for ICL repair and HJ resolution nor its
telomeric localization, indicating that PIN1 potentially controls other biological aspects
involving SLX4.
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Zusammenfassung
Jeden Tag wird unser Erbgut - DNS genannt - geschädigt, sei es durch UV-Strahlung,
Tabakrauch oder andere toxische Substanzen, die bei normalen zellinneren Prozessen
entstehen. Jede Veränderung der DNS birgt die Gefahr entscheidende Mechanismen,
welche die Zellteilung und das Zellwachstum kontrollieren, ausser Gefecht zu setzen.
Dies kann zu Zellentartung und schliesslich Krebs führen.
Umso entscheidender ist, dass jede einzelne Zelle mit einem vielfältigen Repertoire an
DNS Reparaturmechanismen ausgestattet ist, welche die Integrität des Genoms schützen.
Das Zusammenspiel einzelner Faktoren in diesem hoch komplexen Netzwerk - unter ih-
nen Schlüsselproteine wie CtIP und SLX4 - ist jedoch bei weitem nicht aufgeklärt.
CtIP ist ein evolutionär hochkonserviertes Protein, welches eine essentielle Rolle in der
Reparatur von DNS Doppelstrangbrüchen (DSB) spielt. Auch wenn in den letzten Jahren
viele Erkenntnisse über CtIP gewonnen wurden, fehlen immer noch entscheidende Mo-
saikstücke um die Funktion von CtIP im Detail zu verstehen. Erschwerend kommt hinzu,
dass die Kristallstruktur von CtIP noch nicht aufgeklärt werden konnte. Diese würde
uns wichtige Anhaltspunkte zum besseren Verständnis der biochemischen Eigenschaften
von CtIP liefern. Der erste Teil meiner Arbeit beschreibt die Charakterisierung von CtIP
des Pantoffeltierchens (Paramecium tetraurelia). PtCtIP besteht größtenteils nur aus den
wichtigsten konservierten Domänen und stellt mit einer Länge von 198 Aminosäuren das
kleinste bisher beschriebene CtIP Ortholog dar. Zusammen mit der Forschungsgruppe
von Dr. Mireille Bétermier zeigen wir, dass PtCtIP essentiell für die sexuelle Reproduktion
in P. tetraurelia ist. Wir charakterisieren die biochemischen Eigenschaften von aufgere-
inigtem, rekombinantem PtCtIP und demonstrieren, dass das RHR Motiv im C-terminus
des Proteins maßgeblich für die Bindung an die DNS verantwortlich ist, aber selbst keine
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DNS schneiden kann, eine Eigenschaft welche für andere CtIP Proteine umstritten ist.
Ausserdem liefern wir Beweise, dass ein intaktes RHR Motiv sowohl für die Lokalisierung
des CtIP Proteins an beschädigte DNS als auch für die DSB Reparatur wichtig ist.
Der zweite Teil meiner Doktorarbeit basiert auf früheren Ergebnissen unserer Arbeits-
gruppe, in denen SLX4, ein Adapterprotein für verschiedene Nukleasen, als neuer Bin-
dungspartner der Peptidyl-Prolyl-Isomerase PIN1 identifiziert wurde. SLX4/FANCP wird
als Fanconi Anemia Gen kategorisiert, dessen Mutation mit der gleichnamigen Erkrankung
assoziiert ist. Mittels verschiedener Experimente bestätigen wir, dass PIN1 und SLX4
direkt und abhängig von bestimmten Phosphorylierungsmotiven (S/T-P) miteinander in-
teragieren. Weitere Resultate deuten darauf hin, dass PIN1 keinen Effekt auf andere
Interaktionspartner von SLX4 hat und auch nicht die Lokalisierung von SLX4 im Zellkern
beeinflusst. Die Frage nach der biologischen Bedeutung der PIN1-SLX4 Interaktion wird
uns also noch eine Weile beschäftigen.
Zusammenfassend liefern unsere Resultate neue Einblicke in die Funktion von CtIP auf
molekularer und zellulärer Ebene und schaffen eine vielversprechende Basis die Funk-
tion der SLX4-Isomerisierung für die Genomstabilität weiter zu erforschen.
x
Introduction
1.1 Genome instability - A hallmark of cancer
The genome is defined as an organism’s complete set of genetic material. It consists of
deoxyribonucleic acid (DNA), which is present in almost every cell of the human body1.
The human genome, which is stored in the nucleus of a cell, comprises 3 x 109 nu-
cleotides of DNA and carries all the information necessary to build and maintain the
organism by governing cell division and survival. Therefore, it is of utmost importance
to preserve genomic stability to faithfully propagate genetic information to subsequent
generations. Failure to do so can lead to the development of cancer – a disease charac-
terized by abnormally proliferating cells that can invade beyond normal tissue boundaries
and metastasize to distant organs2.
A major underlying cause driving carcinogenesis is the accumulation of multiple muta-
tions and clonal expansion3. Mutations can alter the DNA sequence with base pairs
being substituted, changed or deleted but can also affect the structure or number of in-
dividual chromosomes (e.g. translocations, fusions and duplications). The number of
mutations can differ from a considerably small number to hundreds or thousands. Ac-
cordingly, mutations can be either passenger mutations, having a rather modest effect for
the cell, or driver mutations, changing key factors of basic cellular processes4. Conse-
quently, mutations can affect the function of oncogenes and tumor suppressor genes in
a normal cell5. Oncogenes are genes, which hyperactivation have the potential to cause
cancer, whereas the term tumor suppressor refers to those genes whose loss-of-function
leads to tumor development5. Notably, cancer evolves over time and all its stages, rang-
ing from precancerous lesions to already malignant tumors cell, and the underlying mu-
1
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tational processes are highly diverse6. Germline mutations in genes employed in DNA
repair and the maintenance of genomic integrity predispose their carriers to an increased
risk of cancer7,8. To name one example, women carrying mutations in the BRCA1 gene
are at increased lifetime risk for developing breast cancer of 72% compared to 12% in
normal population and for ovarian cancer of 44% compared to 1.5%9,10. In conclusion,
genome instability is a hallmark of cancer cells11,12.
1.2 DNA damage response
Maintaining genetic stability is essential for cell survival and division. Nevertheless, our
genome is constantly exposed to intrinsic or extrinsic factors, provoking different types of
DNA lesions. DNA alterations can arise from exposure to ionizing radiation (IR), ultraviolet
light (UV) or chemical compounds, such as ingredients of tobacco smoke or chemother-
apeutic drugs. Moreover, DNA damage can also be induced by DNA replication errors or
by endogenously generated reactive-oxygen species (ROS), free radicals and nitrogen
species13. It has been estimated that each cell of the human body is challenged by 25
highly dangerous DNA double-strand breaks (DSBs) per day14. Paradoxically, DSB in-
duction is also a fundamental process in generating biological diversity. During meiosis
or development of the immune system, hundreds of DSBs are deliberately induced and
subsequently repaired to generate novel combinations of genes15.
To ensure genomic integrity, eukaryotic cells have evolved a sophisticated signaling net-
work, termed the DNA damage response (DDR). The DDR can be described as a cas-
cade of sequentially activated sensor proteins at sites of DNA lesions, signal transmitters,
and effector proteins to pause cell cycle progression by activating cell cycle checkpoints
and provide time for DNA repair16. If repair fails or cell cycle progression is paused for
too long, the DDR triggers programmed cell death (apoptosis) or senescence to avert
tumorigenesis17.
Upon DNA damage lesion-specific sensing complexes, including MRN complex (MRE11,
meiotic recombination 11 homolog A; RAD50; and NBS1, Nijmegen breakage syndrome
1) and RPA (replication protein A), initiate the DDR by activating signal transducer pro-
2
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teins of the phosphatidylinositol 3-kinase-like protein kinase (PIKK) family, mainly ATM
(ataxia-telangiectasia mutated), ATR (ataxia-telangiectasia and Rad3-related) and DNA-
PKcs (DNA-dependent protein kinase catalytic subunit)18,19. ATM and ATR amplify the
signal by phosphorylation of downstream transducers like the checkpoint kinases CHK1
and CHK220. To transiently pause the initiation of DNA replication, CHK1 and CHK2 act
on a variety of substrates, amongst others CDC25 (cell division cycle 25 family members)
and the kinase Wee1. These in turn, promote the inhibition of CDKs (cyclin-dependent
kinases), which are responsible for progression and proper timing of the cell cycle21. Im-
portantly, CDKs have recently emerged as key players in the regulation of DNA repair
pathways22,23. Furthermore, CHK1, CHK2 and ATM promote stabilization of p53, a key
tumor-suppressor protein triggering cell cycle arrest, altered transcription and apopto-
sis24.
1.3 DNA repair
Each cell is equipped with a toolkit of DNA repair mechanisms. Base excision repair
(BER) facilitates repair of aberrant DNA bases, such as deaminated cytosines, oxidized
guanines and alkylated adenines25. Nucleotide excision repair (NER) is suited to remove
bulky DNA lesions, such as the ones formed during exposure to UV light26. The mis-
match repair pathway (MMR) is responsible for the detection and excision of nucleotides
misincorporated during replication27 28. To overcome obstacles faced during replication,
cells employ specialized translesion synthesis (TLS) polymerases, a process that bears
an increased risk of causing mutagenesis29. Finally, DSBs are mainly repaired by non-
homologous end joining (NHEJ) or homologous recombination (HR)30. Evidently, repair
pathways can overlap. For instance, DNA interstrand cross-links (ICLs) are repaired by
the concerted actions of NER, HR and TLS31. Given the fact that most cancer cells
have lost one or more DDR pathways render them more dependent on the remaining
ones. This vulnerability is currently exploited in targeted cancer treatment based on the
concept of synthetic lethality17,32,33.
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1.3.1 DSB repair
DSBs are considered the most cytotoxic lesions, because the two complementary strands
of the DNA helix are disrupted simultaneously at approximately the same place. Cells
have evolved two major DSB repair mechanisms: non-homologous end-joining (NHEJ)
and homologous recombination (HR)(Figure 1.1). NHEJ is active throughout the cell cy-
cle and directly ligates broken DNA ends. DSB repair by classical NHEJ is initiated by
binding of the KU70/80 heterodimer to two juxtaposed DNA ends that are subsequently
rejoined by the XRCC4-XLF-DNA ligase IV complex31,34,35. In S/G2 phase, however,
when an intact sister chromatid is present for repairing DSBs in an homology-dependent
manner, HR competes with NHEJ31. In mammals, HR is initiated by the MRN complex,
which recognizes the DSB and recruits CtIP (CtBP-interacting protein), preventing the
association of KU70/8036,37. Together with CtIP, MRN tethers the broken DNA and ini-
tiates processing of the DSB ends37,38. A bidirectional DNA-end resection model was
proposed, in which CtIP stimulates the endonucleolytic activity of MRN to generate a nick
in the 5’ strand. In a second step, Mre11 continues to exonucleolytically trim the DNA
in a 3’ to 5’ direction from the nick towards the DSB. Meanwhile, exonucleases such as
Exo1 (exonuclease 1) and Dna2 (together with the helicase BLM) resect the same strand
in 5’ to 3’ direction away from the nick39–41. Generated 3’ ssDNA-overhangs are immedi-
ately protected from degradation and stabilized by the heterotrimeric replication protein A
(RPA). With the help of a BRCA1-BARD1-PALB2-BRCA2 recombination mediator com-
plex, RPA is subsequently replaced by the recombinase Rad51 to form nucleoprotein
filaments that initiate homology search and catalyze invasion of the intact duplex DNA
sequences, ultimately resulting in the formation of a DNA structure called double Hol-
liday junction (dHJ)42. After DNA synthesis, the dHJs can be processed by different
mechanisms to complete HR, generating either non-crossover or crossover recombina-
tion products, depending whether the flanking DNA of the break is exchanged or not43.
In the presence of type IA topoisomerase (BLM-TOP3A in mammals) and a DNA heli-
case dHJ dissolution generates non-crossover products by facilitating branch migration
and decatenation of the JH. In absence of BLM, dHJs are processed by structure-specific
resolvases, giving raise to either non-crossover or crossover products44.
4
Introduction
P P
P P
P
P
Strand invasion
Resolution Dissolution
Short-range resection
Long-range resection
MRN
P
MRN
CtIP
CtIP
P
RPA
Exo
DNA2
BLM
RAD51
- Fast
- Template-independent
- Cell cycle independent
- Often mutagenic
Ligation
NHEJ HR
SLX4
MUS81SLX1
XPF
Double-strand break
KU70/80
BLM
TOPIII
RMI1/2
GEN1
Non-crossover Crossover
or
- Slow
- Requires template
- Only in S/G2 phase
- Largely accurate
Non-crossover
Figure 1.1: Schematic representation of DSB repair pathways. After a DSB occurs, the Ku70/80
heterodimer rapidly associates to the DSBs to facilitate repair by NHEJ. NHEJ is considered to be active
throughout the cell-cycle and does not depend on the presence of template for repair, but is therefore
often mutagenic. Alternatively, the break can be repaired by HR, which is restricted to S/G2. After MRN
senses the DSB, CtIP is recruited to the sites of the break to initiate short-range resection, generating
3’ ssDNA overhangs − a step which ultimately inhibits NHEJ and catalyzes further processing by HR.
ssDNA stretches are immediately protected by RPA while EXO1 or BLM, in conjunction with DNA2,
facilitate long-range resection. Next, RPA is displaced by RAD51, which mediates strand invasion
into the homologous DNA template leading to the formation of a double Holliday junction (dHJ). dHJ
resolution by BLM, topoisomerase IIIα, and RMI1 results in non-crossovers. In contrast endonucleolytic
cleavage and dissolution of the dHJ by GEN1 or the SLX4 protein complex can lead to non-crossovers
and crossovers depending on the incision pattern of the two strands.
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The output strongly depends on which resolvase is employed for the endonucleolytic
cleavage of the dHJ. Key proteins mediating dHJ resolution by introduction of two single-
stranded (ss) incisions are the resolvase GEN1 and a multi-subunit nuclease complex
consisting of SLX1-SLX4 and MUS81-EME145–47.
1.3.2 Meiotic recombination
Meiosis is a specialized form of cell division that generates haploid gametes in most sex-
ually reproducing organisms48. The genetic information is reshuffled to facilitate genetic
diversity in progeny. During the first meiotic division, homologous chromosomes of both
maternal and paternal origin undergo replication to form pairs of sister chromatids. Next,
sister chromatids conglomerate in bivalent pairs, which are stabilized by the synaptone-
mal complex and cohesion proteins49,50. The bivalent association is crucial for the later
formation of crossovers, i.e. the reciprocal exchange of chromosome arms, which occur
by recombination events. In contrast to HR repair in somatic cells, where genome main-
tenance has priority and therefore non-crossovers are preferred, meiotic recombination
promotes generation of at least one crossover per chromosome to mix genetic informa-
tion51 (Figure 1.2). In the last step, the spindle is formed and chromosomes line up along
the metaphase plate before being separated into two daughter cells. Recombination fail-
ures or obstacles occurring during metaphase often lead to meiotic arrest and failure in
correct chromosome segregation, ultimately having negative consequences on fertility49.
Recombination is initiated by the induction of DSBs in a programmed manner – another
major difference to DSBs induced by DNA damage52. Self-inflicted DSBs during meiosis
are catalyzed by the type II-topoisomerase Spo11, which is highly conserved from yeast
to human53,54. Upon cleavage of both DNA strands, Spo11 stays covalently attached to
the 5’ ends of the break. Subsequently, Spo11 is released from DSB ends by endonucle-
olytic single-strand cleavage on each side of the break48,55. This so-called ’clipping’ of
Spo11 is mediated by the MRN complex in concerted action with CtIP and allows subse-
quent resection and recombination40. In yeast, the CtIP homolog Sae2 and the nuclease
activity of Mre11 are essential for the removal of Spo11 and DNA resection56. In a first
step, CtIP enhances MRE11-dependent cleavage activity to clip the protein-blocked DSB
6
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ends, and subsequently induces long-range resection to facilitate homology search and
repair of the DSB57–59. In contrast to DSB repair by HR in somatic cells, meiotic re-
combination requires the replacement of RPA by both Rad51 and the meiosis-specific
strand exchange protein Dmc1. Data from S. cerevisiae suggest that Rad51 and Dmc1
cooperate during meiotic recombination with Rad51 being crucial for recombination while
Dmc1 serves as a supporting factor to stimulate strand exchange activity60,61. Next, the
nucleoprotein filament invades selectively the homologous chromosome instead of the
sister-chromatid, leading to the formation of HJ, which are preferentially resolved produc-
ing crossovers. Thus, key players facilitating the incision of HJ during meiosis are the
structure-specific SLX4 nuclease complex and the GEN1 resolvase47,62.
DSB breaks
Meiotic cell Vegetative cell
Repair template
Strand-exchange protein:
Homologous chromosome
Genetic outcome
Function
≥ one crossover/chromosome 
Programmend, SPO11-induced Accidential 
Sister chromatid
RAD51, DMC1 RAD51
Non-crossover prefered
Exchange of genetic 
information
Maintenance of 
genome instability
Figure 1.2: An overview of the major differences between HR in meiotic and vegetative cells.
1.3.3 Fanconi anemia pathway of ICL repair
ICLs are defined as covalent and irreversible linkages between DNA bases residing in op-
posite strands of the double helix. ICLs can have catastrophic consequences for the cell
because they prevent separation of the DNA strands, thereby blocking essential metabolic
processes such as replication or transcription63. Rapidly proliferating cells, including can-
cer cells, are hypersensitive to ICLs mainly due to DNA replication interference, ultimately
triggering apoptosis. Thus, ICL-forming agents, such as cisplatin or mitomycin C, are
among the most widely used antitumor drugs64,65. Moreover, ICLs can also be induced
during normal cell metabolism by aldehydes that are produced as by-products of lipid
peroxidation66,67.
7
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ICL removal during S-phase is achieved by combination of three classical DNA repair
mechanisms - HR, NER and TLS - coordinated by the Fanconi anemia (FA) pathway31.
ICL repair can be divided into the following steps: sensing of the lesion, incision and un-
hooking of the crosslink and DSB formation, followed by translesion synthesis and repair
completion by HR68,69 (Figure 1.3A).
FA is a rare chromosomal instability syndrome affecting 1 in 100’000 individuals83. Pa-
tients commonly suffer from bone marrow failure, congenital abnormalities and an ex-
tremely high risk of developing leukemia or solid tumors84. FA is an autosomal recessive
disease and the susceptibility to cancer is associated with an abnormal response to DNA
damage and genomic instability. Mutations in FA genes confer extreme cellular hyper-
sensitive to ICL-inducing agents7,69. Currently, nineteen genes specifically mutated in
FA patients are known, with most of them carrying out additional functions in other DNA
repair transactions (Figure 1.3B).
8
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Figure 1.3: Model of ICL repair and list of FA proteins. (A) When a replication fork encounters
an ICL, the translocase FANCM together with FAAP24 (FA-associated protein 24 kDa) and MHF1/2
is recruited to the DNA, which initiates ATR-mediated checkpoint signaling and subsequently leads to
the loading of the FA core complex 70–72. The FANCL subunit then catalyzes monoubiquitination of
FANCD2 and FANCI 73–75. Ubiquitination of FANCD2 triggers the accumulation of additional proteins
that coordinate DNA repair, including the endonuclease FAN1 and the scaffold protein SLX4 (alias
FANCP)76,77. ERCC1-XFP and MUS81-EME1 are SLX4-associated structure-specific nucleases and,
together with the FAN1, assumed to mediate the incision at both 5’ and 3’ sides of the DNA strand
flanking the crosslink, resulting in unhooking of the lesion 78. Still, a crosslinked base is adducted on
one strand, thus TLS has to be used to replicate over the adducted base. Nucleotide excision repair
(NER) removes the bulky base and the gap in the opposite sister strand is repaired by HR, using the
sister chromatid, which has been repaired by TLS, as a template 79. (B) List of FA proteins and their
implication in DNA repair. Most of the FA proteins (FANCA, B, C, D, E, F, G, L, M and T) build the
FA core complex. The FANCL harboring ubiquitin ligase activity ubiquitinates FANCD2 and FANCI to
initiate ICL repair80,81. Adapted from80 and82.
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1.4 Post-translational modifications
Cells need to rapidly react to internal and external cues to facilitate proper cell cycle pro-
gression and development. To ensure accurate and timely communication of metabolic
pathways, most proteins are tightly regulated by post-translational modifications (PTMs).
PTMs are crucial for determining the fate of a protein, its localization, activity or stability
and facilitate interaction with other proteins, often in a dynamic and reversible manner85.
More than 300 different PTMs are known, adding another layer of complexity to the sig-
naling network86. PTMs are described as the covalent attachment of molecules to amino
acid side chains or as conversion of a protein into a different isomer87. The former in-
cludes addition of a chemical group (like phosphorylation) or polypeptides (SUMOylation
or Ubiquitination), the latter can be cis-trans isomerization88–90. Moreover, proteins can
be modified on more than one residue that are in constant crosstalk with each other.
Phosphorylation is the best-characterized and most extensively encountered PTM. It is
estimated that one third of all eukaryotic proteins are phosphorylated91. Protein phos-
phorylation is the covalent addition of a phosphate group donated from ATP to the hy-
droxyl group of serines, threonines and tyrosines with a distribution of 1800:200:1 in ver-
tebrates92. Addition of the charged, dianionic, tetrahedral phosphate group to a neutral
OH side chain alters the chemical environment of the protein and can induce conforma-
tional changes93. Consequently, change of the chemical microenvironment surrounding
modified residues can foster enzymatic activity, interaction with other proteins or influ-
ence other PTMs85. The attachment and removal of the phosphate group is catalyzed
by protein kinases and phosphatases (PPases), respectively. The family of kinases is
extensive and highly diverse with over 500 members. In contrast, PPases only count 150
family members94,95.
Prominent serine/threonine kinases are ATM, ATR, CDKs and MAPKs22,23,96–99. CDKs
and MAPKs are tightly regulated during the cell cycle and specifically phosphorylate
serine or threonine residues preceding prolines (S/T-P motifs). Strikingly, prolyl pep-
tide bond isomerization is tightly intertwined with phosphorylation and is catalyzed by
peptidyl-prolyl cis-trans isomerases (PPIase), such as PIN1, which constitutes a crucial
10
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post-phosphorylation signaling mechanism (see chapter 1.7.1)100.
1.5 CtIP
1.5.1 Sae2/Ctp1/CtIP protein family
First studies in S. cerevisiae described the CtIP ortholog Sae2 as ’sporulation in the ab-
sence of Spo11 protein 2 homolog’ with its mutation resulting in hampered progression
of meiosis at prophase presenting first hints towards its crucial role in DNA-end resec-
tion101,102. CtIP is highly conserved among organisms ranging from yeast to human.
Several studies identified orthologs in S. cerevisiae (Sae2), S. pombe (Ctp1), C. elegans
(COM-1), A. thaliana (AtCOM1), X. laevis (xCtIP), G. gallus and M. musculus37,103–106.
Members of the CtIP protein family vary extremely in size, with the stripped-down version
expressed in Paramecium tetraurelia (PtCtIP) representing the smallest known ortholog
(Figure 1.4).
At the molecular level, human CtIP is a 125 kDa nuclear protein comprised of 897 amino
acids (Figure 1.4). Members of the Sae2/Ctp1/CtIP protein family are predicted to be
largely intrinsically disordered, with exception of the N-terminal coiled-coil domain (NTD)
that mediates tetramerization of homodimers, and the highly-conserved C-terminal do-
main (CTD)107–109. Both terminal domains of CtIP have been reported to interact inde-
pendently with the MRN complex110. CtIP’s role in DNA-end resection has mainly been
attributed to its physical and functional interaction with MRN37. This versatile protein com-
plex consists of a highly conserved MRE11-RAD50 heterodimer and NBS1 functioning
as a signal transducer to foster activation of the ATM kinase111–113. Furthermore, Nbs1
coordinates the interaction of Mre11 with fission yeast Ctp1 at the vicinity of the break
by recognizing phosphorylated Ctp1 and subsequently linking it to the MRN complex
via its FHA domain114,115. A similar mechanism has been proposed for human NBS1
although the MRN complex is not strictly required for CtIP recruitment to DSBs110,116.
Yeast cells lacking one of the components of the MRN complex are viable but present
growth defects, hypersensitivity to DSB-inducing agents and failure in meiosis progres-
sion117. However, in mice all proteins of the MRN complex are essential for survival as
11
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Figure 1.4: Schematic depiction of human CtIP and its orthologs in S. cerevisiae (Sae2) and
P. tetraurelia (PtCtIP) including the most important domains, motifs and PTMs. The N-terminus
of CtIP contains the tetramerization domain (blue) within a coiled-coil (yellow) followed by an intrinsi-
cally disordered middle region (grey). The peptidyl-prolyl isomerase PIN1 interacts with phosphorylated
residues S276 and T315. The C-terminal part (Sae2-like domain, orange) contains the CDK phospho-
rylation site T847 and the CxxC and the RHR motif, which is required for DNA binding. MRN-binding
regions are located in both N- and C-terminal regions of CtIP.
knockout mice display embryonic lethality118–120. Recent in vitro findings highlighted CtIP
as a co-factor of MRN nuclease function and identified phosphorylation at T847 to pro-
mote CtIP-dependent stimulation of the MRE11 endonuclease activity57. Furthermore,
a study in C. elegans demonstrated that COM-1 is not essential for MRN dependent
resection but rather important to inhibit NHEJ during meiosis121. Taken together, CtIP
is thought to play additional roles than stimulating MRE11. Yeast strains bearing null
mutations of Sae2 were more sensitive to DNA-damaging agents than cells expressing
the nuclease dead version of Mre11. Additionally, mouse embryos lacking CtIP die at
day 3.5-4 compared to animals exhibiting MRE11 nuclease dead, which survive to day
7.5-9.5122–125. Moreover, CtIP directly interacts with and stimulates BLM helicase via its
residues 161-369, indicative for a role not only in short-end resection (in concerted action
with MRN) but also in promoting long-range resection126. Similarly, EXO1 is recruited
in a CtIP-dependent manner accompanied by MRN suggesting that CtIP restrains EXO1
activity in vitro127.
CtIP tetramer assembly is critical for its function in DNA-end resection108,128. Detailed
biochemical studies have demonstrated that amino acids 45-160 compose a coiled-coil
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structure facilitating CtIP homodimerization. The preceding residues 20-45 have been
found to compose the tetramerization domain. Disruption of dimers or mutation of the
tetramerization motif resulted in abrogated localization of CtIP to DSB breaks, impaired
HR and strong resection defects108,128,129. Interestingly, a shortened version of CtIP,
comprising residues 1-296, fused to Cas9 endonuclease enhanced homology-directed
repair efficiency, thereby potentially improving CRISPR-based precise genome editing130.
A small region within the CtIP CTD displays the highest degree of amino acid similarity
among all members37,131. Remarkably, the congenital microcephaly syndromes Seckel
and Jawad are caused by mutations in the CtIP gene, leading to the expression of a
C-terminally truncated form of CtIP132. C-terminal deletion of CtIP abrogates MRN in-
teractions, DNA-end resection and activates the G2-M checkpoint37,108. The C-terminal
region was found to be critical for the stimulation of the MRN endonuclease activity, in par-
ticular mediated by the highly conserved T847 CDK phosphorylation site133,134. Closer
examination of the CTD of all orthologs revealed the presence of a so-called ’RHR’ motif,
shown to be important for DNA binding in vitro 107. Fission yeast strains expressing a Ctp1
mutant with disrupted RHR motif were sensitive to various genotoxic agents and showed
chromosomal defects, further emphasizing the importance of this motif for proper DNA-
end resection107. In addition, CtIP orthologs harbor a highly conserved CxxC motif in
their C-termini, which is associated with zinc-binding. Human CtIP contains an additional
N-terminal CxxC (amino acid 82-92), which is thought to stabilize the protein structure108.
Although depletion of the CxxC sensitizes fission yeast to multiple DNA damaging agents,
such as hydroxyurea, CPT or UV, the precise function of the CxxC motif is unknown104.
Finally, two phosphorylation sites (S276 and T315) mediate the CtIP isomerization by
PIN1. Consequently, PIN1-mediated isomerization influences CtIP stability by promoting
its ubiquitination and proteasomal degradation135.
1.5.2 CtIP promotes DNA-end resection
CtIP and its orthologs have emerged as key factors in response to DSBs with multi-
functional roles. Most importantly, CtIP is implied in DNA-end resection and removal of
protein-blocked ends in conjunction with the MRN complex37,56,57,136,137. Yet, the pre-
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cise mechanistic role of CtIP in promoting HR still remains controversial. It has been
demonstrated that CtIP either stimulates MRN activity or functions itself as a nuclease.
Three studies have reported that purified recombinant CtIP and Sae2 exhibit structure-
specific nuclease activity138–140. However, these results could not be confirmed by other
groups, failing to detect any nuclease activity associated with recombinant CtIP, Sae2 and
Ctp157,107,126,136. Alternatively, it was found that CtIP proteins functions as cofactors of
the MRE11 endonuclease, mainly facilitating the removal of protein-blocks at DNA ends
in vitro 57,136. These findings are supported by data showing that Sae2 and Ctp1 are re-
quired for the removal of covalently attached Spo11 from the 5’ DNA ends to allow further
strand resection and meiotic recombination137,141,142.
Besides actively promoting DNA-end resection, several groups proposed a crucial role for
Sae2 in the removal of attached MRX from sites of the DNA break, which would otherwise
prevent strand invasion and HR123,143,144. Intriguingly, it has been suggested that the pro-
tein architecture of multimeric CtIP might be suited to physically link DNA molecules, as it
was reported for purified Sae2 and Ctp1 in vitro 107,145. CtIP/Sae2/Ctp1 binds DNA mostly
via its C-terminal domain, although studies in fission yeast show that the N-terminal do-
main alone exhibits weak DNA binding activity107,108,139. Examining the bridging ability
using various Ctp1 mutants revealed that integrity of the intrinsically disordered region,
the RHR motif and the NTD are all required for DNA bridging107. Thus, rather than acting
as a nuclease itself, the DNA binding and bridging function of CtIP are proposed to modu-
late the nucleolytic activity of a flexibly linked MRN-DNA complex107,108. Notably, also the
MR complex can bridge DNA, emphasizing the importance of keeping DNA-ends in close
proximity to facilitate DSB repair111,113,146,147. It has been proposed that DNA-bridging by
MRN is a prerequisite of Ctp1-mediated tethering and subsequent DSB processing107. In
line with this, Ctp1 interacts with the FHA/BRCT domain of Nbs1 to hold the DSB ends in
proximity and facilitate resection115,148. However, the exact mechanism of DNA bridging
is still not fully understood. Functional roles of CtIP and its orthologs contributing to DSB
repair are summarized in Figure 1.5.
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Figure 1.5: Functional roles of CtIP, Ctp1 and Sae2 in DSB repair. (A) Biochemical activities of CtIP
homologs. Ctp1 and Sae2 were identified to harbor DNA bridging activity. CtIP and Sae2 act as MRN
cofactors. Ctp1 does not exhibit nuclease activity, and characterization studies of the Sae2 and CtIP
protein have conflicting results. (B) Schematic model of three possibilities how Ctp1 tetramers could
bridge DNA breaks. NTD = N-terminal domain, CTD = C-terminal domain, RHR = DNA binding motif.
Adapted from107.
1.5.3 Regulation of CtIP by PTMs
Human CtIP was first discovered as a binding partner of the transcriptional corepressor
CtBP, which is associated with cell proliferation and tumorigenesis149. Interestingly, CtIP
was also identified as a protein interacting with the retinoblastoma protein (RB), thus
alternatively named retinoblastoma binding protein 8 (RBBP8)150. CtIP binding to RB
promotes dissociation of RB from the E2F-responsive promotor. Consequently, CtIP reg-
ulates its own transcription as well as the expression of E2F target genes, including cyclin
D1, triggering S phase entry. Moreover, CtIP was shown to facilitate G1 to S phase tran-
sition by recruiting the transcription factor TFIIB to its own promotor leading to a further
increase of its own transcriptional level151,152. To ensure that DSB resection and HR only
take place when an intact DNA template is available for repair, CtIP expression levels are
highly cell-cycle regulated, increasing during S and G2 phase and decreasing following
15
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mitotic exit153.
Moreover, CtIP’s resection function is tightly governed by multiple PTMs, including phos-
phorylation, ubiquitination and SUMOylation. For example, CtIP recruitment to sites of
damage is dependent on both ATM and ATR protein kinases. In response to DSBs,
DNA-end resection is launched after ATM-mediated phosphorylation of CtIP at S664,
S745 and T859110,154, meanwhile CtIP binding to chromatin requires phosphorylation of
T859 by ATR155. CtIP does not only possess ATM/ATR phosphorylation sites but also
12 potential CDK sites. CDK-mediated phosphorylation of T847 is essential for DNA-end
resection133,134. However, the phosphomimetic T847E mutation only partially restored
resection in the absence of CDKs, indicating that additional sites on CtIP or on associ-
ated proteins are needed for optimal processing of the DNA ends156. Indeed, a cluster
of CDK phosphorylation sites (S233, T245, S276) is required to efficiently stimulate HR
when the CtIP fragment is brought already to sites of the break by fusion to Cas9110,130.
Of note, upon DNA damage, the same cluster of CDK sites promotes interaction with
NBS1, stimulating ATM-mediated phosphorylation and activation of CtIP157.
Complete impediment of the phosphorylation by mutation of T847 to alanine, did not
abrogate the binding with MRE11, suggesting that other interactions occur in the C-
terminus134. However, the underlying mechanism of how CtIP-T847 phosphorylation
supports meiotic and mitotic recombination still remains unclear. Interestingly, located
in close proximity to T847, K896 gets sumoylated by CBX4, thereby promoting CtIP’s
accrual at damaged DNA. Although CtIP is sumoylated probably at more than one site,
conjugation of SUMO to K896 seems to be fundamental for DNA-end resection function
as depletion of CBX4 or mutation of K896 results in reduced HR and increased genomic
instability158. Furthermore, the authors claim that only a small pool of CtIP is sumoylated
– the pool available for DNA-end resection – and that modifications occur sequentially
with CDK-mediated phosphorylation downstream of K896 SUMOylation159. Emphasizing
the intricate network of CtIP regulation, Y842 within a highly conserved FRY motif was
shown to be required for KLHL15-CUL3-mediated CtIP ubiquitination and subsequent
proteasomal degradation, representing a fine-tuning mechanism to regulate DNA-end re-
section160.
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PTMs are also implicated in mediating CtIP protein interactions. During S/G2, CDK-
dependent phosphorylation of S327 triggers its association with the tumor-suppressor
BRCA1161,162. However, the CtIP-BRCA1 interaction is dispensable for DNA-end resec-
tion, because cells with abrogated CtIP-BRCA1 interaction were still able to resect DNA
and mice expressing CtIP mutant polypeptides grew normally and did not develop can-
cer163,164. CtIP mutant cells rather displayed defects in removal of topoisomerase II-DNA
adducted breaks and further studies showed that the BRCA1-CtIP complex accelerates
resection speed, controls DNA damage-induced G2/M transition checkpoint and inhibi-
tion of NHEJ163,165,166.
In contrast to the functions and activation of CtIP in S/G2, the regulatory mechanisms
in G1 are largely unknown. In G1, the polo-like kinase 3 (PLK3) phosphorylates CtIP at
residues S327 and T847 upon damage, fostering DNA repair by alt-NHEJ167.
Furthermore, constitutive acetylation at residue K432, K526 and K604 inhibits CtIP during
G1. It has been found that CtIP is a direct substrate of the deacetylase SIRT6. Deple-
tion of SIRT6 renders cells sensitive to DSB inducing-agents and suppressed DNA-end
resection. Expression of deacetylated CtIP restored HR-mediated repair concluding that
SIRT6-dependent deacetylation promotes DNA-end resection168.
As mentioned above, CtIP protein levels are suppressed in G1 phase and peak during
S and G2 phase, suggesting that CtIP turnover is cell-cycle-dependent. Indeed, our
lab recently showed that CtIP is proteasomally degraded by the anaphase-promoting
complex/cyclosome-Cdh1 (APC/CCdh1) E3 ubiquitin ligase. Upon damage in G2 or fol-
lowing mitotic exit APC/CCdh1 controls CtIP turnover ensuring low levels of CtIP during
G1, consequently contributing to limit HR to S/G2169.
In addition, another E3 ubiquitin ligase SIAH-1 was found to trigger degradation of CtIP
although the physiological impact remained unsolved170.
Notably, it was shown that CtIP stabilization is negatively regulated by PIN1-mediated
isomerization. PIN1-mediated isomerization requires phosphorylation at two sites, S276
and T315, probably mediated by CDK2. PIN1 isomerization controls CtIP turnover by
promoting polyubiquitination of CtIP and subsequently proteasomal degradation, repre-
senting a regulatory mechanism for DNA repair pathway choice135.
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1.5.4 CtIP and its connection to cancer development and therapy
The very first studies associated CtIP with the bona fide tumor suppressor proteins
BRCA1 and RB150,171. However, the role of CtIP in tumorigenesis is highly debated
and the link between CtIP mutation, loss and overexpression in cancer is not yet clarified.
Mice lacking CtIP die at a very early embryonic stage, indicating that CtIP is essen-
tial for development. Notably, heterozygous animals were viable, but their life span was
shortened by the development of multiple tumors, particularly B and T cell lymphomas,
suggesting that haploinsufficiency of CtIP leads to tumorigenesis151. The preference for
lymphoma development may be explained by the fact that lymphocyte development re-
lies on intact DNA repair during rearrangements of antigen receptor genes172. In other
cancer, such as colorectal or endometrial cancers, frameshift mutations of CtIP and other
components of the DSB repair machinery caused by microsatellite instability could be
detected173,174. On the other hand, the fact that CtIP expression levels are very low in
breast cancer cells and downregulation of CtIP is associated with resistance to tamoxifen,
support the idea of CtIP being a tumor suppressor153,175.
In contrast, recent findings suggest CtIP to promote tumorigenesis, as it was shown that
heterozygous mice did not display increased tumor susceptibility and CtIP depletion re-
sulted in decrease of mammary tumorigenesis176. Along the same line, Lin et al. demon-
strated that triapine, a small molecule inhibitor of ribonucleotide reductase, sensitized
cells to PARP inhibitors by inhibiting the BRCA1-CtIP-MRN interaction, subsequently dis-
rupting CtIP-mediated HR of DNA breaks177.
A recently published study connected CtIP phosphorylation to breast cancer by reveal-
ing CtIP to be a substrate of the protein kinase p38α, a MAPK kinase which acts as a
tumor suppressor. P38α possibly phosphorylates CtIP at T847 and depletion of p38α in
breast cancer cells resulted in increased replication fork stalling and elevated DNA dam-
age, thereby negatively impacting tumor proliferation178. Knockdown of CtIP sensitized
breast cancer cells to taxanes, commonly used chemotherapeutic drug inducing chromo-
somal instability. Moreover, p38α inhibitors enhanced the effect of taxanes, suggesting a
potential clinical interest for a simultaneous use of p38α inhibitors with chemotherapeutic
drugs178.
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Recently, whole-genome sequencing data of BRCA1-deficient breast cancer cells re-
vealed that combined mutation of BRCA1 and p53 triggers the increase of distinct tandem
duplication phenotypes (TDP), characterized by rearrangements of segmental tandem re-
peats. According to a characteristic pattern for disruption of tumor suppressor genes or
activation of oncogenes the authors identified six TDP groups. Remarkably, decreased
copy number levels of CtIP were found to be significantly associated with TDP group 2179.
Conclusively, design of CtIP-specific small molecule inhibitors or by cell-penetrating pep-
tides could be of great use to increase the efficacy of radio- and chemotherapy and one
step towards targeted cancer therapy.
1.6 SLX4 - A nuclease scaffold
Slx4 (synthetic lethal of unknown function 4) was first identified in a yeast synthetic-lethal
screen for proteins that are essential in absence of Sgs1 helicase180. Human SLX4 pro-
tein comprises 1834 amino acids with a calculated molecular mass of 200 kDa. Biallelic
mutation of SLX4 causes a subtype of FA in humans and disruption of SLX4 in mice
phenocopies many key features of FA, hence it was renamed FANCP181,182. In addition,
it is hypothesized that monoallelic defects in SLX4 might predispose carriers to develop
hereditary breast cancer183,184.
Over the past years, SLX4 (also known as BTBD12) has been established as a scaf-
fold protein loaded with and controlling the activity of different structure-specific endonu-
cleases - and is therefore referred to as the ’molecular toolkit for DNA repair’76. The
multi-domain protein SLX4 interacts with and enhances the activity of three distinct nu-
cleases76: SLX1, XPF-ERCC1 and MUS81-EME1 (Figure 1.6). In complex with these
endonucleases, SLX4 is involved in the cleavage of various DNA structures including
ICLs, stalled replication forks and HJ185,186.
Cleavage of complex DNA secondary structures is an important step during various DNA
repair and recombination processes. Consequently, cells lacking SLX4 are hypersen-
sitive to ICL and DSB-inducing agents46,186,187. SLX4 coordinates the function of the
interacting endonucleases appropriately to the type of induced DNA lesion. For instance,
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Figure 1.6: Schematic representation of SLX4 including its binding partners and conserved
domains. Human SLX4 serves as a scaffold for multiple proteins, including the XPF-ERCC1, MUS81-
EME1 and SLX1 nucleases. Those interactions are attributed to the conserved domains MLR, SAP
and SBD, respectively. The BTB domain mediated protein dimerization. SLX4 interacts with TRF2 via
its TBM domain, which is responsible for the telomeric localization of SLX4. A CDK consensus site at
S1453 mediates its interaction with PLK1. Additionally, SLX4 contains motifs required for SUMO- and
ubiquitin binding. Furthermore, SLX4 reveals two UBZ domains and three SUMO interaction motifs
(SIMs). Notably, SLX4 contains 41 S/T-P phosphorylation motifs, with almost two thirds located in the
low complexity region between residues 788 and 1540.
XPF-ERCC1 is required for ICL repair, meanwhile MUS81-EME1 in complex with SLX4 is
critical in response to cisplatin-induced DNA damage188. Moreover, both MUS81-EME1
and SLX4-SLX1 nuclease functions are essential for resolving HJs during recombinato-
rial repair47,189. Unprocessed HJ pose a crucial threat demonstrated by the synthetic
lethality of SLX4 and BLM or GEN1 in mitosis189. Furthermore, studies confirmed that
the processing of persistent recombinant intermediates by GEN1 (or YEN1 in yeast) is
timely restricted by inhibitory phosphorylation to the onset of meiosis II, ensuring that
chromosomes can be properly separated190,191. If inhibition fails, activation of the re-
solvase leads to premature resolution of intermediates and premature crossovers. Along
the same lines, SLX4-MUS81 emerged to be a key player in resolving persistent repli-
cation intermediates ensuring that DNA replication and mitosis occur sequentially192.
At the onset of mitosis, CDK1 and PLK1 phosphorylate SLX4 leading to its assembly
with MUS81, which cleaves persistent DNA intermediates. The complex assembly and
subsequent activity occurs only in mitosis and is controlled by the kinase WEE1. Accord-
ingly, inhibition of Wee1 leads to the catastrophic pulverization of S phase chromosomes
caused by unrestrained processing activity of SLX4-MUS81192.
Human SLX4 contains two closely spaced UBZ domains (UBZ-1 and UBZ-2) (see Fig-
ure 1.6). Recent studies revealed that only the UBZ-1 binds to ubiquitin chains, being
required for SLX4 recruitment to ICLs. In contrast, the UBZ-2 was not found to bind
ubiquitin in vitro and rather than contributing to ICL repair, manages HJ resolution193.
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In addition, the intrinsically disordered region of SLX4 comprises three SUMO interac-
tion motifs (SIM) shown to be important for its recruitment to sites of DNA damage and
localization to telomeres maintained by the alternative lengthening of telomeres (ALT-)
pathway194,195. Recently, SLX4 has been found to be a SUMO E3 ligase itself, mediating
SUMOylation of the nuclease XPF and triggering autoSUMOylation194,196. However, it
was demonstrated that levels of SUMOylation of SLX4 itself and XPF does not change
in response to DNA damage. Also, these SUMO-dependent functions of SLX4 are dis-
pensable for ICL repair since the SLX4 SIM mutant could rescue the sensitivity against
ICL-inducing MMC in clonogenic survival assays. Instead, SLX4 SIM domains play a role
during the response to local replication stress. Upon inhibition of DNA replication using
aphidicolin, SLX4 localizes at common fragile sites (CFS) to mediate faithful chromosome
segregation, which requires its intact SIM domains196.
Besides its recruitment to DNA damage, SLX4 plays an important role in telomere biol-
ogy. Via interaction with TRF2, which is a member of the Shelterin-complex, it assembles
at telomeres and negatively regulates telomere length197. In mammals, TRF2-RAP1 di-
rects SLX4 localization to telomeres via PARP1 to protect telomeres from inappropriate
processing by HR198. Loss of SLX4 leads to telomere fragility, indicative that SLX4 is
important for telomere maintenance199. Moreover, an oligomerization motif, the BTB do-
main, facilitates homodimerization of SLX4 and is required for its telomeric localization
as well as for the recruitment of associated nucleases. Disruption of the BTB domain
leads to increased sensitivity to DNA interstrand crosslink agents and defects in telom-
eric maintenance200.
A critical step in the activation of SLX4 is its phosphorylation by the polo-like kinase 1
(PLK1). PLK1 phosphorylates and activates SLX4 at S1453, which positively influences
the interaction between PLK1 and XPF46. PLK1 activation promotes the association of
the SLX4 complex to stalled replication forks in order to nucleolytically process various
DNA structures201. It has been proposed that SLX4 is involved in the recovery of stalled
forks upon replication stress, a function strongly intertwined with its recruitment by the
regulator of Ty1 transposition (Rtt107)202,203. In yeast, fork bypass is orchestrated by the
concerted action of SLX4-Rtt107 by counteracting the function of the Rad53 kinase ac-
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tivator Rad9 leading to the inhibition of the Rad53-mediated DNA checkpoint response,
consequently suggesting a role of SLX4 in controlling the checkpoint reponse204–207.
Of note, 41 in vivo S/T-P phosphorylation sites of SLX4 were identified by mass spec-
trometry (www.phosphosite.org), pinpointing to a regulation by proline-directed kinases,
which constitutes the prerequisite of PIN1-mediated isomerization. Taken together, the
versatile functions of SLX4 are regulated by interaction with a broad range of proteins
and depend on various PTMs.
1.7 PIN1
1.7.1 PIN1 - A molecular switch regulating diverse pathways
For steric reasons, the great majority of peptide bonds in proteins is found in a trans state,
with the CO-NH/omega-angle assuming a value of 180°. However, peptide bonds pre-
ceding a proline residue have the unique ability two exist in two different conformations.
Since the ring structure on the peptide backbone leads to steric similarities between the
carbon atoms of the proline side chain and the backbone atoms, both cis and trans forms
of proline peptide groups are almost isoenergetic208. Indeed, X-ray crystal structure anal-
yses of proteins reveal that about 6% of all prolyl peptide bonds exist in the cis state. In
contrast, the frequency of the cis state is only 0.04% in non-proline peptides209. How-
ever, the interconversion between the two conformations of prolyl peptide bonds is an
intrinsically slow reaction, which can be greatly enhanced by peptidyl-prolyl cis-trans iso-
merases (PPIases). PPIases are grouped into three families: FKBPs (FK506 binding
proteins), cyclophilins and parvulins210,211. PIN1 belongs to the family of parvulins and is
composed of 163 amino acids with a molecular weight of 18 kDa212. It is a two-domain
enzyme - its N-terminal WW domain mediates the phosphorylation-dependent binding
to its substrate, whereas the C-terminal PPIase domain is responsible for the isomer-
ization activity213. The N-terminally located residues Y23 and W34 form an aromatic
clamp necessary for PIN1 binding. Innes et al. suggest that the WW domain, unlike the
PPIase domain, preferentially targets binding sites with a proline at the +1 position214.
The residues R68 and R69, located in the catalytic domain, are responsible for a unique
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phosphorylation-specificity and together with K63 form a positively charged phosphate-
binding hook215–218. In other words, PIN1 isomerizes only proline peptide bonds adjacent
to phosphorylated serines or threonines (S/T-P motif), a unique feature among the PPI-
ases (Figure 1.7).
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Figure 1.7: Two-step model of prolyl cis-trans isomerization by PIN1 after phosphorylation.
Phosphorylation of a protein substrate is mediated by proline-directed kinases. Subsequently, this
enables PIN1 to bind and catalyze the isomerization of the prolyl peptide bond, with various possible
effects for its substrate. The zoom pictures show the conformational change of a phosphorylated serine-
proline peptide bond. The grey background line represents the protein backbone. Modified from 219,220.
These S/T-P motifs are critical and play an important regulatory role for many cell cycle-
regulated proteins including kinases and phosphatases. In fact, many kinases like CDKs,
MAPKs, and GSK3s (Glycogen synthase kinase 3), JNKs (Jun-N-terminal protein ki-
nases) and PLKs (polo-like kinases) act on S/T-P motifs.
Although PIN1 contributes to the activation or inhibition of many regulatory proteins dur-
ing G1/S phase, namely cyclin D, cyclin E and p27, its role in mitosis is investigated the
most (Figure 1.8)210,221,222.
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Figure 1.8: Role of PIN1 during mitosis. During G2/M transition, PIN1 is phosphorylated at Ser16 by
the kinase AuroraA, leading to its translocation into the cytosol, thus preventing PIN1-mediated degra-
dation of phosphorylated hBora, which is a crucial factor for mitotic entry 223–225. AuroraA associates
with hBora to phosphorylate PLK1, which in turn activates cdc25 and downregulates the kinases Myt1
and Wee1226. After mitotic entry, PLK1 restores activation of PIN1 by phosphorylation of Ser65, leading
to degradation of hBora. Restored activation of PIN1 in M-phase also promotes binding and isomeriza-
tion of Wee1, a suppressor of CDK1. Because CDK1 is important to cycle through mitosis, Wee1 must
be inhibited during M-phase, which is achieved by PIN1-mediated isomerization227. Modified from225.
PIN1 was originally identified as a negative regulator of mitosis that interacts with and in-
hibits the ability of NIMA (G2-specific protein kinase nimA), a mitotic regulator protein, to
induce mitotic catastrophe212. Along the same line, deletion of the ortholog Ess1 (essen-
tial in yeast) in S. cerevisiae induces terminal mitotic arrest228. In contrast to its lethality
in yeast, PIN1 knock-out mice develop normally up to the age of seven months until they
display cell proliferative abnormalities (e.g. decreased body weight, testicular and retinal
atrophies, mammary gland proliferative impairment and low bone mass)229. Moreover,
PIN1-/- mouse embryonic fibroblasts (MEFs) were found to grow slower and show defi-
ciencies in restarting proliferation in response to serum starvation after G0 arrest230,231.
In addition, overexpression of PIN1 in Xenopus egg extracts prevents entry into mitosis,
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whereas depletion leads to premature entry into G2/M, suggesting that PIN1 is mediating
mitotic checkpoint control232,233. Studies in HeLa cells substantiate the findings that PIN1
depletion leads to premature entry into mitosis and mitotic arrest and its overexpression
inhibits the G2/M transition, thus it is surprising that expression levels of PIN1 are con-
stant throughout the cell cycle224,232–234. Underscoring evidence that PIN1 drives mitotic
progression comes from a recent study displaying PIN1 as the mitosis promoting factor
in spermatogonial stem cells235.
Consequently, because PIN1 level do not significantly vary during the cell cycle, PIN1’s
action on mitosis-promoting factors must be timely restricted and tightly controlled by
PTMs of its substrates but also of itself.
Furthermore, PIN1 was found to control a broad range of cell-cycle regulatory proteins
including PLK1, cdc25 and cyclin D221,234,236. In addition, PIN1 is involved in the regula-
tion of cell growth, immune response and neuronal differentiation in response to various
cellular stresses100,237–239 (Figure 1.9).
Collectively, the concerted action of protein kinases and PIN1 isomerization is a two-step
mechanism in which proline-directed kinases first phosphorylate the S/T-P motif, thus al-
lowing PIN1 to act on its substrate. Consequently, a change of the protein structure can
have profound regulatory effects for the substrate’s activity, affinity to binding partners
and stability or can modulate the interplay of PTMs240.
1.7.2 PIN1 and its role in tumorigenesis
PIN1 controls numerous cancer-driving pathways due to its stabilizing, destabilizing, ac-
tivating and inhibiting effects on a broad spectrum of important oncoproteins. Plausibly
one of the best described PIN1 substrate is the tumor suppressor protein p53241–243. Re-
cently, the p53-RS (R249S) mutant, harboring an extra PIN1 docking site, which facilitates
its nuclear localization, was frequently detected in human hepatocellular carcinoma244.
PIN1 functions are critical during mitosis and it was shown that PIN1 overexpression
leads to abnormal spindle formation, chromosome instability and finally can induce breast
cancer in mice235. Notably, PIN1 is significantly overexpressed in many human cancers
including breast, cervical, prostate and lung cancer, as well as melanoma and is also
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Figure 1.9: PIN1 acts on various substrates. PIN1-mediated isomerization can have crucial effects
on the activity, stability, protein interaction or localization of its target substrate. Importantly, many factors
regulated by PIN1 play an important role in tumorigenesis, such as cyclins, Wee1 or p53. Adapted
from240.
associated with a higher risk of tumor relapse after tumordissectomy238,239,245–247. Given
that PIN1 overexpression is most likely a prevalent and defined event in human cancer
to promote tumor growth, it is reasonable and nowadays well-established to use PIN1
expression as a prognostic marker in prostate cancer245.
PIN1 is a critical modifier of multiple signaling pathways with important roles in cancer
stem cells248,249. For example, PIN1 sustains Notch signaling by preventing Notch1
and Notch4 proteasomal degradation. Consequently, constantly active Notch signaling
triggers tumor growth and self-renewal in breast cancer stem cells250. Importantly, in
patient-derived primary breast cancer cells, knockdown of PIN1 suppressed expansion
and tumor growth in vitro and in xenograft models251. The fact that PIN1 knockdown can
suppress tumor growth and cancer stem cell expansion renders it as an attractive target
for therapeutic strategy. But these attempts are hampered by the versatility of PIN1, con-
sidering a high risk of possible off-target effects and rather low specificity. Nevertheless,
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first trials were completed with success. It was reported that the therapeutic effects of all-
trans retinoic acid (ATRA), which is clinically used to suppress leukemia, breast and liver
cancer by targeting PIN1, can be potentiated by the combination with arsenic toxide252.
Similarly, Campaner et al. identified the PIN1 inhibitor KPT-6566 covalently binding to the
catalytic site of PIN1, which induces ROS-dependent DNA damage specifically only in
PIN1 cancer cells, resulting in suppression of lung metastasis in vivo 253.
To identify novel PIN1-interacting proteins mass spectrometry analyses of pulldown as-
says revealed more than 600 potential candidates, among them a vast majority of DSB
response factors, supporting a role of PIN1 in the DDR135,254. The kinase ATR has been
reported to be a direct target of PIN1 with implications in response to UV light. Besides
its nuclear function, ATR exhibits antiapoptotic activity associated at the mitochondria.
Hilton et al. showed that PIN1-mediated isomerization suppresses its mitochondrial ac-
tivity and UV light exposure initiates inhibition of PIN1 by DAPK1 leading to stabilization
of active ATR255. Furthermore, one study confirmed a simultaneous overexpression of
PIN1 and hyper-phosphorylated RB, a protein important for cell cycle progression and
DNA damage response in human breast cancer cells. The authors propose an underlying
mechanism in which PIN1-mediated isomerization of RB prevents its dephosphorylation
by PP2A256.
However, the impact of PIN1-mediated prolyl isomerization on different substrates is still
poorly addressed, thus more research is required aimed to elucidate the function of PIN1
in tumor development and its interaction with substrate proteins.
1.8 P. tetraurelia as a model organism to study DSB repair
Paramecium tetraurelia, belonging to the ciliate phylum, is a unicellular eukaryotic organ-
ism naturally found in aquatic habitats. It feeds on bacteria, yeast and algae and can be
easily cultivated in laboratories, where it serves as a useful model organism to study basic
cellular processes of life257. Growing cells can duplicate by binary fission, but once they
find a mating partner, or in response to starvation, initiate sexual processes258. Parame-
cium possesses two modes of sexual reproduction: Conjugation (cross-fertilization) and
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autogamy (self-fertilization), which can be induced by controlling food uptake, thus allow-
ing to study basic molecular processes during meiosis.
Like all ciliates, Paramecium harbors a characteristic nuclear dimorphism and undergoes
spectacular genome-wide genetic rearrangements during development. Its genome is
separated into distinct types of nuclei with somatic and germline function. One large,
highly polyploid somatic macronucleus (MAC, 800n) responsible for gene transcription
during vegetative growth, and two micronuclei (MIC, 2n) undergoing meiosis during each
sexual cycle259,260 (Figure 1.10). Importantly, during meiosis, the parental MAC degrades
and differentiates from copies of the zygotic nucleus after fertilization. MAC development
involves the massive amplification (from 2n to 800n) of the zygote and requires two types
of DNA elimination events to remove 25%-30% of MIC DNA. On the one hand, impre-
cise elimination of 100-200 regions of several kb repeated sequences from the germline
genome leads to chromosome fragmentation261. On the other hand, precise excision
deletes ∼45’000 internal eliminated sequences (IES), which can be regarded as short
(26-882 bp) noncoding ’introns’. IES excision is initiated by creation of a DSB at IES
sites, mediated by the sequential action of PiggyMac, a domesticated (= recruited by
their hosts to perform novel functions) piggyBac transposase262.
Recently, proteins involved in DSB repair by NHEJ were found to play important roles
during the cut-out of IES, such as the Ku70 and Ku80 paralogs, which mediate the reli-
gation of the DNA ends10,263. With regards to recombinatorial repair, a recent inventory
of meiosis-specific genes in ciliates revealed the presence of two gene copies for each
PtMRE11 and PtCtIP, consistent with multiple whole-genome duplication events in the
early stages of P. tetraurelia evolution264,265. In evolution, MRE11 and CtIP were found to
be strictly required for the removal of covalently attached Spo11 from the break site, and
by that initiating DNA-end resection59,137,266.
Remarkably, with a length of only 198 amino acids, PtCtIP paralogs constitute the small-
est Sae2/Ctp1/CtIP protein family members that have been identified so far (see Fig-
ure 1.4). PtCtIP is a potential candidate to be implicated in the processing of DSBs
during genome rearrangements. Therefore, P. tetraurelia serves as an attractive model
to study programmed rearrangements during meiosis and DSB repair.
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Figure 1.10: Nuclear dimorphism and the life cycle of P. tetraurelia. (A) Stages of P. tetraurelia
development. Left : The vegetative growth is illustrated. The two micronuclei (MICs) undergo mitosis,
while the macronucleus (MAC) elongates and splits into two. Right : Upon starvation or having a mating
partner to conjugate with in proximity P. tetraurelia initiates autogamy or the sexual cycle. First, the MICs
undergo meiosis resulting in eight haploid products. Two of them fuse to build a zygote, while the others
are degraded. The zygote undergoes two round of mitosis to form two future MICs and two daughter
MACs. During each sexual cycle, the MAC is completely degraded. (B) A newly somatic MAC is build
from a germline MIC by genome amplification (from 2n to 800n), chromosomal fragmentations and
removal of internal eliminated sequences (IES). The IES are depicted in dark orange and are removed
from the coding genome (dark blue) during MAC development. Modified from267,268.
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Genomic instability drives tumor progression by enabling the acquisition of core and
emerging hallmarks of cancer12 11. Many current therapeutic regiments for treating can-
cer, like ionizing radiation or chemotherapy, rely on the induction of DNA damage to trig-
ger programmed cell death of cancer cells. Nonetheless, these agents cause severe side
effects and often become ineffective when resistance develops. Therefore, a more in-
depth understanding of the DDR is essential to improve the efficacy of existing therapies
and to suggest novel treatment strategies.
Aim 1: Investigating the biochemical function of CtIP in DSB repair
Upon DNA damage, proliferating cells activate a signaling network to arrest the cell cycle
and enable DNA repair. We and others have reported previously that CtIP is a key player
in the DNA double-strand break (DSB) repair by promoting DNA-end resection and ho-
mologous recombination (HR). How members of the Sae2/Ctp1/CtIP protein family func-
tionally integrate with the Mre11-Rad50 (MR) nuclease complex to initiate the processing
of DNA double-strand breaks (DSBs) is not fully understood. Moreover, high-resolution
structural analysis of CtIP is hampered, as it consists of a large intrinsically disordered re-
gion and an N-terminal coiled-coil domain that self-assembles into higher-order oligomers
in solution.
We identified an ortholog of CtIP in the ciliate Paramecium tetraurelia, named PtCtIP,
which represents the shortest known CtIP ortholog of the CtIP/Sae2/Ctp1 protein family
with only 198 amino acids. Therefore, we wanted to uncover the biochemical properties
of PtCtIP in more detail and aimed to translate our findings to the human ortholog. More-
over, we wanted to uncover the biochemical and biological properties of PtCtIP in more
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detail and aimed to translate our findings to the human ortholog (in collaboration with Dr.
Mireille Bétermier, Institut de Biologie Intégrative de la Cellule, France). In summary, we
identified a miniature Sae2/Ctp1/CtIP ortholog from Paramecium tetraurelia that owns a
conserved DNA-binding motif required for DNA-end resection (manuscript submitted to
the scientific journal of DNA Repair).
Aim 2: Deciphering the regulation of human SLX4 by phosphorylation-dependent
isomerization
In a previous study, our lab found that CtIP functions in the DSB repair are controlled
by PIN1, a peptidyl-prolyl isomerase (PPIase), which can catalyze the cis-trans confor-
mation of prolyl peptide bonds adjacent to phosphorylated serines or threonines (S/T-P
motifs)135. In a proteomic screen for potential PIN1 substrates, we discovered several
DNA damage response (DDR) proteins including SLX4. SLX4 (alias FANCP) serves as
a docking platform for different structure-specific endonuclease complexes, thereby or-
chestrating Holliday junction (HJ) resolution during HR, DNA crosslink processing during
ICL repair, restoration of stalled replication forks and regulation of telomere length home-
ostasis. However, if and how SLX4 conformation regulates its function is not yet known.
Thus, we aim to validate the PIN1-SLX4 protein interaction and to identify the potential
pS/T-P motif in SLX4 mediating its interaction with PIN1. Lastly, we want to address the
effects of PIN1-mediated isomerization for SLX4 function in telomere homeostasis and
DNA repair.
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Immunoblotting, immunoprecipitation, far-Western, GST-pulldown and phos-
phatase treatment
If not specified otherwise, cell extracts were prepared in NP40 buffer (50 mM Tris-HCl,
pH 7.5, 120 mM NaCl, 1 mM EDTA, 6 mM EGTA, 15 mM sodium pyrophosphate and
1% NP-40 supplemented with phosphatase inhibitors (20 mM NaF, 1 mM sodium ortho-
vanadate) and protease inhibitors (1 mM benzamidine and 0.1 mM PMSF)). For efficient
cell lysis, the suspensions were snap-frozen, thawed on ice and sonicated in a Biorup-
tor® (Diagenode). Lysates were cleared by centrifugation at 14000 g before determining
protein concentration by Bradford assay. Proteins were separated by SDS–PAGE and
transferred to nitrocellulose. Detection of proteins was carried out using the appropriate
antibodies and proteins were visualized applying the WesternBright (Advansta) and im-
aged on a FusionSolo (Witec AG).
Unless otherwise stated, a total of 0.5 – 1 mg of lysate was used for immunoprecipita-
tion. FLAG-Epitope tagged constructs were immunoprecipitated using the agarose anti-
FLAG resin (Sigma-Aldrich) overnight at 4C. Beads were washed twice with NTEN300
buffer (20 mM Tris-HCl pH 7.4, 0.1 mM EDTA, 0.5% NP-40, 300 mM NaCl), twice with
NTEN500 buffer (20 mM Tris-HCl pH 7.4, 0.1 mM EDTA, 0.5% NP-40, 500 mM NaCl),
followed by a single wash with TEN100 (20 mM Tris-HCl pH 7.4, 0.1 mM EDTA, 100 mM
NaCl), boiled in SDS-sample buffer and analyzed by immunoblotting. HA-epitope tagged
proteins were immunoprecipitated using anti-HA affinity resin (Sigma) and immunocom-
plexes were washed three times with NP40 buffer. GFP-TRAP was performed using
anti-GFP coupled to agarose beads (ChromoTek) according to manufacturer’s protocol.
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Far-Western blot analysis was performed as described previously153. To enrich for FLAG-
SLX4, proteins were immunoprecipitated and eluted in TEN100 buffer supplemented with
FLAG-peptides according to manufacturer’s instructions (Sigma).
GST-pulldown assay was performed by coupling GST-PIN1 (wt or W34A expressed in E.
coli as previously described135 to Sepharose beads for 2 h at 4°C. Recombinant GST-
PIN1 was a kind gift of Stefano Ferrari (University of Zurich, Switzerland). Coupled resin
was washed three times with PBS-1% TritonX before incubation with 0.5 mg protein ex-
tract for 1 h at 4°C. Beads were washed once with NTEN300, twice with NTEN500, once
with NTEN300 and once with TEN100. Recovered complexes were boiled in SDS sample
buffer and analyzed by SDS–PAGE followed by immunoblotting.
For phosphatase treatment, proteins bound to agarose anti-FLAG resin were dephospho-
rylated on beads. In brief, 20 µl beads with bound FLAG-SLX4 constructs were incubated
with 50 µl PMP buffer (NEB) supplemented with MnCl2, benzamidine, PMSF (and in case
of PPase inhibitors plus NaF and sodium orthovanadate) containing 2 µl Lambda-PPase
(NEB) for 30 min at 30°C. Beads were washed twice with PMP buffer prior to elution using
3xFLAG peptides (Sigma-Aldrich).
Antibodies
Primary antibodies used in this study are listed in table 3.1. Secondary HRP-conjugated
anti-mouse and anti-rabbit antibodies were purchased from GE-Healthcare and used in a
dilution of 1:5000. AlexaFluor-488, -594 and -647-conjugated secondary antibodies were
bought from Invitrogen and diluted to 1:500 -1000.
Cell culture and transfection
U2OS, HeLa and HEK293T cells were maintained in Dulbecco’s modified Eagles medium
(DMEM, Thermofisher) supplemented with 10% fetal calf serum (FCS, Thermofisher).
HeLa and U2OS clones stably expressing doxycycline (Dox)-inducible siRNA-resistant
forms of YFP-SLX4 were generated as described previously196 using the Flp-In T-REx
system (Invitrogen, Life Technologies) according to manufacturer’s protocol. Resistant
clones were selected and YFP-SLX4 expression was analyzed by both immunofluores-
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Antibody target Reference/Supplier Dilution Applicationa
α-Tubulin T-9026 (Sigma Aldrich) 1:20000 IB
CtIP (D-4) sc-271339 (Santa Cruz) 1:250 - 500 IB
cyclinD1 RB-010-P1 (Neomarkers) 1:1000 IB
FLAG F3165 (Sigma) 1:1000 IB
GAPDH MAB374 (Millipore) 1:40000 IB
GFP ab290 (Abcam) 1:1000/1:500 IB/IF
HA Sc-7392 (Santa Cruz) 1:500 IB
PIN1 2136-1 (Epitomics) 1:1000 IB
PLK1 P5998 (Sigma) 1:1000 IB
pT1315 Creative Biolabs (Custom made) 1:500 IB
H3pS10 06-570 (Millipore) 1:1000/1:500 IB/flow cytometry
TRF2 NB110-57130 (Novus) 1:1000/1:500 IB/IF
SLX4 A302-270A (Bethyl) 1:1000 IB
a IB: Immunoblot, IF: Immunofluorescence
Table 3.1: Primary antibodies
cence microscopy and immunoblotting. YFP-SLX4 expression was induced with 1 µg/ml
Doxycycline (Sigma) for 24 - 48 h.
Plasmids (5 µg) were transfected either by using the calcium phosphate method or Fu-
GENE 6 transfection reagent (Promega) according to the manufacturer’s instructions.
Transfection of indicated siRNA oligos was carried out using Lipofectamine RNAiMAX
(Life Technologies).
To assess protein turnover, cells were treated with cycloheximide (C7698) purchased
from Sigma and used as indicated.
RNA interference sequences
The following siRNA sequences were used in this study (sequences in 5’ to 3’): siluc
(CGUACGCGGAAUACUUCGA) (used in269, siSLX4 (AAACGUGAAUGAAGCAGAAUU)
(used in46,269 and siPIN1-3’UTR (CCGUCACACAGUAUUUAUU) (used in135), all pur-
chased from Microsynth.
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Plasmids
The pDEST/FRT/TO-based expression vector encoding doxycycline (Dox)-inducible siRNA-
resistant YFP-SLX4 wt was kindly provided by Dr. Henri Gaillard (Centre National de
la Recherche Scientifique, France)196. The pDEST/FRT/TO-based Venus-FLAG-SLX4
wt, 6A, 19A, 22A and 35A expression constructs were a kind of Dr. Joao Matos (ETH
Zurich, Switzerland)192. The pHAGE plasmids containing HA-FLAG-SLX4 full-length and
truncated mutants (covering SLX4 amino acid sequence 1-800, 1-1520, 801-1834) were
kindly provided by Agata Smogorzewska (Rockefeller University, USA)187. The pcDNA3.1
vector for expression of HA-PIN1 wt, W34A and C113A used in this study have been de-
scribed previously135.
Advantage HD polymerase (Clontech) was used to alter single S/T-P sites in SLX4 or to
generate truncated SLX4 expression constructs by side-directed mutagenesis (SDM). In
brief, 50 ng DNA template was mixed with 1x HD buffer, 5 mM dNTPs (Roche), 1.25 µM
combined forward and reverse primers and 0.625 Units Advantage HD polymerase in a
final volume of 25 µl. All DNA oligos used as primers are listed in table 3.2. Sequences
of all constructs were confirmed by sequencing (Microsynth).
Immunofluorescence microscopy
In order to screen the generated clones for YFP-SLX4 expression, cells were grown on
coverslips and fixed directly in formaldehyde. Alternatively, cells were permeabilized or
pre-extracted for 5 min on ice before fixation in 4% formaldehyde (w/v in PBS) for 15 min
as described previously37. After incubation with indicated primary and Alexa Fluor-488,
-594 and -647 conjugated secondary antibodies (1:000) (Life Technologies) coverslips
were mounted with Vectashield® (Vector Laboratories) containing DAPI and imaged ei-
ther using a Leica DMI6000 widefield fluorescence or a confocal Leica CLSM SP5 Mid
UV-VIS microscope at 63X magnification.
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Name Sequence in 5’ to 3’
SLX4_T500A_for GTGGAATTGTCTAGCGCGCCACCACTTCC
SLX4_T500A_rev CAGGAAGTGGTGGCGCGCTAGACAATTCC
SLX4_S1028A_for CTCCCTGGCAGGCAGCTCCACCGCACCC
SLX4_S1028A_rev GGGTGCGGTGGAGCTGCCTGCCAGGGAG
SLX4_S1044A_for AGGGCGGGGCTCCCCGCGGGTCTCATCAC
SLX4_S1044A_rev GTGATGAGACCCGCGGGGAGCCCCGCCCT
SLX4_S1070A_S1075A_for AGGTGGGCGCCCCAACCTTGCTGGCTCCAGCTGTG
SLX4_S1070A_S1075A_rev CACAGCTGGAGCCAGCAAGGTTGGGGCGCCCACCT
SLX4_S1206A_for GATCAGGAACCTTCCCAGGCCCCACCAAGAAGCGAAGC
SLX4_S1206A_rev GCTTCGCTTCTTGGTGGGGCCTGGGAAGGTTCCTGATC
SLX4_T1315A_for GTCATCAGGCCCCAGGCACCACCGCCC
SLX4_T1315A_rev GTCTGGGGCGGTGGTGCCTGGGGCCTG
SLX4_T1320A_for CACCGCCCCAGGCACCGTCCTCATG
SLX4_T1320A_rev CATGAGGACGGTGCCTGGGGCGGTGG
SLX4_T1326A_S1329A_for TCCTCATGCCTCGCTCCCGTCGCTCCAGGAACTTCT
SLX4_T1326A_S1329A_rev AGAAGTTCCTGGAGCGACGGGAGCGAGGCATGAGGA
SLX4_S1342A_for AGAAGGCAAGGCCACAGAGCCCCTTCCCGTCCCCAC
SLX4_S1342A_rev GTGGGGACGGGAAGGGGCTCTGTGGCCTTGCCTTCT
SLX4_S1355A_for CACCCGCACTCCGCTCCGCTGGCTCCACAT
SLX4_S1355A_rev ATGTGGAGCCAGCGGAGCGGAGTGCGGGTG
SLX4_S1377A_for TTCCTGAAACACGCGCCGCCTGGGCCAAGC
SLX4_S1377A_rev GCTTGGCCCAGGCGGCGCGTGTTTCAGGAA
SLX4_S1434A_for CACATGGAGCCCCTCGCGCCAATTCCCATTG
SLX4_S1434A_rev GTCAATGGGAATTGGCGCGAGGGGCTCCATGTG
SLX4_1097stop_for GTCTAAAGAGCCAGGGCACTAGAAAGGCAAAGAGCG
SLX4_1097stop_rev GACGCTCTTTGCCTTTCTAGTGCCCTGGCTCTTTAG
SLX4_1296stop_for CGCCCAGGGCCTCAGTATGAAACAGGGAAG
SLX4_1296stop_rev GTTCCCTTCCCTGTTTCATACTGAGGCCCTGG
SLX4_1338stop_for GACGGCAGAAGGCAATGATAGAGAAGCCCTTCCCGTCCCC
SLX4_1338stop_rev GGACGGGAAGGGCTTCTCTATCATTGCCTTCTGCCGTCAG
SLX4_1383stop_for GCCTGGGCCAAGCTTCTGAACCAGACCCCAG
SLX4_1383stop_rev CGCTGGGGTCTGGTTCAGAAGCTTGGCCCAG
SLX4_1536stop_for CCAAGCGCTGGTGGAGCTTAGAAGCCCGAAGG
SLX4_1536stop_rev GGTGTCTCTAACCCTTCGGGCTTCTAAGCTCCACCAGCG
SLX4_A1315T_for GTCATCAGGCCCCAGACACCACCGCCCCAG
SLX4_A1315T_rev CTGGGGCGGTGGTGTCTGGGGCCTGATG
SLX4_A1320T_for CACCGCCCCAGACACCGTCCTCATGCCTC
SLX4_A1320T_rev GAGGCATGAGGACGGTGTCTGGGGCGGTG
Table 3.2: Oligonucleotides used as primer
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Coupled Immunofluorescence-FISH
In coupled immunofluorescence-FISH experiments a Cy3-conjugated PNA probe was
used to detect telomeres. Proteins were first immunofluorescently labeled as described
above, before cells fixed on coverslips were further processed as followed. Coverslips
were washed three times with PBS and cells fixed again in 4% formaldehyde (in PBS)
for 5 min. After repeated washing with PBS, cells were serially dehydrated in 70%, 95%
and 100% EtOH for 5 min each and air-dried. Coverslips were incubated with Cy3-labeled
PNA probe (Eurogentec) at a final concentration of 100 nM in hybridizing solution (10 mM
Tris pH 7.4, 70% formamide (deionized), 0.5% blocking reagent from a 2% stock (blocking
reagent (Roche 11096176001) in 100 mM maleic acid, 150 mM NaCl pH 7.5) for 3 min
at 85°C followed by 2 h at room temperature. After hybridization, cells were washed
twice with wash buffer 1 (10 mM Tris pH 7.4, 70% formamide) for 15 min each and three
times with wash buffer 2 (10 mM Tris pH 7.4, 150 mM NaCl, 0.08% Tween-20) for 5 min
each before dehydration in EtOH as described above. Coverslips were mounted with
Vectashield® (Vector Laboratories) containing DAPI and imaged using a Leica DMI6000
wide field fluorescence microscope at 63x magnification. Quantitative image analysis was
carried out using CellProfiler to assess the number of foci per nucleus and colocalization
(Broad Institute270).
Flow cytometry
For flow cytometry analysis, cells were harvested by trypsinization, whereby the super-
natant of each wash step was collected, preventing loss of rounded-up mitotic cells. Cells
were either pre-extracted in 0.3% TritonX-100 (v/v in PBS) for 10 min or directly fixed in
4% formaldehyde (v/v in PBS) for 15 min. For H3pS10 staining, non-preextracted cells
were permeabilized after fixation and incubated with 0.5% saponin/1% BSA/PBS contain-
ing the primary antibody for 2 h at RT, followed by incubation with Alexa 647 conjugated
secondary antibody (1:500) (Life Technologies). After a subsequent wash step with 0.5%
saponin/1% BSA/PBS, cells were resuspended in 0.5% saponin/1% BSA/PBS containing
100 µg/ml Rnase A and 1 µg/ml DAPI and incubated for 30 min at room temperature. Flu-
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orescence intensity was measure on an Attune NxT flow cytometer (Thermofisher) and
analyzed with FlowJo X (Tree Star).
Statistics
Statistics were calculated in Graph Pad Prism (GraphPad Software Inc.). Statistical anal-
yses were performed using unpaired, two-tailed t-test. P values expressed as * (P<0.05),
** (P<0.001) and *** (P<0.0001) were considered significant.
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Results
4.1 Investigating the biochemical function of CtIP in DSB repair
4.1.1 Identification of a miniature Sae2/Ctp1/CtIP ortholog from Paramecium
tetraurelia required for sexual reproduction and DNA double-strand
break repair
Manuscript submitted to DNA Repair
Authors:
Julia Godau*, Lorenza P. Ferretti*, Christine von Aesch, Raphaël Guérois, Antoine
Marmignon, Lauriane Simon, Emeline Dubois, Aurélie Kapusta, Mireille Bétermier and
Alessandro A. Sartori (* equal contribution)
Contribution:
For this study, I have cloned, expressed and purified recombinant PtCtIP wild-type and
RHR mutant proteins from insect cells and performed all gel shift assays (Figure 4). More-
over, I have generated U2OS-TLR cells stably expressing FLAG-CtIP RHR mutant used
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Abstract 
DNA double-strand breaks (DSBs) induced by clastogens can cause cell death 
or contribute to genomic instability, a major driving force of cancer. By contrast, Spo11-
dependent DSBs formed during meiosis are aimed at generating genetic diversity. In 
eukaryotes, CtIP and the Mre11 nuclease complex are essential for accurate 
processing and repair of both unscheduled and programmed DSBs by homologous 
recombination (HR). Here, we applied bioinformatics and genetic analysis to identify 
Paramecium tetraurelia CtIP (PtCtIP), the smallest known Sae2/Ctp1/CtIP ortholog, 
as a key factor for the completion of meiosis and the recovery of viable sexual progeny. 
Using in vitro assays, we find that purified recombinant PtCtIP preferentially binds to 
branched, double-stranded DNA substrates. Moreover, mutation of the evolutionarily 
conserved RHR motif abrogates DNA binding of recombinant PtCtIP but not its ability 
to physically interact with Mre11. Translating our findings into human cells, we provide 
evidence that the RHR motif is important for efficient loading of CtIP at DSBs. 
Consequently, cells expressing a CtIP-RHR mutant are defective in DSB resection 
and HR. Collectively, our work highlights minimal structural requirements for CtIP 
protein family members to facilitate the processing of DSBs, thereby maintaining 
genome stability as well as enabling sexual reproduction. 
 
Author summary 
In all living organisms, DNA repair by homologous recombination (HR) is crucial 
for achieving genetic diversity during meiosis and for maintaining genome stability in 
response to DNA double-strand breaks (DSBs). DNA-end resection is a prerequisite 
for the initiation of HR and involves the collaborative action of two protein factors: CtIP 
and the Mre11 nuclease complex. However, the mechanistic contribution of CtIP to 
DNA-end resection is still rather poorly understood. Biochemical studies have 
demonstrated that CtIP plays an important, but as-yet undefined, structural role in 
promoting DNA cleavage by Mre11. Here, we identify two miniature paralogs of the 
Sae2/Ctp1/CtIP protein family in Paramecium tetraurelia required for efficient repair of 
meiotic DSBs. Simultaneous loss of both PtCtIP genes results in impaired zygotic 
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nucleus formation and reduced viability of the sexual progeny. In addition, we show 
that PtCtIP utilizes a highly conserved RHR motif for DNA substrate binding. Mutation 
of the RHR motif in human CtIP abrogates its localization to damaged chromatin, 
resulting in reduced HR events. Our work thus establishes PtCtIP as a model minimal 
protein to gain structural insights into meiotic recombination and emphasizes DNA-
binding as an essential feature of CtIP proteins to promote DNA-end resection. 
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Introduction 
DNA double-strand breaks (DSBs) are the most lethal type of DNA damage, and, if 
incorrectly repaired, can drive tumorigenesis1. On the other hand, induction of DSBs 
by ionizing radiation (IR) or DNA topoisomerase poisons like camptothecin (CPT) 
represents a common therapeutic strategy to effectively eliminate cancer cells2. Cells 
have evolved two major pathways for the repair of DSBs: Non-homologous end-joining 
(NHEJ), which ligates broken ends without the need of extensive processing, and 
homologous recombination (HR), which requires an intact homologous DNA template 
for repair3,4. The first step of HR is termed DNA-end resection and involves nucleolytic 
processing of DSB ends to generate 3’ single-stranded DNA (ssDNA) overhangs that 
are immediately covered by the replication protein A (RPA). RPA subsequently gets 
replaced by the Rad51 recombinase, which initiates homology search and strand 
invasion5. In eukaryotes, DNA-end resection is initiated by the concerted action of the 
Mre11-Rad50-Xrs2/Nbs1 (MRX/N) nuclease complex in association with 
Sae2/Ctp1/CtIP5. 
At the protein level, human CtIP and its counterparts in other species are 
predicted to be largely intrinsically disordered, with the exception of a conserved N-
terminal coiled-coil domain that assembles into a tetrameric 'dimer-of-dimers' 
complex6,7. In addition, a short C-terminal stretch showing the highest degree of amino 
acid sequence similarity within CtIP protein members is commonly referred to as the 
'Sae2-like' domain7. Human CtIP and its functional counterparts in S. pombe (Ctp1), 
A. thaliana and C. elegans have been identified as homologs of S. cerevisiae Sae2 
(for Sporulation in the Absence of Spo Eleven), a protein that is required for the 
initiation of DNA-end resection in meiotic and mitotic yeast cells8–13. 
The biochemical properties of recombinant Sae2/Ctp1/CtIP proteins have been 
extensively studied in recent years, significantly contributing to our mechanistic 
understanding of DNA-end resection7. First, both Sae2 and CtIP were shown to 
directly associate with the MRX and MRN complex, respectively, and to stimulate 
Mre11's weak endonuclease activity in cleaving the 5' strand13–19. In a second step, 
DNA is processed in 3' to 5' direction from the nick towards the DSB end by Mre11's 
intrinsic exonuclease activity, meanwhile 5' to 3' exonucleases such as Exo1 and Dna2 
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progressively resect the 5’ DNA strand, ultimately generating a 3' single-stranded DNA 
(ssDNA) overhang compatible for Rad51 binding20–23. 
In the germline, the formation of programmed DSBs, generated by the topoisomerase-
like Spo11 protein, is required for genetic recombination during meiosis24. Throughout 
evolution, CtIP and the Mre11 nuclease complex are strictly required for meiotic 
recombination by removing covalently attached Spo11 from DSB ends and, thereby, 
allowing DNA-end resection to start25–29. 
Paramecium tetraurelia, like all ciliates, is a unicellular eukaryote that contains two 
functionally distinct types of nuclei: a large somatic macronucleus (MAC, 800n) 
responsible for gene expression, but not transmitted to sexual progeny, and two 
identical diploid germline micronuclei (MIC) that undergo meiosis during the sexual 
cycle (34). In P. tetraurelia, correct assembly of newly developing MACs requires the 
elimination of 25-30% of MIC DNA, including the precise excision of thousands of 
~45'000 short internal eliminated sequences (IES). DNA elimination is mediated 
through the sequential action of PiggyMac, a domesticated piggyBac transposase 
essential for cleaving DNA at IES ends, and the NHEJ pathway30–34. With regards to 
recombinatorial repair, a recent inventory of meiosis-specific genes in ciliates revealed 
the presence of two gene copies each for PtMRE11 and PtCtIP, consistent with 
multiple whole-genome duplication events in the early stages of P. tetraurelia 
evolution35,36. Remarkably, with a length of only 198 amino acids, PtCtIP paralogs 
would constitute the smallest Sae2/Ctp1/CtIP protein family members that have been 
identified so far. 
In the present study, we sought to characterize the function of PtCtIP in vivo and 
in vitro. Comparative sequence analysis reveals that PtCtIPa and PtCtIPb, collectively 
termed as PtCtIP, share the minimal domain architecture present in all Sae2/Ctp1/CtIP 
proteins. PtCtIP expression is required for the processing of Spo11-dependent meiotic 
DSBs, an essential prerequisite to the production of gametic nuclei and subsequent 
development of a new somatic MAC in sexual progeny. Purified recombinant PtCtIP 
binds with high affinity to double-stranded branched DNA molecules but lacks 
detectable intrinsic nuclease activity. Moreover, PtCtIP-DNA interaction, but not 
PtCtIP-Mre11 interaction, strongly depends on a highly conserved RHR motif located 
in the C-terminus. Finally, we provide evidence that the RHR motif mediates efficient 
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recruitment of human CtIP to sites of DNA damage ensuring efficient DSB resection 
and repair by HR. 
 
Results 
The Paramecium tetraurelia genome encodes two protein copies with a domain 
organization shared by CtIP homologs 
CtIP protein sequences are poorly conserved across the eukaryote phylogeny 
and vary greatly in their molecular size, particularly between yeast and mammalian 
homologs (Fig 1A). Schizosaccharomyces pombe Ctp1 (294 amino acids, aa) 
represents the smallest CtIP homolog that has been characterized so far10. To screen 
for additional members of the Sae2/Ctp1/CtIP protein family in other species, we ran 
iterative PSI-BLAST searches using as query the amino acid sequence of the 
conserved C-terminal domain of human CtIP (~75 aa). Interestingly, we retrieved two 
putative CtIP-like polypeptides in Paramecium tetraurelia comprised of only 198 aa 
sharing more than 80% sequence identity (Figs 1A and S1A). Closer examination of 
the P. tetraurelia predicted proteome indeed revealed the existence of two closely 
related CtIP paralogs, PtCtIPa and PtCtIPb (ParameciumDB accession numbers 
GSPATP00020534001 and GSPATP00027328001)37. PtCtIPa and PtCtIPb gene 
copies resulted from the most recent whole genome duplication (WGD) that took place 
before the evolutionary split of the Paramecium aurelia genus into 15 sibling species 
including P. tetraurelia 36. 
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Fig 1. Comparative protein sequence analysis of PtCtIP. 
(A) Upper panel, predicted protein scheme of Paramecium tetraurelia CtIP (PtCtIP), with putative coiled-
coil (CC) and C-terminal regions indicated in coloured boxes. Lower panel, coiled-coil-forming 
probabilities predicted by the PCOILS program (window length of 21 residues) for the indicated CtIP 
proteins. (B) Phylogenetic tree obtained from the sequence analysis of the CtIP C-terminal region from 
35 species using PhyML algorithm. (C) Sequence alignment of the C-terminal region of PtCtIPa and 
PtCtIPb with 12 CtIP proteins from different species. Gene accession numbers (gi) and species names 
are color-coded according to the phylogenetic tree shown in (B). Insertions and extensions were 
trimmed and marked by dashed lines with the number of residues indicated below. Evolutionarily 
conserved CxxC, RHR and S/TP motifs are indicated in black boxes. 
 
To gain further insight into the protein sequence and domain architecture of 
PtCtIP, we adopted a hierarchical alignment procedure allowing us to align different 
evolutionarily conserved regions of CtIP homologs. The N-terminus of PtCtIP features 
five repeating heptad sequences, which are predicted to assemble into a coiled-coil 
structure typically present in Sae2/Ctp1/CtIP proteins (Figs 1A and S1B). Moreover, 
upstream of the heptad repeats, a short α-helical region previously reported to mediate 
CtIP tetramerization can be distinguished with high confidence in PtCtIP (Fig S1B)6,7. 
The phylogenetic tree built from a multiple sequence alignment restricted to the 
conserved C-terminal domain demonstrates that PtCtIP cluster together with 
protozoan sequences, as expected, while strong sequence divergences are primarily 
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observed between ascomycetes, including S. cerevisiae Sae2 (Figs 1B and 1C). 
Closer examination of the PtCtIP C-terminal region revealed the presence of two 
conserved, closely spaced, short linear sequence motifs: CxxC and RHR (Fig 1C). 
The RHR motif, located at aa positions 181-183 of PtCtIP, was shown to promote 
DNA-bridging activity of Ctp1 in vitro7. We further noted that PtCtIP is the only family 
member lacking a C-terminal amino-acid extension after the cyclin-dependent kinase 
(CDK) consensus sequence motif (S/TP) required for DNA-end resection in yeast and 
human cells (Fig 1C)38,39. In fact, PtCtIP is devoid of any additional CDK 
phosphorylation sites, some of which were reported to promote the interaction of 
human CtIP with Nbs1 FHA/BRCT domains40. Consistent with this observation, no 
apparent homolog of Nbs1 exists in P. tetraurelia. In conclusion, our in silico 
bioinformatic analysis predicts that PtCtIP is mainly composed of the conserved N- 
and C-terminal regions of the Sae2/Ctp1/CtIP family, making it the smallest CtIP 
protein known to date. 
 
Paramecium CtIP genes are required for the recovery of viable progeny during 
autogamy 
Autogamy is a self-fertilization process encountered in the Paramecium aurelia 
group of species. Upon starvation, mature P. tetraurelia cells that have undergone at 
least 20 vegetative fissions can start MIC meiosis in the absence of a sexual partner. 
A fully homozygous zygotic nucleus is formed through the fusion of two identical 
gametic nuclei. Following two successive nuclear divisions that take place in the 
absence of cell division, two mitotic copies of the zygotic nucleus give rise to the new 
MICs while new MACs differentiate from the other two copies. We surveyed the 
expression of PtCtIP compared to PtSPO11 in P. tetraurelia cells at different autogamy 
stages. Northern blot analysis revealed an early transcription induction peak during 
MIC meiosis for both PtCtIP genes simultaneously to PtSPO11 (Fig S2A). This result 
was confirmed by deep sequencing of mRNAs (Fig 2A)41. As expected from the 
conservation of the meiosis process in Paramecium, the genome of P. tetraurelia 
carries two recently duplicated PtMRE11 genes. Northern blot hybridization and deep 
sequencing of mRNAs revealed that PtMRE11 genes have quite different patterns of 
expression: PtMRE11a (ParameciumDB accession number GSPATG00020413001) 
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exhibits a constitutively low level of expression at all stages of the sexual cycle, while 
PtMRE11b (ParameciumDB accession number GSPATG00023641001) is strongly 
induced during meiosis (Figs 2A and S2A)37. Notably, PtMRE11b levels peak at the 
same time during meiosis as both PtCtIP and PtSPO11 mRNAs (Figs 2A and S2A). 
 
Fig 2. PtCtIP genes are required for recovery of viable sexual progeny. 
(A) Steady-state levels for PtCtIP, PtSPO11 and PtMRE11 mRNA at different developmental stages. 
Curves show the average normalized values calculated for each autogamy stage (n ³ 2). RNA-Seq 
data extracted from41. Veg: vegetative cells; Mei: starved cells with meiotic stages; Frg: fragmented old 
MAC but no visible developing new MACs; Early: early stages of MAC development; Inter: intermediate 
stages of MAC development; Late: late stages of MAC development. (B) Quantification of PtCtIPa and 
PtCtIPb mRNA levels during autogamy. P. tetraurelia 51 cells were submitted to control (ND7) RNAi 
(upper panel) or to RNAi against both PtCtIPa and PtCtIPb (lower panel). Autogamy stages were 
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defined as in (A) following DAPI staining of nuclei (Fig S2B). Northern blots of total RNAs extracted at 
indicated time-points for each RNAi condition were hybridized with PtCtIPa- or PtCtIPb-specific labeled 
probes A2 or B2, respectively (Fig S2B and Table S1). Viable post-autogamous progeny yields in this 
experiment: 97%, control RNAi; 23%, PtCtIPa+b RNAi. 17S rRNA signal was used for normalization. 
Y-axes are in arbitrary units, with mRNA signals normalized to 1 at the Mei stage for both genes. (C) 
Combined depletion of PtCtIPa and PtCtIPb impairs new MAC development in Paramecium sexual 
progeny. Histograms show the fraction of sexual progeny harboring functional new MACs after silencing 
of the respective genes by RNAi. Data are presented as the mean ± SD with n between 2 and 15 for 
each condition. Statistical differences were determined by paired t-test. ns, non-significant; **P < 0.005; 
****P < 0.0001. CNTL: RNAi-mediated targeting of either ND7 or ICL7 non-essential genes. For 
simultaneous silencing of both PtMRE11 genes, different constructs were used (cross-reacting a2 and 
b2 constructs, either alone or together; gene-specific a1 and b1 constructs, together; see Table S1). 
 
To gain insight into the function of CtIP in P. tetraurelia, we used an RNAi 
strategy to silence the expression of PtCtIP genes during autogamy, individually or 
altogether. Because both genes are actively transcribed during meiosis (Figs 2A and 
S2A), vegetative growing cells were fed on dsRNA-producing bacteria and left to 
starve in the feeding medium until autogamy started. Quantitative analysis of mRNA 
levels using northern blot hybridization demonstrated an efficient RNAi-mediated 
downregulation of PtCtIPa and b (up to ~10 fold) relative to control RNAi (Figs 2B and 
S2B). During autogamy of cells silenced for the expression of both PtCtIPa and b 
genes, the development of new MACs in the sexual progeny was monitored after DAPI 
staining. Strikingly, in all PtCtIP knockdowns, a large fraction of autogamous cells 
harboured only fragments from the old MAC, but did not develop new MACs (Figs S2B 
and S2C). No MICs could be detected in these cells either, suggesting that depletion 
of PtCtIP triggers an early defect during the sexual cycle and prevents the formation 
of a functional zygotic nucleus. At later stages, cells with two MICs and a single large 
nucleus surrounded by several smaller fragments started to appear in PtCtIP 
knockdowns (orange population in Fig S2B). These could result from the overgrowth 
of a minority of viable post-autogamous progeny that succeeded in making their new 
MACs, throughout the long incubation time of each experiment (3 to 4 days).  
To check whether knockdown of PtCtIP or PtMRE11 genes has a debilitating 
effect on the ability of sexual progeny to resume vegetative growth, we measured the 
percentage of post-autogamous survivors with functional new MACs. Knockdown of 
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individual PtCtIPa or b genes did not cause any reduction of viable progeny, 
suggesting that PtCtIP genes can compensate each other (Fig 2C). However, the 
concomitant inactivation of both PtCtIPa and b expression resulted in ~30% lethality 
in the sexual progeny (Fig 2C). In contrast, silencing of PtSPO11 or PtMRE11b alone 
was sufficient to induce strong lethality in the post-autogamous progeny, consistent 
with their respective meiosis-specific expression profiles (Figs 2A and S2A). These 
results indicate that, despite its short size, PtCtIP, like PtMre11, is fully functional and 
essential for DSB repair during meiosis in P. tetraurelia. 
 
Abnormal meiosis and lack of new developing MACs in cells depleted for PtCtIP 
genes 
The complete absence of new MICs and MACs in PtCtIP knockdowns likely 
reflects an early defect in the formation of a functional zygotic nucleus. In the ciliate T. 
thermophila, SAE2/COM1 knockout was shown to block the progression of MIC 
meiosis at the meiosis I stage, as a result of defective repair of meiotic DSBs and 
inefficient pairing of homologous chromosomes, eventually leading to chromosome 
“disintegration” and MIC degeneration42. Because autogamy is poorly synchronous in 
P. tetraurelia, we switched to conjugation in order to synchronize MIC meiosis and 
zygotic nucleus formation in the population43. We used anti-γ-tubulin antibodies to 
specifically label the MICs, the zygotic nucleus and its mitotic division products44 in 
conjugating cells co-silenced for both PtCtIP genes (Fig 3A). This experiment 
confirmed that MIC meiosis proceeded normally at the cytological level, until the 4-
MIC stage (i.e. meiosis I) in a large majority of cells. Abnormal patterns started to 
appear at meiosis II, with partial or complete loss of MIC meiotic products and 
complete absence of a zygotic nucleus in a majority of mating pairs, while normal 
fragmentation of the old MAC was still observed, suggesting that no fragmentation 
checkpoint exists in P. tetraurelia. Therefore, CtIP depletion in P. tetraurelia does not 
allow the formation of a zygotic nucleus, because it triggers an arrest right after meiosis 
I. 
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Fig 3. PtCtIP silencing impairs new MAC development due to abortive meiosis. 
(A) PtCtIP RNAi during conjugation triggers a meiotic defect and impairs zygotic nucleus formation. 
Reactive cells prepared in control (ND7) or PtCtIPa+b RNAi medium were crossed at T0 and mating 
pairs were permeabilized and fixed 4.5, 6 and 7.5 hours following the start of conjugation. Fixed cells 
were pooled before proceeding to immunofluorescence staining using anti-γ-tubulin antibodies (green) 
and DAPI staining of nuclei. The progression of conjugation was monitored according to the state of the 
old MAC. Arrowheads (yellow in one partner, white in the other) point to meiotic micronuclei, or to 
zygotic nuclei and their mitotic products. 22 and 30 mating pairs were analysed for the control (ND7) 
and for PtCtIP RNAi, respectively. Numbers in orange refer to pairs in which loss of micronuclei ('Mic 
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loss') was detected in one or both partners. In the experiment shown here, 37% of mating pairs yielded 
viable progeny in the PtCtIP RNAi (100% in the control RNAi). (B) MAC development is inhibited 
following PtCtIPa+b RNAi in wild-type cells and restored at the cytological level in a SPO11 knockout 
Paramecium strain submitted to PtCtIPa+b RNAi. Cultures of isogenic wild-type and ΔPtSPO11 cells 
were allowed to undergo autogamy in control (ND7) or PtCtIP RNAi-inducing medium. The histograms 
show the progression of autogamy in the four cultures, as monitored by DAPI staining of cells at 
indicated time-points (hours), with the different cellular stages indicated below. Veg: vegetative cells; 
Mei: meiotic cells; Ske: cells with MAC skeins; Frg: cells with old MAC fragments but no visible new 
developing MACs; Dev: cells with two developing MACs; postA: post-autogamous cells with one new 
MAC and remaining old MAC fragments. Viable post-autogamous progeny yields in this experiment: 
93%, wild-type cells, control RNAi; 10%, wild-type cells, PtCtIP RNAi, 7%, ΔPtSPO11 cells, control 
RNAi; 0% ΔPtSPO11 cells, PtCtIP RNAi. 
 
In other organisms, the absence of CtIP also results in abortive meiosis, due to 
the accumulation of unrepaired Spo11-dependent DSBs. In S. pombe, ctp1 C-terminal 
mutations severely reduce the yield of viable spores26. In budding yeast, sae2∆ mutant 
cells do not form tetrads, but sporulation is restored in the sae2∆spo11∆ double mutant 
background, even though the resulting spores are not viable11,45. To get further insight 
into the meiotic function of the P. tetraurelia CtIP homologs, we knocked down 
PtSPO11 by inducing a ∆SPO11 somatic deletion (∆SPO11MAC) in strain 51 new (see 
Methods). We then submitted wild-type and ∆SPO11MAC cells to RNAi against PtCtIP 
genes and to a control RNAi against ND7. As expected, ∆SPO11MAC cells did not yield 
viable progeny in either condition (PtCtIP or control RNAi, Fig S3A). During the 
progression of autogamy, significant differences were observed between ∆SPO11MAC 
and wild-type cells (Fig 3B). In wild-type cells, PtCtIP silencing strongly impaired the 
formation of developing new MACs, as already observed. In the ∆SPO11MAC mutant 
submitted to a control RNAi, new developing MACs were detected, although not quite 
with the same efficiency as in the wild-type background. However, as indicated by the 
low survival rate in the progeny of ∆SPO11MAC cells (Fig S3A), these new MACs were 
not functional, suggesting that in P. tetraurelia, similar to other organisms, Spo11-
dependent DSBs are essential for the successful segregation of homologs during 
meiosis. A dramatic difference was observed between wild-type and ∆SPO11MAC cells 
upon the silencing of PtCtIP. Indeed, the development of new MACs, strongly impaired 
in a PtCtIP knockdown, was partially restored in the double PtSPO11 + PtCtIP 
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knockdown, indicative of a role for the Paramecium CtIP homologs in the repair of 
Spo11-dependent meiotic DSBs. Likewise, a double RNAi experiment revealed that 
MAC development is restored following PtMRE11b RNAi if cells are simultaneously 
submitted to RNAi against PtSPO11 (Figs S3B and S3C). Taken together, these 
results demonstrate a key function of PtCtIPa+b and PtMRE11b in repairing Spo11-
induced DSBs during meiosis and indicate that PtCtIP, despite its short size, is fully 
functional for promoting HR in P. tetraurelia. 
 
PtCtIP DNA-binding depends on a conserved C-terminal RHR motif 
Our genetic analyses underscored an essential role for CtIP during autogamy 
and conjugation in P. tetraurelia. In order to investigate how PtCtIP contributes to 
DNA-end resection at the molecular level, we purified full-length recombinant PtCtIPa 
protein from insect cells (Figs S4A and S4B). First, we aimed to characterize its DNA-
binding properties by in vitro gel shift assays using 5'-end radiolabelled 50-mer 
oligonucleotide substrates (Table S1). At a fixed protein/DNA molar ratio, we observed 
that PtCtIPa specifically interacts with double-stranded, but not single-stranded 
nucleic acids (Fig 4A). Further protein titration experiments revealed that PtCtIPa 
exhibits higher binding affinity for forked compared to blunt-ended DNA (Fig 4B). We 
noted that PtCtIPa-DNA complexes migrated near the top of the gel, indicative of the 
formation of rather large multimeric assemblies, in particular when considering the low 
molecular weight of Paramecium CtIP (Figs 4A, 4B and S4B). Interestingly, however, 
recent studies demonstrated that both Ctp1 and human CtIP N-terminal domains can 
form stable tetramers consisting of two coiled-coil dimers6,7. Thus, given that both 
structural motifs mediating Ctp1/CtIP tetramerization are conserved in PtCtIP (Fig 
S1B), it is conceivable to predict that recombinant PtCtIPa also exists as a tetramer in 
solution resulting in the formation of high molecular weight complexes upon DNA 
binding. Indeed, we observed a similar mobility shift behavior of Ctp1-DNA and 
PtCtIPa-DNA complexes (Fig 4B). Moreover, the fact that we were unable to 
effectively cleave off the MBP-tag from all PtCtIPa protein molecules (Fig S4B) might 
explain why the mobility shift observed for PtCtIPa is even slightly bigger compared 
with Ctp1 (Fig 4B).  
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Fig 4. PtCtIP binding to DNA requires a highly conserved RHR motif. 
(A) PtCtIP binds double-stranded DNA. Electrophoretic mobility shift assay (EMSA) was carried out 
with 10 nM of various 5’-labelled DNA substrates and 600 nM of PtCtIPa. (B) PtCtIP preferentially binds 
to forked DNA. EMSA was carried out with 10 nM of the indicated 5’-labeled DNA substrates and Ctp1 
(380 nM) or increasing concentrations of PtCtIPa (100 nM, 200 nM, 400 nM, 700 nM and 1 µM). (C) 
Alignment of the amino acid sequences adjoining the conserved RHR motif in CtIP homologs from P. 
tetraurelia (Pt), S. pombe (Sp) and H. sapiens (Hs). The R181A/R183A and R837A/R839A (AHA) 
mutations in PtCtIP and HsCtIP are indicated, respectively, above and below the alignment. (D) 
Mutation of the RxR motif in PtCtIP abolishes DNA binding. EMSA was carried out with 10 nM of 5’-
labeled forked DNA substrates and increasing concentrations of PtCtIPa wild-type (wt) or AHA mutant 
(200 nM, 400 nM, 600 nM, 800 nM and 1 µM). Ctp1 (380 nM) was used as positive control in lanes 2 
and 9. (E) MBP or MBP-tagged PtCtIPa was coupled to amylose beads and incubated with purified 
recombinant human Mre11-Rad50 (MR) complex. Mre11 and Rad50 proteins in input and pull-down 
fractions were detected by immunoblotting using the indicated antibodies. MBP and MBP-CtIP proteins 
were detected by Ponceau staining. In (A, B and D), DNA binding was calculated based on 
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disappearance of the substrate band and indicated as percentages (%) below the respective gels. 32P-
labeled strands are indicated with asterisks. 
 
Notably, employing the same radiolabeled forked-DNA substrates, we could not 
detect any DNA cleavage activity associated with recombinant PtCtIPa (Figs S4C and 
S4D). 
In addition to the N-terminal multimerization domain, Andres et al. reported a 
'RHR' DNA-interaction motif located at the Ctp1 C-terminus7. As the 'RHR' motif is 
evolutionarily highly conserved among CtIP homologs from different species including 
P. tetraurelia (Fig 1C), we expressed and purified recombinant PtCtIPa-AHA with 
R181 and R183 mutated to alanine residues (Figs 4C and S4B). Gel shift assays 
showed that the PtCtIP-AHA mutant was completely defective in binding to the forked-
DNA substrate, confirming the C-terminal RHR motif as a critical determinant of DNA-
binding by CtIP proteins (Fig 4D). Remarkably, MBP-pulldown assays revealed that 
both wild-type PtCtIPa and PtCtIP-AHA mutant are able to interact with recombinant 
human Mre11-Rad50 (MR) complex, suggesting an evolutionarily conserved mode of 
interaction between the two factors (Fig 4E). Taken together, our combined genetic 
and biochemical analysis of PtCtIP strongly supports its key role in DSB repair-related 
processes.  
 
The RHR motif in CtIP is required for DNA-end resection and HR 
The significance of the contribution of CtIP's DNA-binding ability to DNA-end 
resection and HR in human cells has so far not been investigated. Williams and 
coworkers demonstrated that S. pombe strains expressing Ctp1 RHR mutant versions 
exhibited intermediate sensitivity to various genotoxic agents and failed to reconstitute 
full-length chromosomes following IR treatment, indicating a DSB repair defect7. 
To determine whether disruption of the RHR motif in human CtIP confers cellular 
phenotypes in response to DNA damage, we generated stable U2OS Flp-In T-REx 
clones expressing doxycycline (Dox)-inducible siRNA-resistant GFP-tagged wild-type 
(wt) CtIP or a DNA binding-defective CtIP-AHA mutant (R837A/R839A; Fig 4C). 
Importantly, flow cytometry and immunofluorescence microscopy analysis revealed 
that the two cell lines display similar cell cycle profiles and GFP-CtIP nuclear 
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localisation patterns (Figs S5A and S5B). Given that recombinant PtCtIP-AHA was 
defective in DNA binding, we first examined the assembly of GFP-CtIP at DNA lesions 
induced by laser micro-irradiation. Importantly, previous studies have shown that 
Sae2/CtIP and Mre11 are independently recruited to sites of DSBs46–48. Remarkably, 
we observed that the GFP-CtIP fluorescent intensity at DSB-containing tracks marked 
with γH2AX was significantly reduced in the AHA mutant compared with the wt, 
suggesting that DNA binding is a critical determinant for CtIP retention at damaged 
chromatin (Figs 5A and S5C). CtIP is required for CPT-induced hyperphosphorylation 
of RPA2 at serines 4/8, a surrogate marker for DSB resection revealed by western 
blotting (Fig 5B, lanes 1-3)13,49. We observed that re-expression of CtIP-wt fully 
restored RPA2 hyperphosphorylation in CtIP-depleted cells, whereas the rescue with 
CtIP-AHA was only partial (Fig 5B). Of note, GFP-CtIP expression as well as ATM 
phosphorylation levels were comparable between the two cell lines, indicating 
proficient upstream DSB signalling (Fig 5B). Consistently, using a flow cytometry-
based approach to measure DNA-end resection50,51, we found that RPA retention on 
damaged chromatin is strongly reduced in AHA mutant compared to wt expressing 
cells (Fig 5C). To further evaluate the impact of CtIP DNA binding on the processing 
of replication-associated DSBs formed at collapsed replication forks, we depleted 
endogenous CtIP from our U2OS clones and measured their viability following chronic 
exposure to CPT. In agreement with previous data51, activation of CtIP-wt expression 
by Dox administration efficiently rescued CPT hypersensitivity of CtIP-depleted cells 
(Fig 5D). By contrast, cells expressing the CtIP-AHA mutant remained sensitive to 
CPT, indicative of an HR defect (Fig 5D). Finally, to directly measure HR efficiency, 
we made use of the traffic-light reporter (TLR) assay system6  and engineered U2OS-
TLR clones stably expressing siRNA-resistant FLAG-tagged CtIP-wt and -AHA (Fig 
5E). Strikingly, whereas HR and DNA-end resection were largely restored in CtIP-
depleted cells expressing CtIP-wt, they were still significantly compromised in both 
RHR-mutant expressing clones (Figs 5E and S5D), indicating that the DNA-binding 
ability of CtIP is a critical determinant of resection-dependent DSB repair by HR. 
Collectively, these findings establish that CtIP-DNA interaction via the 'RHR' motif 
promotes efficient recruitment of CtIP to DSBs, thereby facilitating DNA-end resection 
and HR in human cells. 
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 Fig 5. Mutation of the RHR motif impairs CtIP accrual at DSBs, DNA-end resection and HR. (A) 
U2OS clones harbouring inducible wt and AHA mutant GFP-CtIP were transfected with siCtIP for 48 h. 
24 h later, cells were grown on coverslips in the presence of doxycycline (Dox) and BrdU for 24 h prior 
to laser micro-irradiation. 20 min post-irradiation, cells were fixed, immunostained for γH2AX and 
counterstained with DAPI for DNA and analysed by fluorescence microscopy. Upper panel: 
representative images. Scale bar, 10 µM. Lower panel: Scatter plot of relative fluorescent intensities of 
GFP-CtIP laser stripes normalized to γH2AX stripe intensity (see Fig S5C). Data are presented as the 
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mean (indicated by red bars) ± SD. Statistical difference was determined by Mann-Whitney test; **** (P 
< 0.0001). For each condition, more than 20 cells from two independent experiments were quantified. 
(B) The same cells as described in (A) transfected with control (CNTL) or CtIP siRNA were cultivated 
for 24 hr in absence (-) or presence (+) of Dox. 48 h post siRNA-transfection, cells were mock-treated 
(lane 1) or treated with CPT (1 µM) for 1 h and whole cell lysates were analysed by immunoblotting 
using the indicated antibodies. Asterisks indicate hyperphosphorylated forms of endogenous CtIP and 
RPA2, respectively. (C) The same cells as described in (B) were treated with with CPT (1 µM) for 1 h 
and harvested for FACS analysis. Dot plots show fluorescent intensities (a.u., arbitrary units) of RPA2 
signals (y-axis) against the DNA content (x-axis). Quantification gates were established in untreated 
samples and the percentages of cells within the gates are indicated. One representative out of three 
experiments with similar results is shown. (D) The same cells as described in (A) were treated with 
indicated doses of CPT and survival was determined after 4 days using the CellTiter-Blue® cell viability 
assay. Data are represented as the mean ± SD (n = 3). (E) HR events were quantified in stable U2OS-
TLR clones expressing siRNA resistant FLAG-CtIP-wt or -AHA (two different clones). Cells were 
transfected with siCtIP and 8 h later co-transfected with IFP-I-SceI nuclease and BFP-Donor expression 
plasmids. 72 h post-siRNA transfection, cells were harvested for flow cytometry and immunoblot 
analysis. Data are represented as the mean ± SD (n = 3). Statistical differences were determined by 
ordinary one-way ANOVA test; ** (P < 0.005). 
 
Discussion 
Spontaneous or damage-induced DSBs need to be accurately repaired to 
maintain genome integrity and suppress tumorigenesis. During meiosis, however, 
hundreds of DBSs are deliberately induced by Spo11-dependent cleavage and 
subsequently repaired by homologous recombination to generate genetic diversity. In 
mammalian cells, faithful processing of both accidental and programmed DSBs 
requires the concerted action of the MRN complex and CtIP. Remarkably, while Mre11 
and Rad50 are highly conserved and present throughout evolution, CtIP-related 
proteins have so far only been identified in eukaryotes52,53. Moreover, CtIP homologs 
have rapidly diverged in primary sequence and size ranging from 294 aa (S. pombe 
Ctp1) to 897 aa (human CtIP). In this study, we have characterized the genetic and 
biochemical activities of P. tetraurelia CtIP (PtCtIP), with only 198 aa in size, 
representing the smallest member of the Sae2/Ctp1/CtIP protein family known to date. 
Our primary sequence analysis revealed that PtCtIP is basically composed of the two 
hallmark structural elements common to all CtIP proteins: an N-terminal coiled-coil 
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domain critical for dimer/tetramer assembly and a highly conserved C-terminus 
harboring a short linear motif implicated in DNA binding (Figs 1 and S1). In contrast, 
the large, intrinsically disordered middle region in human CtIP, shown to coordinate 
multiple protein-protein interactions and to harbor nuclease motifs54,55, is strongly 
contracted in PtCtIP, comprising less than 50 amino acids (Figs 1 and S1). 
Nonetheless, the miniature PtCtIP is fully functional for HR-mediated repair of meiotic 
DSBs, emphasizing the interest of this homolog as a model to disentangle the core 
function of the CtIP-MR machinery from other regulatory functions. 
 
P. tetraurelia contains two paralogous CtIP genes required for completion of 
meiotic recombination 
An essential role for CtIP-related proteins in DSB repair was first described in S. 
cerevisiae, where Sae2 acts in concert with MRX to remove Spo11-oligonucleotide 
complexes from DSB ends during meiosis11,45. Consequently, Mre11 nuclease-
deficient and sae2∆ mutant yeast strains fail to sporulate. Similar meiotic 
recombination defects were later observed for CtIP mutants in S. pombe, A. thaliana, 
C. elegans, and T. thermophila10,42,56,57. Furthermore, spore viability of 'CtIP' mutant 
cells could be partially rescued in a Spo11-deficient background in most species, 
indicating that it functions downstream of Spo11 in the repair of meiotic DSBs29. 
Due to a recent whole genome duplication event36, two closely related CtIP gene 
copies, PtCtIPa and PtCtIPb, were identified in the model ciliate P. tetraurelia37. 
Interestingly, we found that PtCtIPa and PtCtIPb gene expression profiles are 
comparable to that of PtSPO11 and PtMRE11a, displaying highest mRNA transcript 
levels in early meiosis (Figs 2A and 2B). Simultaneous silencing of both PtCtIP genes 
impaired the recovery of functional new MACs in sexual progeny to a similar extent as 
Mre11b or Spo11 knockdowns (Fig 2C), indicative of an essential function of PtCtIP 
during meiotic recombination. Specifically, we show that PtCtIP knockdown cells 
exhibit a defect in the progression of meiosis I with complete absence of new 
developing MACs at late stages of the sexual cycle (Fig 3). Strikingly, PtCtIP disruption 
in a Spo11-deleted strain partially restored the physical development of new, yet non-
viable MACs (Fig 3B), establishing that PtCtIP is a bona fide ortholog of 
Sae2/Ctp1/CtIP.  
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RHR motif is critical for PtCtIP DNA-binding and DSB resection in human cells 
We demonstrated that purified recombinant PtCtIP preferentially recognizes 
branched (or flap) DNA substrates through a highly conserved RHR motif located at 
the C-terminus in all CtIP homologs (Fig 4)7. Our gel shift assays further suggested 
that PtCtIP binds to DNA in a multimeric state, giving rise to a high molecular weight 
complex. These results are in line with structural studies establishing an N-terminal 
tetrameric oligomerization scaffold in Ctp1 and CtIP6,7, core residues of which are 
conserved in the PtCtIP protein sequence. Remarkably, while being unable to cleave 
DNA on its own, PtCtIP interacts with recombinant human MR complex, indicative of 
an evolutionary conserved protein-protein interaction module. 
It has been reported that mutations of the RHR motif in Ctp1 resulted in an 
intermediate level of DNA damage sensitivity in S. pombe strains, suggesting that 
additional factors can partially compensate for DNA-binding defects7. Here, we 
provided evidence that mutation of the RHR motif in human CtIP abrogates its spatial 
redistribution in response to DNA damage, supporting the importance of the DNA-
binding activity across different species (Fig 5A). In addition, we observed that human 
cells expressing a CtIP-AHA DNA-binding mutant display DNA-end resection and HR 
defects, ultimately resulting in profound hypersensitivity to CPT treatment (Figs 5B-E). 
Notably, however, PtCtIP-AHA mutant is proficient for MR interaction in vitro (Fig 4E), 
potentially suggesting that DNA-binding function of CtIP proteins is mechanistically 
separable from MR activation in DSB repair processes. Similarly, it was reported that 
DNA-binding of Sae2 is not necessary for the stimulation of the MRX endonuclease58. 
In conclusion, our study provides converging evidence that the minimal 
Paramecium CtIP ortholog, being deprived of most of the regulatory motifs found in 
other CtIP protein species, has retained the ability to repair Spo11-induced meiotic 
DSBs. Our combined biochemical and functional analyses further imply that the DNA-
binding activity of CtIP-related proteins is critical for the maintenance of genomic 
stability. Clearly, further investigations are required to elucidate how CtIP structurally 
integrate with the MR complex to promote efficient repair of DSBs. We propose that 
the contracted PtCtIP might provide an ideal source for high resolution structural 
analyses aiming to answer this question. 
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Methods 
Bioinformatics analysis of protein sequences 
Due to the high sequence divergence among eukaryotic CtIP orthologs, a hierarchical 
approach was used to build the global alignment. First, six sequence profiles were 
independently generated from the full sequences of CtIP proteins in vertebrates (35 
sequences), nematodes (10 sequences), plants (16 sequences), arthropods (19 
sequences), protozoa (15 sequences) and fungi (63 sequences) using the MAFFT 
v7.0 algorithm with the E-INS-i iterative refinement method59. Next, using the 
HHsearch algorithm60, these profiles were hierarchically aligned together resulting in 
a large multiple sequence alignment of 158 protein sequences. From this alignment, 
35 sequences from model organisms were extracted and trimmed so that only the 
most conserved C-terminal domain was considered for the phylogenetic tree 
reconstruction. Phylogenetic tree was calculated using the PhyML algorithm61 
focusing on the C-terminal domain spanning residues 122-198 of PtCtIP with standard 
parameters (LG model of amino acids substitution, discrete gamma model with 6 
categories and gamma shape factor of 1.729). Representation of the tree was 
performed using Dendroscope 362. Coiled-coil predictions were performed using 
PCOILS63. 
 
P. tetraurelia strains, cultivation, and gene silencing 
Autogamy and conjugation experiments were carried out at 27°C with strain 
51new64. Cells were grown in a wheat grass powder (WGP, Pines International Inc.) 
infusion medium bacterized the day before use with Klebsiella pneumoniae and 
supplemented with 0.8 µg/ml β-sitosterol. Somatic SPO11 knockout strain was 
generated as described previously65. In brief, following conjugation of reactive 51new 
cells from mating types 7 (mt7) and 8 (mt8), stable mating pairs were transferred to 
WGP medium inoculated with Escherichia coli HT115 bacteria harbouring plasmid 
PtSPO11-1 and induced for dsRNA production31. 
For RNAi-mediated gene silencing experiments during autogamy, cells were grown 
for 20 to 25 vegetative divisions under standard conditions, before transfer to WGP 
medium inoculated with HT115 bacteria harbouring the appropriate dsRNA-producing 
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plasmids66. To monitor the progression of autogamy, cells were permeabilized and 
fixed prior to DAPI staining as described33. Nuclear developmental stages were 
observed using a Zeiss Axioplan 2 Imaging epifluorescence microscope with 63x/1.4 
Plan-Apochromate or 40x/1.3 Plan-Neofluar oil objectives. The capability of sexual 
progeny to develop a functional new MAC was monitored following individual transfer 
of 30 autogamous cells to standard culture medium30. 
RNAi experiments during conjugation were performed as described31. In brief, 
reactive 51new mt7 and mt8 cells were prepared in each RNAi medium and mixed to 
start conjugation. Following 1.75 h incubation at 27°C, freshly induced RNAi medium 
was added to the mix to synchronize conjugation. Mating pairs were transferred 
manually to each RNAi medium and incubated at 27°C to complete MAC development 
and resume vegetative growth. To monitor sexual processes, conjugating cells were 
permeabilized, fixed and processed for immunostaining as described32. To reveal 
micronuclei and the zygotic nucleus during conjugation, cells were incubated for 1 h 
with primary anti-γ-tubulin antibodies (1:40044), then washed with TBST (10 mM Tris-
HCl pH 7.4, 0.15 M NaCl, 0.1% Tween) + 3% BSA prior to 15 min incubation with 
secondary Alexa Fluor 488-conjugated anti-rabbit antibodies (1:300, ThermoFisher 
Scientific), followed by DAPI staining. Imaging was performed using a Zeiss Axioplan 
2 Imaging epifluorescence microscope with a 63x/1.4 Plan-Apochromate oil objective. 
 
dsRNA-producing plasmids for silencing P. tetraurelia genes 
All RNAi plasmids are derivatives of vector L444067 and carry a target gene 
fragment between two convergent T7 promoters. Each insert was chosen in order to 
minimize the risk of cross-silencing by using the "RNAi off-target" tool of 
ParameciumDB37. Plasmids p0ND7c68, pICL7a69 and pL4440-SPO11-131 were used 
to target Paramecium ND7, ICL7a and SPO11 genes, respectively. RNAi plasmids 
targeting PtCtIP and PtMRE11 genes were constructed as follows: pL4440-PtCtIPa: 
a 354-bp fragment from PtCtIPa (nt 266-619) was amplified by PCR from total genomic 
DNA from P. tetraurelia, using primers PtCtIPa-SpeI-F and PtCtIPa-SpeI-R (Table S1) 
and the Phusion High-Fidelity DNA polymerase (New England Biolabs). Following 
SpeI-restriction, the PCR fragment was inserted into the unique XbaI site of vector 
L4440. pL4440-PtCtIPb: same cloning procedure for a 354-bp fragment from PtCtIPb 
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(nt 266-619) amplified using primers PtCtIPb-SpeI-F and PtCtIPb-SpeI-R. pL4440-
PtMRE11a1: same cloning procedure for a 492-bp fragment from PtMRE11a (IF2: nt 
1422-1913) amplified using primers PtMRE11a1-SpeI-F and PtMRE11a1-SpeI-R. 
pL4440-PtMRE11b1: same cloning procedure for a 510-bp fragment from PtMRE11b 
(IF2: nt 1420-1929) amplified using primers PtMRE11b1-SpeI-F and PtMRE11b1-
SpeI-R. pL4440-PtMRE11a2: same cloning procedure for a 507-bp fragment from 
PtMRE11a (IF1: nt 24-530) amplified using primers PtMRE11a2-SpeI-F and 
PtMRE11a2-SpeI-R. The IF1 sequence from PtMRE11a cross-reacts with PtMRE11b. 
pL4440-PtMRE11b2: same cloning procedure for a 508-bp fragment from PtMRE11b 
(IF1: nt 24-531) amplified using primers PtMRE11b2-SpeI-F and PtMRE11b2-SpeI-R. 
The IF1 sequence from PtMRE11b cross-reacts with PtMRE11a. 
 
Northern blot analysis 
Total RNA was extracted from ~400,000 cells for each indicated time point during 
autogamy of 51new cells grown in standard K. pneumoniae medium and processed 
for northern blot hybridization using 32P-labeled probes as described31. Unless 
otherwise stated, PCR fragments of PtSPO11, PtCtIPa, PtCtIPb, PtMRE11a and 
PtMRE11b RNAi-targeting plasmids were used as gene-specific double-stranded 
probes (Table S1). The sequence of the 17S rRNA oligonucleotide probe is shown in 
Table S1. Hybridization signals were collected using a Typhoon TRIO Variable Mode 
Phosphorimager (GE Healthcare). Quantification was performed using the ImageJ 
software and mRNA levels were normalized relative to 17S rRNA hybridization signals. 
Cloning, expression and purification of recombinant PtCtIPa 
The PtCtIPa open reading frame (NCBI database GI accession number 
145537105) was synthesized, cloned into pUC57 and verified by sequencing 
(GeneScript, Piscataway, NJ, USA). PtCtIPa was PCR-amplified using the primers 
listed in Table S1 and cloned into the pFastBac(FB)-MBP-His vector. PtCtIPa-
R181A/R183A amino acids substitutions were generated by site-directed mutagenesis 
using PfuTurbo DNA polymerase (Agilent Technologies) and appropriate primers 
(Table S1). Recombinant PtCtIPa proteins were expressed using the pFB-MBP-
PtCtIP-His vectors and the Bac-to-Bac baculovirus expression system (Invitrogen) in 
insect cells as described previously70. In brief, Sf9 cells (1x106 cells/ml) cultured in 
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HyClone SFX-Insect cell culture medium (GE Healthcare) were transduced with high-
titer viruses and grown for 52 h at 27°C. All subsequent steps were performed at 4°C. 
Pellets of 200 ml cultures were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 
1 mM EDTA, 1 mM DTT, 1 x Halt Protease Inhibitor Cocktail (Thermo Scientific), 1 
mM PMSF, 30 µg/ml leupeptin) and incubated stirring for 20 min before adding 0.5 
volumes of 50% glycerol. 5 M NaCl was added dropwise to the sample, to reach a 
final concentration of 300 mM NaCl, and the solution was incubated 30 min before 
centrifugation at 38,000 g for 30 min. Soluble extracts were bound to pre-equilibrated 
amylose resin (New England Biolabs, UK) for 1 h and the resin was washed with wash 
buffer (50 mM Tris-HCl, pH 7.5, 1 M NaCl, 10% Glycerol, 1 mM PMSF, 2 mM β-
mercaptoethanol, 10 µg/ml leupeptin). Proteins were eluted with wash buffer 
containing 10 mM maltose. To cleave the MBP tag, samples were incubated for 3 h 
with recombinant prescission protease (PP) expressed in E. coli and purified using 
standard procedures {Anand:2018kn}. Next, imidazole was added to a final 
concentration of 20 mM before adding 0.5 ml Ni-NTA-agarose (Qiagen). The resin was 
extensively washed with NTA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% 
glycerol, 0.5 mM PMSF, 2 mM β-mercaptoethanol, 10 mM imidazole) and proteins 
eluted with NTA buffer supplemented with 400 mM imidazole. Peak fractions 
containing PtCtIPa-His were incubated with amylose resin to remove the remaining 
uncleaved MBP-tagged PtCtIPa, pooled, and dialyzed against dialysis buffer (50 mM 
Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, 0.5 mM PMSF and 5 mM β-
mercaptoethanol). Small aliquots of the purified PtCtIPa proteins were snap frozen 
and stored at -80°C. Recombinant Mre11-Rad50 (MR) complex was expressed and 
purified as described previously71. 
 
DNA substrates 
The sequences of 50mer oligonucleotides used in DNA binding and nuclease 
assays are listed in Table S1. Where indicated, the 5′ end was labeled with T4 
polynucleotide kinase (PNK; New England Biolabs) in the presence of [γ-32P]-ATP, 
while 3′ end labeling was performed with terminal deoxynucleotidyl transferase (TdT; 
New England Biolabs) in the presence of [α-32P]-cordycepin-5′-triphosphate. 
Unincorporated nucleotides were removed using MicroSpin G25 columns (GE 
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Healthcare). The double-stranded oligo substrates were annealed by heating the 
oligonucleotides at 95°C and slow gradual cooling to room temperature in either 1x 
TdT or PNK buffer. 
 
DNA binding assay 
All steps were performed at 4°C under native conditions. Recombinant proteins 
were incubated with 10 nM of the indicated radiolabeled DNA substrates for 20 min at 
20°C in 20 µl binding buffer (20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 0.5 mM DTT, 10 
µg/ml BSA, 4% glycerol). Protein-DNA complexes were separated on a 4-20% TBE 
precast gel (Novex) for 120 min at 100 V, respectively, dried and exposed to a 
phosphor screen before imaging using a Typhon FLA 9500 scanner (GE Healthcare). 
Data were quantified with ImageQuant TL software (GE Healthcare).  
 
DNA cleavage assays 
Recombinant proteins were incubated with 10 nM of 5' or 3' radiolabelled DNA 
substrates for 60 min at 37°C in 10 µl reaction buffer (20 mM Tris-HCl, pH 7.5, 10 mM 
NaCl, 0.5 mM DTT, 10 µg/ml BSA, 4% glycerol) supplemented with either 5 mM MgCl2 
or 1 mM MnCl2. 10 nM of purified recombinant human DNA2 was used as a control. 
Nuclease reactions were stopped by adding an equal volume of 80% formamide 
loading dye. Samples were boiled for 5 min and products were separated on a 20% 
polyacrylamide gel containing 7 M urea. Gels were fixed in 1x TBE buffer containing 
10% acetic acid, 50% EtOH and 10% glycerol for 20 min, dried and exposed to a 
phosphor screen before imaging on a Typhoon FLA 9500 scanner (GE Healthcare). 
 
MBP pull-down assay 
Soluble protein extracts of Sf9 cells expressing MBP alone or MBP-PtCtIPa-His 
were incubated with amylose resin for 1 h at 4°C. Resin was washed three times with 
NTEN buffer (20 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, 0.5% NP-40) containing 300 
mM NaCl and once with TEN100 buffer (20 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, 100 
mM NaCl). MBP proteins coupled to amylose beads were mixed with 0.5 µg of 
recombinant human Mre11-Rad50 (MR) complex for 2 h at 4°C. Beads were washed 
with NTEN buffer containing 500 mM NaCl and proteins were eluted in TEN100 buffer 
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containing 20 mM maltose. Samples were analysed by SDS-PAGE followed by 
immunoblotting. 
 
Plasmids, antibodies and siRNA  
The pcDNA5/FRT/TO-GFP-CtIP-wild type (wt) and 3x Flag-CtIP-wt expression 
vectors were described previously6,51. CtIP-R837A/R839A amino acids substitutions 
were generated by site-directed mutagenesis using PfuTurbo DNA polymerase and 
appropriate primers (Table S1). All CtIP constructs are siRNA-resistant13. Antibodies 
for immunoblotting were: anti-FLAG M2 (Sigma F3165, 1:1000), anti-GFP (Santa Cruz 
B-2, 1:1000), anti-Mre11 (GeneTex 12D7, 1:1000), anti-Rad50 (GeneTex 13B3, 
1:1000), anti-TFIIH p89 (Santa Cruz S-19, 1:1000), anti-RPA2 (Calbiochem NA19L, 
1:1000), anti-phospho RPA2 (S4/S8) (Bethyl A300-245A, 1:5000), anti-phospho ATM 
(S1981) (Abcam ab81292, 1:5000). Control siRNA (luciferase 5′-
CGUACGCGGAAUACUUCGA-3′) and CtIP siRNA (5′-
GCUAAAACAGGAACGAAUC-3′)13 were purchased from Microsynth. 
 
Cell lines, cell culture, transfections and treatments 
U2OS cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml 
streptomycin. The Flp-In T-REx system (Invitrogen Life Technologies) was used to 
generate U2OS cells stably expressing siRNA-resistant GFP-tagged CtIP-wt or CtIP-
R837A/R839A under the control of a doxycycline-inducible promoter. In brief, 
pcDNA5/FRT/TO-GFP-CtIP and the Flp recombinase expression plasmid, pOG44, 
were mixed in a 1:9 ratio and transfected into U2OS Flp-In T-REx cells. 24 h later, 
cells were plated at different dilutions and 48 h post-transfection the medium was 
supplemented with 250 mg/ml hygromycin B and 12.5 mg/ml blasticidin S. The 
medium was replaced every 2–3 days and cells were selected for approximately 14 
days. Resistant colonies were picked and single-cell clones analysed for GFP 
expression by immunoblotting and immunofluorescence microscopy after 24 h 
induction of protein expression with 1 μg/ml doxycycline (Dox, Sigma-Aldrich). The 
CtIP-R837A/R839A mutation in stable U2OS cells was verified by genomic 
sequencing. U2OS-TLR cells6 stably transfected with Flag-tagged versions of CtIP 
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were grown in in the presence of 0.5 μg/ml puromycin and 0.5 mg/ml geneticin. 
Plasmid transfections were performed using the Fugene 6 transfection reagent 
(Promega) according to the manufacturer’s instructions. siRNA transfections were 
performed using Lipofectamine RNAiMax (Life Technologies) according to the 
manufacturer’s instructions. Camptothecin (CPT) was purchased from Sigma. Laser 
micro-irradiation was performed as described previously51. In brief, cells were grown 
in medium supplemented with 10 µM BrdU for 24 h. Cells were microirradiated using 
a MMI CELLCUT system containing a UVA laser of 355 nM (Molecular Machines and 
Industries). The laser intensity was set to 50% energy output and each cell was 
exposed to the laser beam for 300 ms. 
 
Immunofluorescence microscopy  
Cells grown on coverslips were fixed directly in formaldehyde (4%, w/v in PBS) 
for 15 min and permeabilized for 5 min in 0.5% Triton X-100 in PBS. Cells were 
incubated for 1 h with primary anti-H2AX-pS139 antibody (Cell Signalling 20E3, 1:500), 
followed by 1 h incubation with secondary Alexa Fluor 594-conjugated anti-rabbit 
antibody (Life Technologies, 1:1000). Coverslips were mounted with Vectrashield® 
(Vector Laboratories) containing DAPI and imaged using a Leica DM6B fluorescence 
microscope at 63X magnification. 
 
DNA-end resection assay 
Flow cytometry-based resection assay was performed as described previously51. 
Briefly, U2OS cells were transfected with CtIP siRNA. Where indicated, 24 h post-
transfection, doxycycline was added to the cells to induce the expression of GFP-CtIP. 
48 h post-transfection, cells were either mock-treated or treated for 1 h with 1 μM CPT. 
Cells were harvested, pre-extracted with 0.3% Triton-X100 in PBS for 15 min on ice 
and fixed with 4% formaldehyde (w/v) for 10 min at room temperature. Cells were 
incubated for 1 h with anti-RPA2 antibody (Calbiochem NA19L, 1:100) or anti-H2AX-
pS139 antibody (Cell Signalling 20E3, 1:200), followed by 30 min incubation with Alexa 
Fluor 647- or 488-conjugated secondary antibody (Life Technologies, 1:250) and 
counterstained with DAPI/RNase. Samples were analysed by flow cytometry on a 
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CyAn ADP 9 (Dako). Data analysis was performed using FlowJo X software (Tree 
Star). 
 
CellTiter-Blue® Cell viability assay 
Cell viability was measured as previously described51. Briefly, U2OS clones 
stably expressing doxycycline-inducible siRNA-resistant forms of GFP-CtIP were 
transfected with indicated siRNAs. 24 h post-transfection, cells were seeded in 
triplicates at a density of 500 cells/well in a 96-well plate in medium supplemented with 
1 μg/ml doxycycline. 24 h later, cells were continuously treated with indicated doses 
of CPT and grown for 4 days at 37°C. To measure viability, CellTiter-Blue® reagent 
(Promega) was added on the last day and incubated for 4 h at 37°C before 
fluorescence was measured at 560/590 nm using a microplate reader (Molecular 
Devices). 
 
Homologous recombination reporter assay   
Homologous recombination (HR) was measured using the TLR assay as 
described6. In brief, U2OS-TLR cells stably expressing siRNA-resistant forms of 
3xFLAG-CtIP were seeded at a density of 500'000 cells per 6-cm dish. 6 h after siRNA 
transfection, cells were co-transfected with 2 μg of BFP donor and 3 μg of IFP-I-SceI 
endonuclease plasmids. 3 days after siRNA transfection, cells were harvested, fixed 
in 2% paraformaldehyde/PBS for 20 min at room temperature, washed and 
resuspended in 300 ul of PBS supplemented with 1 mg/ml BSA. Flow cytometry 
analysis was performed using the LSR-Fortessa Cell Analyzer (BD Biosciences). A 
minimum of 10,000 BFP/IFP double-positive cells were scored for GFP signal 
representing HR. Data analysis was performed using FlowJo X software (Tree Star). 
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• Fig S1. PtCtIPa and PtCtIPb protein sequence analysis. 
• Fig S2. Analysis of PtCtIP, PtMRE11 and PtSPO11 expression and PtCtIP 
RNAi efficiency during autogamy. 
• Fig S3. MAC development is restored in cells silenced for both 
PtMRE11b and PtSPO11. 
• Fig S4. Recombinant PtCtIPa is devoid of intrinsic nuclease activity. 
• Fig S5. Characterization of U2OS clones stably expressing CtIP-wt and -
AHA. 
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Table S1. Oligonucleotides used in this study 
Name Sequence (5' to 3') Use 
Spo11-02-SpeI 
ggactagtATGAACTTACCATTATTGCAT
GAAGAATG 
PtSPO11-1 feeding insert and 
gene-specific probe on Northern 
blot Spo11-08-SpeI 
ggactagtGCATTTCATTTATCAAGTGAA
AATACACAG 
PtCtIPa-SpeI-F 
ggactagtCTTCTTGATAATCAACCAAAA
TCAACCAAG 
PtCtIPa feeding insert and gene-
specific probe A1 on Northern 
blot PtCtIPa-SpeI-R 
ggactagtCATTCTGGAGTTAATAGTAAT
TTTTCTTG 
PtCtIPa-1USpeI 
ggactagtATGTTTTTCTCACCTTAATTT
TAAGAATTT 
Gene-specific probe A2 on 
Northern blot (does not hybridize 
with feeding insert) PtCtIPa probe 3’ 
AAGTACTTCACTTATTGTTGTctatttatttt
attc 
PtCtIPb-SpeI-F 
ggactagtCTTATCGATAATCAACCAAAA
TCAGCTAAA 
PtCtIPb feeding insert and gene-
specific probe B1 on Northern 
blot PtCtIPb-SpeI-R 
ggactagtCATTCTGGAGTTAATAATAAT
TTTTCTTG 
PtCtIPb-1USpeI 
ggactagtATGTTTTTCGCTCCTCAATTT
CAAGAGTTC 
Gene-specific probe B2 on 
Northern blot (does not hybridize 
with feeding insert) PtCtIPb probe 3’ 
AAGTAAATCATTAAGTTTTTACTATTT
ATTTTATTC 
PtMRE11a1-SpeI-F 
ggactagtCTATCGACTAAGTTGTATCAA
TA 
PtMRE11a1 feeding insert and 
gene-specific probe (IF2 
fragment) on Northern blot PtMRE11a1-SpeI-R 
ggactagtATTCTTAGGCAAAGAGTCAT
C 
PtMRE11b1-SpeI-F ggactagtCTATCACAAAAGTTGTTTCAG PtMRE11b1 feeding insert and 
gene-specific probe (IF2 
fragment) on Northern blot 
PtMRE11b1-SpeI-R ggactagtCTAGCCATATCTAGGAAAA 
PtMRE11a2-SpeI-F 
ggactagtCATCAAAGTATTTGACTTTCA
CAAT PtMRE11a2 feeding insert 
(crossreacting with PtMRE11b) 
PtMRE11a2-SpeI-R 
ggactagtGGTTTTATACAAACATTTGAT
TAATCAG 
PtMRE11b2-SpeI-F 
ggactagtCATTAAAGTATTTGACTTTCA
AAT PtMRE11b2 feeding insert 
(crossreacting with PtMRE11a) 
PtMRE11b2-SpeI-R 
ggactagtGGTTTAATAGAAACAAAGGA
TTAATC 
17Sext_NcoI 
ACCCGTGACTGCCATGGTAGTCCAA
TACA 
17S oligo probe on Northern blot 
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A
PtCtIPa MFFSPQFQEFMENEKSIYSTLQKHLDIILANQLDFTYHSVFQLFCHISIL  50
PtCtIPb MFFAPQFQEFMEKEKSIYSSLQKHLDIILADQLDFTYHSVFQLFCHISIL  50
PtCtIPa HNTQASVFQALMKMIGSLVEQNKQTTISEVLLLDNQPKSTKFLQPNFLEI  100
PtCtIPb HNTQATVFQALMKMMGSLVEQNKQQKLNDLLLIDNQPKSAKILQPNFFEI  100
PtCtIPa FEDKQTQASKIQKPLNASEENKKISIQTEIDLPKEKVFRETVKNRKERQQ  150
PtCtIPb FEDRQTQSSKTHKLQKTNEEQKKFSIQTEVELPKEKVFREVVKNRKERQQ  150
PtCtIPa INAHECEECEQFYKALPNSNQAEKLKQDFSRHRINHKLNQEKLLLTPE    198
PtCtIPb MDAHQCEECERFYKALPNNNQTEKLKQDYSRHRMNHKINQEKLLLTPE    198
coiled-coil heptad repeats
'  '   '  '   '  '   '  '   '  'gi|145537105|P_tetra.a
gi|145553397|P_tetra.b
gi|118371089|T_thermo
gi|392896584|C_elegans
gi|4506441|H_sapiens
gi|124487005|M_muscu
gi|148227670|X_laevis
gi|528520334|D_rerio
gi|21356119|D_melano
gi|30693587|A_thaliana
gi|85088732|N_crassa
gi|67537884|A_nidulans
gi|6321263|S_cerev
gi|295442775|S_pombe
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S1 Fig. PtCtIPa and PtCtIPb protein sequence analysis.
(A) Amino acid (aa) sequence alignment of full-length Paramecium tetraurelia (Pt) CtIPa and CtIPb. N-terminal and C-terminal regions (76 aa residues each) 
are indicated by dashed lines.
(B) Sequence alignment of the N-terminal region of PtCtIPa and PtCtIPb with 12 CtIP proteins from different species. Gene accession numbers (gi) and 
species names are color-coded according to the phylogenetic tree shown in Figure 1B. Insertions and extensions were trimmed and marked by dashed lines 
with the number of residues indicated below. Conserved structural elements implicated in CtIP tetramerization and dimerization (positions 'a' and 'd' of the 
coiled-coil 'a-g' heptad repeat are highlighted in blue) are indicated in black boxes.
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Figure S2: Analysis of PtCtIP, PtMRE11 and PtSPO11 expression and PtCtIP RNAi efficiency during autogamy.
(A) Northern blot analysis of PtCtIP, PtSPO11 and PtMRE11 mRNAs during autogamy. 17S rRNA is used as loading control for each sample. Veg: 
vegetative cells. Samples were taken at the indicated time-points with respect to a reference time 0, when 50% of the cells display a fragmented old 
MAC. PtCtIP probes were A1 and B1 for PtCtIPa and PtCtIPb, respectively (Supplementary Table S1).
(B) Northern blot analysis of PtCtIPa and PtCtIPb mRNA in RNAi experiments. P. tetraurelia 51 cells were submitted to control (ND7) RNAi or to RNAi 
against both PtCtIPa and PtCtIPb. Upper panel, the histograms show the progression of autogamy, monitored by microscopic imaging of DAPI-stained 
nuclei, with the different cellular stages indicated on top. Veg: vegetative cells; Mei: meiotic cells; Ske: cells with MAC skeins; Frg: cells with old MAC 
fragments but no visible new developing MACs; Dev: cells with two developing MACs; postA: post-autogamous cells with one new MAC and remaining 
old MAC fragments. Lower panel, Northern blots of total RNAs extracted at indicated time-points for each RNAi condition were hybridized with PtCtIPa- 
or PtCtIPb-specific labeled probes A2 and B2, respectively (Supplementary Table S1). Relevant autogamy stages are indicated at the bottom: for ND7 
RNAi, the T15 time-point was selected for further quantification of PtCtIP mRNA at the “inter” stage (Figure 2C). Viable post-autogamous progeny yields 
in this experiment: 97%, control RNAi; 23%, PtCtIPa+b RNAi.
(C) Representative images of DAPI-stained nuclei of cells at T20 (control ND7 RNAi) and T25 (PtCtIPa+b RNAi) during autogamy progression as 
described in (B). Yellow arrowheads in control-depleted cells indicate developing new MACs. Numbers in parentheses indicate the number of cells at the 
corresponding stage shown in the picture relative to the total number of cells that were observed on the microscope slide.
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(A) Analysis of the progeny of wild-type and ΔSPO11MAC cells submitted to RNAi against PtCtIPa+b. Each histogram shows the percentage of 
progeny with a functional new MAC obtained for each condition (same experiment as in Figure 3B).
(B) Quantification of PtMRE11b mRNA levels in cells submitted to control ND7 or PtMRE11a+b RNAi (here a ΔSPO11 clone was used). For 
simultaneous silencing of both PtMRE11 genes, a combination of gene-specific a1 and b1 constructs was used (see Supplementary Table S1). 
The PtMRE11b-specific IF2 fragment was used as a probe for northern blot hybridizations. 17S rRNA signal was used for normalization. Y-axes 
are in arbitrary units.
(C) Progression of MAC development upon single and combined PtMRE11 and PtSPO11 gene silencing. For simultaneous silencing of both 
PtMRE11 genes, the cross-reacting b2 construct was used (see Supplementary Table S1). Monitoring of MAC development was performed 
following DAPI staining. Veg: Vegetative cells; Mei: mic meiotic stages; Ske: MAC skeins; Frg: fragmented old MAC with no visible new MACs; 
Dev: cells with two developing new MACs; postA: post-autogamous cells with one new MAC and fragments of the old MAC. Viable post-autoga-
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4.1.2 Paramecium CtIP stimulates MRE11 nuclease activity
As summarized in the manuscript, we could show that PtCtIP binds preferentially to 5’
flap DNA substrates via its RHR motif but lacks intrinsic nuclease activity. It has been
reported that Sae2 and human CtIP associates with and stimulates MRE11’s endonucle-
ase activity37,40,41,57,136. To investigate whether the same applies to PtCtIP, we performed
pulldown experiments with MBP-tagged PtCtIPa and recombinant human MRE11-RAD50
(MR) complex. As shown in the manuscript, both wild-type (wt) and the AHA DNA-binding
mutant of PtCtIPa were proficient in binding to MR, confirming an evolutionarily conserved
mode of interaction between the two factors (Figure 4.1A).
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Figure 4.1: PtCtIP binds to and stimulates human MR endonuclease activity. (A) MBP or MBP-
tagged PtCtIPa was coupled to amylose beads and incubated with purified recombinant human Mre11-
Rad50 (MR) complex. Mre11 and Rad50 proteins in input and pulldown fractions were detected by
immunoblotting using the indicated antibodies. MBP and MBP-CtIP proteins were detected by Ponceau
staining. (B) PhiX174 substrate was incubated with human MR (50 nM), human CtIP (200 nM) or
PtCtIPa (wt and AHA, 200 nM) in presence of 5 mM MnCl2 for 2 h at 37C. DNA was separated on
an agarose gel and stained with SYBR Gold. Size markers (in kb) are shown on the left site. ssc =
single-stranded circular DNA. Relative DNA cleavage (normalized to buffer alone) is indicated below
the gel. (C) PhiX174 cleavage assay as described in (B) but in presence of 5 mM MgCl2.
Using closed-circular single-stranded PhiX174 virion DNA as a substrate, human CtIP
was found to stimulate MR-dependent endonuclease activity in the presence of mag-
nesium but not manganese37. Remarkably, under the exact same assay conditions,
we observed that PtCtIPa is able to specifically enhance MR-mediated cleavage (Fig-
ures 4.1B and 4.1C). Interestingly, PtCtIP-AHA promoted MR activity to the same extent
as PtCtIPa-wt, suggesting that DNA-binding function of PtCtIP is dispensable for stimu-
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lating MR endonuclease activity. Taken together, our combined genetic and biochemical
analysis of PtCtIP support its role in DSB repair.
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4.2 Deciphering the potential regulation of SLX4 by PIN1-
mediated isomerization
4.2.1 Validation of the PIN1-SLX4 interaction
Regulation of the DDR by phosphorylation-dependent signalling is essential to maintain
genome integrity and prevent tumorigenesis271. Our lab has recently published a study
about the contribution of PIN1-mediated isomerization of CtIP in the regulation of DSB re-
pair135,254. We demonstrated that upon CDK-mediated phosphorylation of CtIP at S276
and T315, PIN1 catalyses a conformational change in CtIP, thereby controlling its DNA-
end resection function in DSB repair135. However, besides CtIP, our proteomic analysis
revealed other DDR proteins as putative PIN1 substrates, including the multidomain scaf-
fold protein SLX4. Importantly, using GST pulldown and co-immunoprecipitation assays
we could corroborate the interaction between PIN1 and SLX4 (Figure 4.2A and 4.2B).
Moreover, we observed that PIN1 binding to SLX4 is abrogated in a WW domain mutant
of PIN1 (W34A), indicating that the interaction is most likely mediated through specific
S/T-P phosphorylation sites within SLX4 (Figure 4.2A and 4.2B)272. Similarly, treating
cell lysates with lambda phosphatase (PPase) abolished the interaction between PIN1
and SLX4, further substantiating the assumption that the interaction is phosphorylation-
dependent (Figure 4.2C). Additionally, co-immunoprecipitation experiments from HeLa
nuclear extracts using anti-PIN1 antibody confirmed a robust interaction between en-
dogenous PIN1 and SLX4 (Figure 4.2D).
4.2.2 Identification of the PIN1-interaction motif in SLX4
PIN1 binding occurs within the central part of SLX4
PIN1-mediated conformational changes regulate the activities of numerous proteins, there-
by affecting diverse cellular processes, including cell cycle progression, cell growth and
various stress responses213. Therefore, in order to determine the significance of PIN1-
mediated isomerization for any given PIN1 target, it is critically important to define sub-
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Figure 4.2: SLX4 interacts with PIN1 isomerase. (A) Extracts from untreated HEK293T cells (1
mg) were subjected to GST pulldown experiments using recombinant PIN1 wild type (wt), the catalytic
dead mutant (C113A) or the phosphobinding-deficient mutant (W34A) as baits. Isolated proteins were
separated by SDS-PAGE and analyzed by immunoblotting. Equal amounts of recombinant GST-PIN1
were confirmed by Ponceau staining. (B) HEK293T cells were co-transfected with plasmids encoding
GFP-tagged SLX4 and HA-tagged PIN1. Cell extracts (1 mg) were subjected to immunoprecipitation
(IP) using HA-antibodies. Precipitated immunocomplexes were separated by SDS-PAGE and analyzed
by immunoblotting. (C) HEK293T lysates were pre-treated with lambda-phosphatase (PPase) or solvent
control and subjected to GST pulldown assays. PPase activity was inhibited by the addition of 50 mM
NaF and EDTA. Asterisks indicate unspecific bands. (D) Immunoprecipitation was performed with 1 mg
of HeLa nuclear extracts (HNE) using either protein A beads alone or beads coupled with anti-PIN1
antibodies. Immunocomplexes were analyzed by Western blotting. Blots (B-D) were kindly provided by
Dr. Lorenzo Lafranchi, a former colleague in the lab.
strate-specific PIN1 binding site(s). According to publicly available high-throughput mass
spectrometry data, human SLX4 (1834 aa) is phosphorylated at 30 out of 41 minimal
CDK consensus sites (S/T-P) scattered throughout the entire protein (source: http://
www.phosphosite.org). Thus, to narrow down the region in SLX4 critical for PIN1 bind-
ing, we first screened different FLAG-tagged SLX4 truncation mutants for their ability to
interact with PIN1 (provided by Dr. Agata Smogorzewska, Rockefeller University, US)273.
GST-PIN1 pulldown experiments revealed that the first 800 amino acids in SLX4 are dis-
pensable for PIN1 binding (Figure 4.3A).
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Figure 4.3: PIN1-SLX4 interaction motif lies within the low complexity region of SLX4. (A)
HEK293T cells were transfected with FLAG-tagged SLX4 constructs covering different stretches of
the protein sequence. Cell extracts were subjected to GST-PIN1 pulldown assays using either PIN1 wt
or W34A mutant and bound proteins were analyzed by immunoblotting. (B) Truncated protein variants
derived from the FLAG-SLX4 801-1834 construct were tested in a GST-PIN1 wt pulldown applying the
same experimental procedure as in (A). (C) The binding ability of SLX4 S/T-P cluster mutants to GST-
PIN1 wt was analyzed by GST-PIN1 pulldown. Same experimental approach as in (A). (D) Summary of
the results of GST-PIN1 pulldown experiments shown in A-C.
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To further map the interacting region, we generated several C-terminal deletion mutants
by introducing Stop-codons into FLAG-SLX4_801-1834. We found that SLX4_801-1296
failed to interact with PIN1, whereas longer fragments were proficient in PIN1 binding,
albeit with quite variable efficiency (Figure 4.3B). To more specifically focus on SLX4
phosphorylation sites, we applied SLX4 S/T-P cluster mutants in which multiple serines
or threonines adjacent to proline residues were mutated to alanines (6A, 19A, 22A and
35A; provided by Dr. Joao Matos, ETH Zurich)192. In large agreement with our previous
mapping analysis, we found that PIN1 is proficient in binding to the 6A and 19A mutant but
severely impaired in binding to the SLX4-22A and -35A mutant (Figure 4.3C and 4.3D).
Collectively, these findings indicate that PIN1-SLX4 interaction is mediated by one or
multiple phosphorylated S/T-P sites located within a 200 aa long stretch between residues
1300-1500 (Figure 4.3D).
Analysis of single S/T-P motifs within SLX4 potentially required for PIN1 binding
The region in SLX4 responsible for mediating PIN1 interaction is overall poorly conserved
and contains 13 potential S/T-P phosphorylation sites (Figure 4.3D). Therefore, we next
took an unbiased approach and generated YFP-tagged full-length SLX4 expression con-
structs harboring individual single S/T to A substitution mutations. Unfortunately, using
GST-PIN1 pulldown assays, we found that none of the mutants exhibited reduced PIN1
binding, indicating that PIN1 most likely binds to several S/T-P motifs in this region (Fig-
ures 4.4A-C). Of note, we observed reduced amounts of PLK1, a known SLX4 interactor
(Figure 1.6), when the pulldown was performed with SLX4-S1452A/S1453A, encompass-
ing the mutated ’SSP’ polo-box domain binding motif (Figure 4.4C, lane 9)46. This finding
suggests that PIN1 binds to the SLX4-PLK1 complex but, at the same time, that PLK1-
dependent SLX4 phosphorylation is dispensable for PIN1-SLX4 interaction.
T1315 and T1320 are sufficient for binding of PIN1 to SLX4
It has been proposed that substrate binding of PIN1 occurs via the WW domain and iso-
merization is mediated by the PPIase domain217,274. If these steps happen in a sequential
manner or simultaneously is still unclear214. However, it is likely that multiple S/T-P sites
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Figure 4.4: PIN1-SLX4 interaction does not depend on a single phosphorylated S/T-P motif. (A-
C) Whole cell lysates of HEK293T cells transfected with the indicated YFP-tagged SLX4 single S/T to
A mutant constructs were subjected to GST-PIN1 pulldown (PD) experiments. Bound proteins were
separated by SDS-PAGE and analyzed by immunoblotting.
are required for efficient PIN1-mediated isomerization214,272. For instance, CtIP phos-
phorylation at two neighboring sites are responsible for PIN1 binding135. Therefore, we
assessed whether combined mutation of closely spaced S/T-P sites in SLX4 abrogate
PIN1 interaction. Unfortunately, none of the tested double and triple S/T-P motif mutants
displayed reduced PIN1 binding (Figure 4.5A and 4.5B).
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Figure 4.5: Double and triple S/T-P mutations do not abolish PIN1-SLX4 interaction. (A) and (B)
HEK293T cells were transfected with indicated YFP-tagged SLX4 constructs harboring either single
or combined mutations. Cell extracts were subjected to GST-PIN1 pulldown (PD) assays and bound
proteins analyzed by Western blot.
Intriguingly, high-throughput proteomics analysis revealed that T1315 and S1329 are by
far the most predominant phosphorylation sites in human SLX4, repeatedly scoring in
independent mass spectrometry screens (Figure 4.6).
T1315
S1329
Figure 4.6: Schematic SLX4 protein with illustrated scorings of PTM from mass spectrometry screens.
Number of records in which the indicated PTMs were determined using proteomic discovery mass
spectrometry. Adapted from phosphosite.org.
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We further noticed that most of the SLX4 phosphorylation sites potentially implicated in
PIN1 interaction (including T1315 and S1329) are not conserved in mouse or frog SLX4
but appear rather primate-specific (Figure 4.7).
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Figure 4.7: Alignment of SLX4 orthologs arising from BLAST searches with human SLX4 1288-1346.
Red boxes indicate S/T-P motifs. Numbers indicate records in which the corresponding site was as-
signed by phosphoproteomics to be phosphorylated.
At first glance, this is somewhat surprising. However, a similar scenario has been re-
ported for the TRF2 binding motif in SLX4, which is conserved in primates but not in
other mammalian species including mouse197. As we were unable to identify SLX4 S/T-P
mutants abrogating PIN1 interaction, we changed our approach and reconstituted func-
tional S/T-P motifs at T1315 and T1320 into the SLX4-22A cluster mutant defective in
PIN1 binding (see Figure 4.3C). Strikingly, incorporating functional S/T-P motifs at T1315
and at T1315/T1320 in SLX4-22A, resulting in SLX4-21A and 20A, respectively, restored
SLX4 binding to PIN1 (Figure 4.8), indicating that these two phosphorylation sites are
sufficient for PIN1 interaction.
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Figure 4.8: S/T-P motifs T1315 and T1320 are sufficient for PIN1 interaction. Reconstituting wild-type
T1315 (21A) or T1315/T1320 (20A) into the compound SLX4-22A mutant restored PIN1 binding in
GST-pulldown assays.
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PIN1-SLX4 interaction is direct and dependent on phosphorylation
Next, we aimed to investigate whether PIN1-SLX4 interaction is indeed direct or poten-
tially mediated through an unknown accessory protein. To this end, immunoprecipitated
FLAG-SLX4 was subjected to far-western blotting using recombinant GST-PIN1. Inter-
estingly, PIN1 was efficiently binding to SLX4-wt but not to SLX4-22A, indicative of a
direct physical link between SLX4 and PIN1 mediated by S/T-P phosphorylation motifs
(Figure 4.9A). Prompted by this promising result, we tested the binding ability of GST-
PIN1 to FLAG-SLX4 harboring the minimal PIN1-interaction region (aa 801-1383, see
Figure 4.3B) using far-western blotting. In line with our pulldown experiments, PIN1 as-
sociated with SLX4 801-1383 but not with SLX4 801-1296, (Figure 4.9B). Importantly,
the binding was abrogated following treatment of SLX4 with lambda phosphatase but
rescued in presence of phosphatase inhibitors (Figure 4.9B), further substantiating that
phosphorylation of multiple S/T-P motifs located within residues 1296-1383 (including
T1315, T1320, T1326, S1329 and S1342, see Figure 4.3D) is critical for SLX4-PIN1 in-
teraction.
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Figure 4.9: PIN1-SLX4 interaction is direct and phosphorylation-dependent. (A) Anti-FLAG im-
munoprecipitates from HEK293T cells transfected with FLAG-tagged CtIP and SLX4 variants were sub-
jected to far-western analysis using purified GST-PIN1 as a probe followed by anti-GST immunoblotting.
After stripping, the same membrane was reprobed using anti-FLAG antibody. 22A is the SLX4 phos-
phorylation cluster mutant (kind gift of Dr. Joao Matos, ETH Zurich). (B) Same experimental procedure
as in (A) after transfection of FLAG-tagged SLX4 truncation mutants. SLX4 truncation constructs bound
to FLAG-beads were either incubated in the presence of phosphatase-inhibitors or treated with lambda-
phosphatase before eluted and subjected to far-western analysis.
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In conclusion, our results suggest that SLX4 and PIN1 physically interact in a phospho-
rylation-dependent-manner and that SLX4-T1315 is a critical residue supporting PIN1
binding.
4.2.3 Establishing a phospho-SLX4 (T1315) antibody
The S/T-P site comprising T1315A is the phosphorylation site scoring highest in in-
dependent mass spectrometry screens (Figure 4.6). In order to test whether T1315
is indeed phosphorylated in vivo we ordered customized phospho-specific antibodies.
To this end, Creative Biolabs immunized rabbits with a phospho-epitope (CSVIRPQ(p-
T)PPPQT-NH2) and we subsequently tested the specificity of the obtained antibodies
using whole cell extracts or YFP-SLX4 enriched protein fractions. The antibody raised
against pT1315 specifically recognized YFP-SLX4-wt but not the SLX4-2A protein, har-
boring the T1315A/T1320A mutation, indicating that T1315 is most likely phosphorylated
in vivo (Figure 4.10).
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Figure 4.10: Phospho-specific antibody recognizes SLX4 when phosphorylated at T1315A. Ex-
tracts (1 mg) from HEK293T cells transfected with YFP-tagged SLX4 -wt or -T1315A/T1320A (2A) for
48 h were subjected to a GFP-trap with subsequent immunoblotting.
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4.2.4 Investigating the potential role of PIN1 in regulating SLX4 function
PIN1 is not regulating known SLX4 protein-protein interactions
PIN1 provides a molecular timer to regulate the function of many phosphoproteins by al-
tering protein-protein interactions275. SLX4 is known to be a scaffold protein for various
nucleases engaged in multiple protein-protein interactions with some of them being regu-
lated by phosphorylation185,276. For instance, the assembly of SLX4 with MUS81-EME1
occurs at the entry of M phase mediated by CDK phosphorylation of EME147. Further-
more, phosphorylation of SLX4 at S/T-P sites within its SAP motif (residues 1540-1623)
are important for MUS81 binding during mitosis192,277. The interaction with the kinase
PLK1 is suggested to be dependent on S145346. Moreover, it was shown that SLX4 in-
teracts via S1260 with TOPBP1 in a CDK-dependent manner constituting a crucial step
to recruit SLX4 to chromatin278.
Thus, we wanted to interrogate whether the binding of specific partners of SLX4 are con-
trolled by PIN1. To this end, we performed anti-FLAG co-immunoprecipitations from cells
transiently transfected with FLAG-SLX4 and HA-tagged PIN1 expression constructs (wt,
W34A: binding-deficient mutant, C113A: isomerase-dead mutant). However, PIN1 over-
expression did not alter SLX4 interactions with PLK1, MUS81, TRF2 (Figure 4.11A), XPF
or SLX1 (Figure 4.11B). Similar results were obtained when endogenous SLX4 interac-
tions were analyzed following knockdown of PIN1 (Figure 4.11C). Of note, PIN1 could
not be retrieved in any of the anti-SLX4 co-immunoprecipitates tested, suggesting a very
transient interaction between the two proteins (Figures 4.11A-C). Interestingly, however,
we observed that overexpression of PIN1 mutants caused a reduction in FLAG-SLX4
protein levels (Figures 4.11A and 4.11B).
Given that PIN1 was shown to regulate the stability of many of its substrate proteins,
we investigated whether PIN1 regulates SLX4 protein turnover. Our preliminary analysis
revealed that knockdown of PIN1 accelerates SLX4 degradation in presence of the trans-
lation inhibitor cycloheximide, suggesting that PIN1 may protect SLX4 from proteasomal
degradation (Figure 4.12). Clearly, further experiments are required to verify a potential
role for PIN1 in stabilizing SLX4 molecules.
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Figure 4.11: PIN1 status has no major effect on the interaction between SLX4 and PLK1, MUS81,
TRF2, XPF and SLX1. (A) HEK293T cells were co-transfected with plasmids encoding FLAG-SLX4 wt
and HA-tagged PIN1 variants or empty vector (EV) instead. Cell extracts were subjected to immunopre-
cipitation (IP) using FLAG-antibodies. Precipitated immunocomplexes were separated by SDS-PAGE
and analyzed by immunoblotting. SE= short exposure, LE= long exposure. (B) Same experimental
approach as in (A) but immunoblotting was performed for different proteins. (C) HEK293T were trans-
fected with siluc (control) or siPIN1. 48h later, immunoprecipitation was performed with 1 mg of cell
extracts using either protein A beads (p. A) alone or beads coupled with anti-SLX4 antibodies. Im-
munocomplexes were analyzed by Western blotting. Experiments shown in (B) and (C) were performed
by Dr. Lorenzo Lafranchi (Sartori Lab).
PIN1 is not regulating SLX4 localization to telomeres
Chromosome ends are protected by DNA structures called telomeres to ensure ge-
netic stability and to counteract replication-dependent degradation of genetic informa-
tion. Telomeres consist of short tandem DNA repeats ending in a single-stranded 3’
overhang, which are covered by the shelterin complex279. The shelterin complex pro-
motes the formation of a telomeric loop structure (called the T-loop) thus protecting
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Figure 4.12: Knockdown of PIN1 affects SLX4 protein stability. HEK293T cells transfected with
siluc (control) or siPIN1 were treated with 50 µg/ml cycloheximide (CHX) for the indicated times (in
hours) and whole cell lysates were analyzed by immunoblotting using the indicated antibodies.
the telomeres from being misidentified as DNA breaks. In addition, the complex facil-
itates telomere maintenance. Especially in telomerase-negative cancer, cells counter-
act telomere attrition by alternative lengthening of telomeres (ALT), a mechanism de-
pendent on homologous recombination280. These cells aim to achieve homeostasis of
HR-dependent synthesis of new telomeric DNA versus ’telomere trimming’, to not risk
generation of too long or too short telomeres. The shelterin complex consists of several
DNA-binding proteins, most prominently TRF2, which prevent chromosome end-to-end
fusions279. Via its TRFH domain, TRF2 recruits also non-shelterin proteins important
for telomere maintenance281,282. It was reported that SLX4-SLX1 complex interacts and
colocalizes with TRF2 at telomeres, mediating the resolution of certain DNA structures
(D-loops)197,283, leading to a cleave-off the T-loop and by that playing a role in telom-
ere trimming46,197,199,200,276. It is suggested that disruption of the SLX4-TRF2 interaction
causes telomere fragility, as cells from SLX4-/- mice exhibit very long and fragile telom-
eres197,199.
Thus, we wondered if SLX4 function at telomeres is regulated by phosphorylation-depen-
dent isomerization. To examine whether PIN1 regulates context-dependent subnuclear
localization of SLX4, we generated U2OS cells inducibly expressing siRNA-resistant
YFP-SXL4 (kindly provided by Dr. Pierre-Henri Gaillard, Centre National de la Recherche
Scientifique, France)196. Importantly, we were able to confirm telomeric localization of
SLX4 by indirect immunofluorescence microscopy using either anti-TRF2 antibodies or
FISH analysis with a Cy3-labeled telomeric probe (Figures 4.13A and 4.14A).
100
Results
B C
U2OSYFP-SLX4 + Dox
%
 
o
f a
nt
i-G
FP
/P
NA
 
fo
ci
PNA-probeanti-GFP Merge
siCNTL
siPIN1
siSLX4
+Dox
CtIP
PIN1
TRF2
GAPDH
GFP
+Dox-Dox
A
100
50
0
siCNTL siPIN1 siSLX4
nss
iC
NT
L
siP
IN
1
siS
LX
4
siC
NT
L
siP
IN
1
siS
LX
4
1 2 3 4 5 6
Figure 4.13: Knockdown of PIN1 does not affect SLX4 telomeric localization. (A) Representative
immunofluorescence microscopy images of U2OS Flp-In T-REx cells stably expressing Dox-inducible
YFP-SLX4, transfected with indicated siRNA oligos. A Cy3-labeled PNA-probe was used for fluorescent
in-situ hybridization to visualize telomeres. Simultaneously, the YFP-labeled SLX4 was detected using
anti-GFP antibody. (B) Same cells as in (A) were subjected to immunoblotting. (C) Quantification
of YFP-SLX4 foci visualized using anti-GFP staining colocalizing with the telomeric probe (as in A)
was performed using a customized CellProfiler 270 pipeline as described in Figure 4.15 and statistics
calculated in Graphpad Prism. Data are presented as mean ± s.d. Numbers of cells analyzed: siluc =
100, siPIN1 = 135, siSLX4 = 37.
Acquired microscopic images were analyzed using CellProfiler, an open-source software
tool for quantitative analysis of biological images, to extract the number of colocalizing
foci270.
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Figure 4.14: Overexpression of PIN1 does not affect localization of SLX4 to TRF2. (A) Repre-
sentative immunofluorescence microscopy images of U2OS Flp-In T-REx cells stably expressing Dox-
inducible YFP-SLX4, transfected with plasmids encoding for HA-PIN1-wt or W34A. Cells were stained
with anti-TRF2 antibodies. (B) Same cells as in (A) were subjected to immunoblotting. (C) Same cells
as in (A) were analyzed by immunofluorescence microscopy and YFP-SLX4 foci colocalizing with TRF2
foci were assessed using CellProfiler automated foci counting. Data are presented as mean ± s.d.
Numbers of cells analyzed: EV = 76, HA-PIN1 wt = 156, HA-PIN1 W34A = 95.
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Figure 4.15: Customized CellProfiler pipeline setup. Single nuclei were identified and used to mask
the pictures from channels of SLX4 and TRF2 (or the telomeric probe). Subsequently, SLX4 foci were
identified and outlines of TRF2 foci determined in each single nucleus. As a last step, SLX4 foci were
used as a mask to detect SLX4 foci positive for TRF2 and the information extracted.
To identify nuclei (DAPI channel) and the number of YFP-SLX4 foci colocalizing with ei-
ther TRF2 foci or the telomeric PNA-probe we generated a customized analysis pipeline
as illustrated in Figure 4.15.
However, neither PIN1 depletion (Figures 4.13A-C) nor PIN1 overexpression (Figures 4.14A-
C) caused any significant change in telomeric localization of SLX4. Conclusively, our re-
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sults suggest that PIN1 in general, but most likely also its interaction with SLX4, is not
critical for telomere maintenance. This data is also consistent with our previous finding
that overexpression of PIN1 (wt or catalytic dead) is not affecting SLX4-TRF2 interaction
(see Figure 4.11A). To completely rule out a role for PIN1 in affecting SLX4 function at
telomeres, further analyses have to be performed measuring telomere length, such as
Telomere Restriction Fragment analysis and Telomere Repeat Amplification284.
HeLa cells overexpressing SLX4-T1315A/T1320A undergo increased mitosis
Although not strictly required for PIN1 binding, we have identified T1315 and T1320 as
potential PIN1 interaction motifs in SLX4. It has been shown that the interplay SLX4
with its nucleases differ between cell cycle stages, suggesting cell cycle-specific func-
tions45,285,286. In yeast, association with Dpb11 (TOPBP1), Rtt107 and the nuclease
SLX1 is S-phase specific and is proposed to have a role in dampening the DNA dam-
age checkpoint, while the assembling with Mus81 is promoted in M phase to resolve
DNA joint molecules285. Indeed, SLX4 has a prominent role in resolving under-replicated
regions and joint molecules in mitosis to ensure chromosome segregation and preserva-
tion of genome integrity47,286,287. Moreover, cells lacking SLX4-MUS81 were shown to
exhibit defects in chromosome segregation and concomitant micronucleus formation278.
At the onset of mitosis, the SLX4-MUS81 complex is brought to chromatin via TOPBP1
in a CDK1-regulated fashion278,288. In addition, PLK1- and CDK-dependent phosphory-
lation controls complex formation of SLX4 with MUS81 in G2/M, an important step which
is normally suppressed by Wee1 during S phase to prevent unscheduled processing of
replication intermediates192. These reports clearly showed that SLX4 functions are gov-
erned by cell-cycle-dependent phosphorylation events. Because PIN1 is a known driver
of mitotic progression and depletion of PIN1 promotes premature entry into mitosis233,234,
we aimed to investigate whether PIN1-mediated isomerization might add another layer of
complexity to SLX4 regulation during G2/M transition and mitosis.
To this end, we created stable HeLa clones inducibly expressing siRNA-resistant YFP-
SLX4-wt and T1315A/T1320A (2A) double mutant (Figure 4.16A). First, screening of
clones expressing SLX4-T1315A/T1320A by immunofluorescence microscopy analysis
103
Results
did not reveal any change in SLX4 localization and foci formation compared to SLX4-wt
cells (Figure 4.16A).
HeLaYFP-SLX4 + Dox
merge
wt
2A
YFP-SLX4
tubulin
SLX4-pT1315
-Dox +Dox 
YPF-SLX4 wt 2A wt 2A
GFP
1 2 3 4
A
B HeLaYFP-SLX4 
Figure 4.16: (A) Representative immunofluorescence microscopy images of HeLa Flp-In T-REx cells
stably expressing YFP-SLX4-wt and T1315A/T1320A (2A) mutant (clone 7) grown in the presence of
Dox for 24 h hours before fixation. (B) Extracts from same cells as in (A) were subjected to immunoblot-
ting using the indicated antibodies.
To confirm that SLX4 is phosphorylated in our HeLa clones, we made use of the phospho-
specific antibody raised against pT1315 (Figure 4.10). Indeed, our results indicate that
YFP-SLX4-wt is phosphorylated, whereas the YFP-SLX4 T1315A/T1320A mutant (2A) is
not (Figure 4.16B).
Remarkably, in the course of our microscopic inspection, we noticed that HeLa cells
expressing YFP-SLX4-2A revealed a higher frequency of cells displaying condensed
metaphase chromosomes compared to wild-type cells (Figure 4.17).
To substantiate these findings, we monitored the level of histone H3 phosphorylation at
S10, a surrogate marker of cells undergoing mitosis, using immunoblotting. Consistent
with our immunofluorescence data, overexpression of SLX4-2A resulted in increased H3-
pS10 levels compared to YFP-SLX4-wt (Figure 4.18A). To assess whether the increase in
H3-pS10 levels is dependent on SLX4-2A expression levels, we titrated the Dox concen-
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Figure 4.17: HeLa cells overexpressing YFP-SLX4-T1315A/T1320A (2A) display elevated number of
mitotic cells. Immunofluorescence microscopy of HeLa Flp-In T-REx cell clones stably expressing doxy-
cycline (Dox)-inducible YFP-SLX4-2A mutant. Cells were cultivated in the presence of 1 µg/ml Dox for
24 h before being fixed, permeabilized and imaged. Merged image is shown.
trations in the culturing media (Figure 4.18B). Interestingly, we observed that H3-pS10
induction correlated with higher amounts of SLX4-2A mutant but not of SLX4-wt.
To further corroborate these findings, we applied flow cytometry analysis of HeLa clones
expressing similar levels of SLX4-wt and -2A (clone 7) (Figure 4.18A) and also displayed
similar percentage of YFP-positive cells (Figure 4.19A). Upon gating for YFP/H3-pS10
double-positive cells, we observed a two-fold increase of the mitotic fraction in cells ex-
pressing SLX4-2A (Figure 4.19B). Of note, as endogenous SLX4 is still present in both
cell lines, we speculated that SLX4-2A is acting in a dominant-negative manner to block
cells in mitosis. However, as the 2A mutant is still proficient in interacting with PIN1, it
remains to be established whether this phenotype is linked to dysregulation of SLX4 by
PIN1. During mitosis, SLX4 is homogenously distributed among the nucleus in contrast
to its foci-formation in interphase (Figure 4.17). Investigating mitotic cells means to focus
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Figure 4.18: Expression of YFP-SLX4 T1315A/T1320A but not wt did result in increase in H3-
pS10 level. (A) U2OS Flp-In T-REx or HeLa Flp-In T-REx cells inducibly expressing YFP-SLX4 wt or
T1315A/T1320A were cultivated in the presence or absence of 1 µg/ml Dox for 24 h. Lysates were
subjected to immunoblotting using the indicated antibodies. SE = short exposure time, LE = long
exposure. (B) wt and clone 7 of YFP-SLX4 T1315/T1320A cells were cultivated in the absence or
presence of increased Dox (0 – 1000 ng/ml) concentrations. 24 h later, cells were lysed and subjected
to immunoblotting using the indicated antibodies.
on a small population, thus more experiments are needed to analyze SLX4 localization
patterns between mitotic from interphase cells. Therefore, we are currently establish-
ing a method combining flow cytometry analysis with immunofluorescence microscopy.
This would equip us with the ability to analyze highly heterogeneous samples and rare
subpopulations in a flow cytometry format and to simultaneously determine cell cycle
distribution, signal intensity and subnuclear localization patterns.
In conclusion, our observation that expression of YFP-SLX4-2A mutant triggers increased
mitosis, suggest that T1315 phosphorylation of SLX4, involved in promoting PIN1 binding,
is required to ensure proper mitosis.
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Figure 4.19: HeLa clones expressing YFP-SLX4-wt and -2A mutant (clone 7) were cultivated in the
presence or absence of 1 µg/ml Dox for 24 h. Cells were permeabilized, fixed, immunostained with anti-
H3-pS10 antibodies and analyzed by flow cytometry analysis. Quantification gates were established in
untreated samples. Data are presented as mean HeLa ± s.d (n=4). (A) Percentage of YFP-positive
cells. (B) Mitotic index of YFP-positive cells. To illustrate equal amount of mitotic cell before YFP-SLX4
induction, cells cultivated in the absence of Dox were gated for H3-pS10. After induction of protein
expression gating was set to double-positive YFP/H3-pS10 cells.
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Discussion and Outlook
5.1 Investigating the biochemical function of CtIP in DSB repair
In the first part of my Ph.D. thesis, we characterized Paramecium tetraurelia CtIP (PtCtIP),
representing the shortest known CtIP ortholog in evolution. Remarkably, multiple se-
quence alignments revealed that PtCtIP largely consists of the conserved N- and C-
terminal domains but lacks most of the internal, intrinsically disordered region containing
multiple PTMs and short linear motifs mediating protein-protein interactions. In collabora-
tion with the group of Dr. Mireille Bétermier (Institut de Biologie Intégrative de la Cellule,
France), our goal was to validate PtCtIP as a true CtIP ortholog and examine its phys-
iological role in vivo. Moreover, we aimed to investigate the biochemical properties of
PtCtIP in vitro and address whether a highly conserved C-terminal RHR motif is required
for the repair of DSBs by HR.
P. tetraurelia encodes two PtCtIP paralogs (PtCtIPa and PtCtIPb) that have emerged from
the most recent whole genome duplication event. We found that both PtCtIP genes are
induced during autogamy. During the sexual cycle of P. tetraurelia, meiotic processes
take place during the formation of the zygote, giving rise to the MICs and a new MAC.
Microarray analyses revealed early transcription of both PtCtIPa and PtCtIPb during MIC
meiosis, which we confirmed by deep sequencing of mRNA and northern blot analysis.
To get insights into the function of the PtCtIP genes, we used an RNAi strategy to silence
their expression during autogamy. The simultaneous inactivation of PtCtIPa and PtCtIPb
resulted in a significant decrease in viability of sexual progeny, meanwhile individual gene
silencing did not show any effect. Consequently, we concluded that the paralogs are func-
tionally redundant during meiosis.
109
Discussion and Outlook
Microscopic monitoring of P. tetraurelia autogamy stages demonstrated a pronounced
meiotic defect upon co-silencing of PtCtIPa and PtCtIPb. Autogamous cells depleted for
PtCtIP displayed old MAC fragmentation and a defect in new MAC development. Ad-
ditionally, MIC generation was also impaired. The complete absence of new MICs and
MACs likely reflected an early defect in the formation of the zygotic nucleus.
In large agreement with our findings, COM-1 knockout in Tetrahymena thermophila was
shown to block the progression of MIC meiosis as a result of defective meiotic break re-
pair and inefficient pairing of homologous chromosomes289. In budding yeast, Sae2∆
and Mre11 nuclease-defective mutants were unable to resect meiotic DSBs with SPO11
covalently attached to the break site290,291. Furthermore, mutant strains displayed sen-
sitivity towards DSB-inducing agents292. However, sporulation could be restored in a
Sae2∆/SPO11∆ double mutant background, even though the resulting spores were not
viable101,102. Taking advantage of a ∆SPO11 somatic strain subjected to RNAi silencing
of PtCtIP genes, we could show that new MACs developed, although these MACs were
not functional indicated by the low survival rate in the progeny. This demonstrated the
importance of the CtIP-mediated cleavage ability to initiate resection at Spo11-induced
DSB ends that are otherwise inaccessible for subsequent repair steps. These results co-
incided with previous findings of CtIP counterparts in other organisms and corroborated
the assumption of PtCtIP being a functional ortholog of CtIP in P. tetraurelia with impor-
tant implications in the repair of Spo11-dependent meiotic DSBs37,104–106. Nevertheless,
it would be important to determine if PtCtIP is also required for cell survival upon induc-
tion of DSBs in vivo. For instance, a pilot experiment could be performed to examine
hypersensitivity of P. tetraurelia wild-type and PtCtIP knockdown cells following exposure
to DSB-inducing agents, such as CPT or MMC.
Our study further highlighted P. tetraurelia as a model organism to study DNA repair
processes, particularly considering its unique separation of MAC and MIC genome and
the enormous genome rearrangements during each sexual cycle. The development of
a MAC is a complex process in which the 2n MIC genome is amplified to approximately
800n and internal eliminated sequences (IES), which are transposon-like sequences, are
removed prior to chromosome fragmentation and telomere addition260,293. IES excision
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is facilitated by cleavage on each site of the sequence and was shown to generate DSBs
with 4 nts 5’ overhangs294. It was demonstrated that the broken DNA ends align and
undergo limited processing before being repaired by employing a cut-and-close mech-
anism similar to NHEJ to ensure functional somatic chromosomes. Until now, several
essential factors have been identified in P. tetraurelia to process DNA ends during IES
excision, many of them known for their DNA repair functions in other organisms such as
Ku70/8010,260. Thus, it would be interesting to investigate whether CtIP plays a role in the
5’ end processing of the DNA or is implied in bridging of IES ends.
In the context of this project, we aimed to investigate DNA binding and cleavage proper-
ties of recombinant PtCtIP as well as its interaction with the MR complex in vitro. Previ-
ous attempts to express PtCtIP in bacteria yielded low amounts of soluble protein. We
therefore switched to a baculovirus-insect cell expression system with the capacity to
produce high levels of recombinant proteins with PTMs approaching that of mammalian
cells. Based on the functional redundancy of the two PtCtIP paralogs in vivo, we de-
cided to focus our biochemical studies on PtCtIPa. However, as PtCtIPa and PtCtIPb
only share 80% sequence identity, it could be worth exploring whether PtCtIPb behaves
identical to PtCtIPa in terms of DNA binding. Our tandem affinity purification strategy,
utilizing N-terminal MBP- and C-terminal His-tags, provided good yields of pure recombi-
nant PtCtIPa-wt and PtCtIPa-AHA, harboring a mutated RHR motif. Employing mobility-
shift assays, we showed that PtCtIPa, presumably in a multimeric state, efficiently binds
to double-stranded DNA substrates with a slight preference towards flap-structures. In
large agreement with this, a C-terminal region of human CtIP (aa 769 to 897) contain-
ing the RHR motif was previously reported to possess DNA-binding ability in vitro108.
In contrast, the PtCtIP-AHA mutant failed to produce shifted bands, emphasizing that the
evolutionarily highly conserved RHR motif is required for DNA binding. These findings are
in line with a recent study in fission yeast, identifying a ’RHR’ DNA binding motif104,107.
Sae2/CtIP collaborates with MRX/N in DSB processing. In the proposed bidirectional
DNA-end resection model, CtIP stimulates the endonucleolytic activity of MRN to gener-
ate a nick in the 5’ strand. Then, MRE11 continues to exonucleolytically degrade the DNA
towards the break. As a second step, exonucleases such as EXO1 and DNA2-BLM start
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at the generated nick to resect the same strand in a 5’ to 3’ direction40,41,136. Whether
CtIP has intrinsic nuclease activity has been debated extensively. Interestingly, it has
been reported earlier that CtIP and Sae2 exhibit endonuclease activity in vitro139,140,295.
However, an increasing number of publications provide strong evidence arguing against
CtIP being an endonuclease57,107,126,136. In fact, we could not detect any nuclease activ-
ity associated with recombinant PtCtIPa. The different findings might, at least partially, be
explained by the different protein purification protocols used. However, Daley et al. did
not observe nuclease activity in recombinant human CtIP despite using same expression
construct and purification protocol as described by Makharashvili et al.126,139.
Remarkably, in cross-species experiments, we found that PtCtIP functionally interacts
with recombinant human MR complex and moderately stimulates its endonuclease activ-
ity in vitro. It was recently reported that MR endonuclease activity is greatly enhanced by
NBS1 and by CtIP phosphorylation at T84757. To our great surprise, we could not iden-
tify an open reading frame encoding for an NBS1 ortholog in P. tetraurelia, suggesting
that NBS1 is dispensable for MR and CtIP-dependent DSB processing in this organism.
Along that line, a recent study in C. elegans showed that NBS-1 is not essential for Spo11
removal from DSBs, suggesting an MR-independent function during meiotic recombina-
tion121. With regards to the potential role of CtIP phosphorylation in facilitating DSB
processing, alignment of the PtCtIP amino acid sequence revealed the presence of T196
located at the very C-terminal end, potentially corresponding to the T847 in human CtIP
(Figure 5.1).
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Figure 5.1: Sequence alignment of the C-terminal region of PtCtIPa and PtCtIPb with 12 CtIP proteins
from different species.
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Consequently, phosphorylation of T196 in PtCtIP may be required for efficient stimulation
of MR. However, as protein expression in insect cells should increase the chance of intact
PTMs, we speculate that PtCtIP-T196 is either not phosphorylated or that our purification
scheme is incompatible with retaining phosphorylated residues.
An important goal of our study was to translate our findings from P. tetraurelia to human
cells. Previously, it has been reported that mutation of the RHR motif in S. pombe Ctp1
leads to cellular hypersensitivity to DNA-damaging agents107. Consistently, CtIP-AHA
expressing human cells demonstrated reduced capability for DNA-end resection and HR
repair and displayed hypersensitivity to CPT treatment. Interestingly, disruption of the
RHR motif in human CtIP resulted in its defective localization to sites of DNA damage,
indicating that DNA binding is a critical determinant for efficient localization of CtIP to
DSBs. To distinguish in more detail whether initial recruitment of CtIP to DSBs or rather
retention of CtIP at damaged chromatin is affected in the RHR mutant, we consider ap-
plying live cell imaging analysis of GFP-tagged CtIP (wt vs. AHA) in combination with UV
laser-induced DSB damage.
Intriguingly, the PtCtIP-AHA mutant is proficient in MRN binding and stimulation in vitro,
despite its inability to bind DNA. These findings suggest that the DNA-binding function
of CtIP most likely serves another purpose in DSB repair than to simply enhance MRN
endonuclease activity. However, as our in vitro assays were performed with recombinant
proteins using naked DNA substrates, we cannot exclude the possibility that DNA-binding
of CtIP acts cooperatively with MR to promote DSB processing in the context of damaged
chromatin in live cells. Indeed, we found that human CtIP-AHA mutant is largely defective
in accumulating at DSBs generated by micro-laser irradiation. In addition, we observed
that disruption of the RHR motif in human cells does not fully abrogate DSB resection
and HR repair, suggesting that additional DNA binding sites in CtIP may compensate.
There is increasing biochemical evidence suggesting that DNA tethering function of CtIP
and MRN is critical for HR. For example, CtIP/Ctp1 were found to form tetramers in so-
lution able to bridge DBS ends in vitro 107,108,296. Crystallographic analyses revealed the
formation of dimer-to-dimer tetrads mediated by the coiled-coil segments located in the N-
terminal part of the protein107,296. Andres et. al further reported that the tetramerization
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domain and the length of the internally disordered region are crucial for Ctp1 bridging
activity in vitro 107. Our gel mobility shift assays indicated that PtCtIP binds to DNA in
an oligomeric state, further corroborating the assumption that protein tetramerization is
an important and evolutionary conserved feature of CtIP proteins. The MRN complex
promotes DSB repair by tethering of the DSB strands holding them in close proximity
for subsequent processing113,114,297,298. Recently, MRN was found to bridge DSBs on a
broken chromatid with its intact sister chromatid, thereby assisting chromatid recombina-
tion147.
Taking into consideration the bidirectional model of DNA-end resection, many questions
arise as to how DSB tethering by CtIP, MRN or CtIP-MRN together guides DSB pro-
cessing to promote efficient HR. For instance: Does MRN-CtIP-mediated DNA bridging
causes the formation of a certain DSB structure/configuration (e.g. a loop) that is favour-
ing further processing and HR repair? Does CtIP remain at the nick, that is generated by
the MRN endo activity, in order to bridge DNA molecules while MRN leaves the nick to ex-
onucleolytically degrades the DNA? Alternatively, CtIP’s DNA binding ability might coordi-
nate the second step, which is called long-range resection. Interestingly, CtIP was shown
to directly interact with proteins involved in long-range resection, such as BLM helicase
and EXO1. Interestingly, while binding of CtIP to BLM increases BLM helicase activity
and simultaneously stimulates DNA2 nuclease activity, CtIP restrains EXO1 exonuclease
activity126,127. Taken together, elucidating mechanistic details of the CtIP-MRN interac-
tion and its interconnection with DNA binding and cleavage is extremely challenging and,
to our opinion, would ultimately require the availability of high-resolution structures of
MRN-CtIP complexed to DNA.
As PtCtIP comprises a stripped-down version of the human CtIP protein, consisting of
only 198 amino acids, it might facilitate in-depth structural and biochemical analysis.
Hence, to gain insights into structural conformation and considering the feasibility to ob-
tain high yields of soluble PtCtIP protein from insect cells, solving the three-dimensional
structure of purified recombinant PtCtIP alongside with MR complex or/and DNA sub-
strates would lead to a better understanding of the function of CtIP in DNA bridging and
interaction with MR.
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5.2 Deciphering the potential regulation of SLX4 by PIN1-
mediated isomerization
In the second part of my PhD thesis, we aimed to uncover how SLX4 functions in genome
stability maintenance are controlled by combined site-specific phosphorylation and sub-
sequent PIN1-mediated isomerization. The peptidyl-prolyl isomerase (PPIase) PIN1 be-
longs to a class of enzymes that catalyse cis/trans isomerization, thereby controlling a
broad range of protein functions. Interestingly, PIN1 was shown to regulate diverse bi-
ological processes, including cell cycle progression, cell growth and various stress re-
sponses213,225. Further studies associated PIN1 overexpression and its regulatory iso-
merization activity with tumorigenesis244,250–253. However, our knowledge of the implica-
tions of PIN1-mediated isomerization in the DDR is very limited299. Interestingly, a cur-
rent study found PIN1 to control anti-apoptotic activity of ATR at mitochondria upon UV
exposure255. Furthermore, PIN1 inhibits phosphatase activity of PP2A during DNA dam-
age repair in S-phase256. Additionally, our lab demonstrated that PIN1-mediated isomer-
ization promotes CtIP ubiquitination and subsequent proteasomal degradation, thereby
controlling DSB repair pathway choice135. The former study was launched following an
unbiased mass spectrometry-based approach to identify novel PIN1 interactors, of which
CtIP and SLX4 were ranked among the top candidate hits135.
SLX4 is a multi-domain scaffold protein for several structure-specific nucleases involved
in the cleavage of ICLs, resolution of HJs as well as in the trimming of telomeric
loops106,186,200,276. Consistent with our mass spectrometry screen, we found a robust
and direct phosphorylation-dependent interaction between PIN1 and SLX4. As PIN1 ex-
clusively binds to and isomerizes phosphorylated S/T-P motifs in its target proteins, a
major goal of this project was to identify PIN1 binding site(s) in SLX4. Unfortunately, the
fact that SLX4 contains 41 potential S/T-P phosphorylation sites made it a rather tedious
process to unveil the responsible PIN1 binding motif(s). Using SLX4 S/T-P cluster mu-
tants and truncation mutants enabled us to narrow-down the PIN1 interacting region to
a 200 aa stretch of SLX4 encompassing 13 S/T-P sites. However, none of our single
or double S/T-P mutants displayed decreased PIN1 interaction, suggesting that a spe-
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cific combination of multiple phosphorylated S/T-P sites in this region is responsible for
PIN1 binding. In line with that, CtIP-pT315 serves as a docking site for PIN1, meanwhile
CtIP-pS276 is the major isomerization site135. These and other findings reported in the
literature implied a scenario in which PIN1 binds pS/T-P motifs via its WW domain to fa-
cilitate isomerization of one or several pS/T-P motifs in close proximity214. In fact, we still
have to proof that PIN1 can indeed isomerize SLX4 molecules, which we plan to do using
partial proteolysis assays135,300.
Interestingly, by reintroducing intact phosphorylation sites into a SLX4-22A S/T-P cluster
mutant defective in PIN1 binding, we could show that T1315 and, to a lesser extent,
T1320 are sufficient for PIN1 interaction. Moreover, we have developed a phospho-
specific antibody specifically detecting SLX4-wt but not SLX4-T1315A/T1320A (2A), pro-
viding us with a powerful tool to investigate the signalling mechanisms regulating SLX4-
T1315 phosphorylation, and, consequently, SLX4 isomerization. In detail, we plan to
follow SLX4-T1315 phosphorylation levels during cell cycle progression and identify the
protein kinase responsible for SLX4-T1315 phosphorylation.
Analyses of HeLa cells stably expressing inducible YFP-SLX4-2A revealed a roughly two-
fold increase in the mitotic index compared to cells expressing YFP-SLX4-wt, suggesting
that these sites are important for cells to properly undergo mitosis and cytokinesis. To
corroborate our findings, we will conduct time-lapse microscopy experiments in order to
monitor spatial distribution of YFP-SLX4 during the cell cycle. Additionally, we plan to
make use of the ImageStreamX (Amnis) to analyze the mitotic fraction in a more elab-
orate way. It would be interesting to investigate whether this mitotic arrest is caused by
aberrant chromosome segregation as it was reported that SLX4 promotes resolution of
underreplicated regions and joint molecules in mitosis to ensure mitotic progression and
cell division47,192,286. To do so, SLX4 associates with MUS81 with kinases CDK1 and
PLK1 acting as a timer for MUS81-SLX4 assembly to promote cleavage of persisting
replication intermediates at the onset of mitosis192. Although our findings indicate that
PIN1 does not affect interaction of SLX4 with MUS81, the question arises to whether
PIN1 is implicated in controlling SLX4’s function during mitosis.
Besides serving as a scaffold for structure-specific nucleases, SLX4 interacts and is re-
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cruited to telomeres via TRF2, a member of the shelterin complex, important for telomere
maintenance198,283. Surprisingly, also the TRF2 motif in SLX4 located in the central re-
gion of the protein is primate-specific, and so are the phosphorylated S/T-P motifs scoring
the highest in high-throughput mass spectrometry data. That prompted us to investigate
if the telomeric localization of SLX4 is regulated by phosphorylation-dependent isomer-
ization. However, neither PIN1 overexpression nor knockdown altered the telomeric local-
ization pattern of SLX4, suggesting that PIN1 is not governing SLX4 function in telomere
maintenance.
Upon replication fork stalling, ATR is activated and promotes fork repair301. However,
when ATR is inhibited, stalled forks collapse due to SLX4/MUS81-dependent nucleolytic
cleavage, resulting in an increased number of DSBs and resection-dependent nascent-
strand ss-DNA formation201,302. Noteworthy, the versatile functions of the SLX4 complex
at damaged DNA, stalled forks and telomeres are controlled through its interaction with
ubiquitinated or SUMOylated proteins via UBZ or SIM motifs. Furthermore, SLX4 was
shown to contain SUMO E3 ligase activity that SUMOylates itself and XPF-ERCC1194,196.
Interestingly, SLX4 SIMs are located close to the region important for PIN1 interaction,
suggesting a potential crosstalk between SLX4 isomerization and sumoylation. The
SUMO-related functions of SLX4 are not essential for ICL repair but are responsible for
the accumulation of DSBs after replication fork stalling. In addition, PLK1 was also shown
to lead to replication fork collapse in ATR-deficient cells upon replication stress, suggest-
ing that PLK1 enhances activity of SLX4 or makes DNA replication fork structures more
accessible for subsequent cleavage201. Therefore, it could be interesting to investigate
the effect of PIN1 on the SUMOylation function of SLX4 and to test the effect of PIN1
depletion or overexpression in replication fork restart or collapse by fiber analysis and
BrdU/EdU pulse labeling. Interestingly, our interaction studies revealed the co-existence
of a PIN1-SLX4-PLK1 tripartite complex, indicating that PIN1 and PLK1 may act in con-
junction to regulate SLX4 function(s) in a phosphorylation- and cell cycle-dependent man-
ner, most likely during G2/M transition and in mitosis.
Mutations of SLX4/FANCP are associated with Fanconi Anemia (FA), a rare recessive
genetic disease characterized by predisposition to cancer and bone marrow failure84.
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Consequently, cells lacking SLX4 are hypersensitive to ICL-inducing agents and display
increased chromosomal instability, cellular hallmarks of FA276,303. Whether SLX4 phos-
phorylation at T1315 and other residues critical for PIN1 binding is critical for the repair of
ICLs remains another key open question. To address this issue, we consider employing
clonogenic survival assays and metaphase spread analysis upon MMC treatment in cells
expressing S/T-P mutants. However, first and foremost, it will be of utmost importance to
generate an SLX4 mutant clearly defective in PIN1 binding. To this end, we are currently
in the process of making an SLX4-5A mutant, with residues T1315, T1320, T1326, S1329
and S1342 simultaneously substituted with alanine residues. If this mutant fails to inter-
act with PIN1, cell lines will be generated stably expressing SLX4-5A and phenotypically
analysed (e.g. SLX4 PPIs, SLX4 stability, telomere fragility, ICL repair, etc.)
In summary, the second Ph.D thesis project highlights prolyl isomerization as potential
mechanism for controlling SLX4 activity, We believe that a detailed investigation of the
PIN1-SLX4 regulatory axis will be important for evaluating the therapeutic potential of
PIN1 inhibitors in cancer.
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Small Molecule Therapeutics
A Short BRCA2-Derived Cell-Penetrating Peptide
Targets RAD51 Function and Confers
Hypersensitivity toward PARP Inhibition
Anika Trenner, Julia Godau, and Alessandro A. Sartori
Abstract
Under conditions of genotoxic stress, cancer cells strongly
rely on efﬁcient DNA repair to survive and proliferate. The
human BRCA2 tumor suppressor protein is indispensable for
the repair of DNA double-strand breaks by homologous
recombination (HR) by virtue of its ability to promote RAD51
loading onto single-stranded DNA. Therefore, blocking the
interaction between BRCA2 and RAD51 could signiﬁcantly
improve the efﬁcacy of conventional anticancer therapies.
However, targeting protein–protein interaction (PPI) inter-
faces has proven challenging because ﬂat and large PPI surfaces
generally do not support binding of small-molecule inhibi-
tors. In contrast, peptides are more potent for targeting
PPIs but are otherwise difﬁcult to deliver into cells. Here, we
report that a synthetic 16-mer peptide derived from the BRC4
repeat motif of BRCA2 is capable of blocking RAD51 binding
to BRCA2. Efﬁcient noncytotoxic cellular uptake of a nona-
arginine (R9)-conjugated version of the BRC4 peptide inter-
feres with DNA damage–induced RAD51 foci formation and
HR. Moreover, transduction of the BRC4 peptide impairs
replication fork–protective function of BRCA2 and triggers
MRE11-dependent degradation of nascent DNA in response
to DNA replication stress. Finally, the BRC4 cell-penetrating
peptide (CPP) confers selective hypersensitivity to PARP
inhibition in cancer cells but spares noncancerous cells.
Taken together, our data highlight an innovative approach to
develop novel peptide-based DNA repair inhibitors and estab-
lish BRCA2-derived CPPs as promising anticancer agents.
Mol Cancer Ther; 17(7); 1392–404. 2018 AACR.
Introduction
Double-strand breaks (DSB) are highly detrimental DNA
lesions because, if left unrepaired or misrepaired, they can
trigger cell death and genomic instability, ultimately causing
cancer (1). To circumvent this threat, cells are equipped with
diverse DSB repair mechanisms, including nonhomologous
end joining (NHEJ) and homologous recombination (HR) as
the two major pathways (2). Furthermore, recent work has
established that in response to DNA replication stress, several
key HR factors play a crucial role in protecting stalled DNA
replication forks from nucleolytic degradation (3). Because
rapidly dividing cancer cells rely on efﬁcient DSB repair and
fork protection mechanisms for their survival, inhibiting HR
represents an attractive strategy for the development of novel
therapeutic drugs, in particular when used in combination with
DNA-damaging agents (4, 5).
The human BRCA2 protein plays an essential role in HR by
promoting homology search and stimulating strand invasion
into the sister chromatid (6). Speciﬁcally, following DNA-end
resection, BRCA2 directs RAD51 ﬁlament nucleation onto
RPA-coated single-stranded DNA (ssDNA; ref. 7). RAD51 inter-
acts with two distinct regions in BRCA2, the BRC repeat motifs
and a C-terminal domain (8–10). Importantly, the eight evo-
lutionarily conserved BRC repeats, each consisting of about
35 amino acids, signiﬁcantly differ in their capacity to bind
RAD51 with BRC4 displaying the highest afﬁnity (11, 12).
Consequently, it was proposed that BRC repeats 1–4 facilitate
nucleation of RAD51 by binding monomeric RAD51 and
reducing its ATPase activity (11, 13). Structural analysis of the
BRC4 repeat identiﬁed residues 1523-GFHTASG-1529 of
BRCA2 to structurally mimic the self-oligomerization motif
of RAD51 (14). In addition to the FHTA motif, a second
consensus tetrameric module in BRC4, denoted as LFDE motif,
was shown to bind to a distinct pocket in RAD51 distant from
the oligomerization interface (15). In contrast to the BRC
repeats, the C-terminal domain does not bind monomeric
RAD51 but instead stabilizes RAD51 nucleoprotein ﬁlaments
(9, 10). Taken together, compounds that selectively and efﬁ-
ciently block BRCA2–RAD51 interaction could advance into
the clinic as bona ﬁde HR inhibitors for both monotherapy and
add-on therapy with DNA-damaging agents.
The physical nature of protein–protein interaction (PPI) inter-
faces often renders them unable to support binding of small-
molecule inhibitors (SMI). Instead, peptide therapeutics offer an
alternative way to target PPIs with key advantages over SMIs,
including their direct similarity to protein fragments and the
coverage of extensive PPI interfaces (16). However, poor mem-
brane permeability has previously limited their use to extracel-
lular targets (17). Thus, hydrophilic peptides are reliant on a
permeation-enhancing strategy that facilitates targeting of intra-
cellular molecules (18). Recently, cell-penetrating peptides (CPP)
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have been developed to enhance the cellular uptake and nuclear
translocation of membrane-impermeable cargo molecules (19).
They comprise a highly diverse class of short, primarily cationic
peptides that combine a limited cytotoxicity and the ability to
mediate receptor-independent transport of cargoes across cell
membranes (20). Notably, the nona-arginine (R9) peptide is one
of the most potent CPPs, giving a high transduction efﬁciency
combined with low cytotoxicity (21).
Here, we design a CPP comprised of a 16-amino acid stretch
of the BRCA2 BRC4 repeat able to inhibit BRCA2–RAD51
interaction. Our detailed functional analysis reveals that an
R9-fused BRC4 CPP prevents RAD51 loading onto ssDNA,
resulting in defective homology-mediated repair of DSBs as
well as increased MRE11-dependent degradation of stalled DNA
replication forks. Consequently, peptide incubation renders
cells hypersensitive to the PARP inhibitor olaparib, providing
a potential use for BRCA2-derived peptides in the treatment of
certain types of cancer.
Materials and Methods
Cell culture
HeLa, U2OS, RPE1, MRC5 (all from ATCC), and HeLa
DR-GFP were cultured in DMEM (Gibco) supplemented
with 10% FCS (Sigma-Aldrich), 100 U/mL penicillin, and
100 mg/mL streptomycin (Life Technologies). PEO1 and PEO4
cells were purchased from the Health Protection Agency Cul-
ture Collections and cultured in RPMI medium (Gibco) sup-
plemented with 10% FCS, 2 mmol/L sodium pyruvate (Gibco),
and penicillin/streptomycin. MCF10A cells were purchased
from ATCC and cultured in DMEM/F12 (Gibco) containing
5% Horse Serum (Gibco), 20 ng/mL human EGF (Sigma-
Aldrich), 0.5 mg/mL hydrocortisone (Sigma-Aldrich), 10 mg/mL
insulin, and penicillin/streptomycin. Stable U2OS cells expres-
sing GFP-RAD51 (22) were grown in DMEM supplemented
with 10% Tet system approved FCS (GIBCO) and penicillin/
streptomycin. To induce GFP-RAD51 expression, cells were
treated with 1 mg/mL doxycycline (Sigma-Aldrich) for 24 hours.
All cell lines were conﬁrmed to be free of mycoplasma con-
tamination on a regular basis (PCR Mycoplasma Test Kit,
AppliChem). Cells were passaged for no longer than 2 months
after thawing of early-passage stocks. For cells that have been
received from secondary sources, no cell line authentication
was performed. Irradiation was performed using a Faxitron
X-ray machine.
Chemicals and peptides
Camptothecin, RAD51 inhibitor B02 (23), cycloheximide,
hydroxyurea (HU), and mirin (24) were purchased from Sig-
ma-Aldrich. Olaparib (AZD2281) was provided by Selleck
Chemicals. Thymidine analogs CIdU, IdU, and EdU were
purchased from Sigma-Aldrich and Life Technologies, respec-
tively. Custom-designed peptides were purchased from
Bachem AG and, if not speciﬁed, synthesized according to
standard practice (L-amino acids, N-terminal tag or acetylation,
C-terminal amidation). Lyophilized peptides were dissolved in
PBS at 1 mg/mL.
Antibodies
A detailed list of all primary and secondary antibodies can be
found in Supplementary Tables S1 and S2, respectively.
siRNA
A detailed list of siRNA oligonucleotide sequences used in
this study can be found in Supplementary Table S3. siRNA
oligos were used at a ﬁnal concentration of 10 nmol/L and
transfected using Lipofectamine RNAiMAX (Invitrogen) accord-
ing to the manufacturer's instructions.
Recombinant protein expression
BRCA2GST-fusion plasmids (GST-BRC1-2, GST-BRC3-5, GST-
BRC6-8, GST-C-term) have been described before (25). BRCA2
GST-fusion proteins were expressed in BL21-CodonPlus-RIL
Escherichia coli (E. coli) by growing them overnight at 18C using
100 mmol/L isopropyl b-D-thiogalactoside. Recombinant full-
length RAD51 was prepared as described previously (26).
Immunoblotting
If not speciﬁed otherwise, cells were lysed in Laemmli buffer
(4% SDS, 20% glycerol, 120 mmol/L Tris-HCl pH 6.8) and
resolved by Tris-glycine SDS-PAGE. To probe for BRCA2, 3%–
6%NuPAGE Tris-Acetate gels (Thermo Fisher Scientiﬁc) were run
according to the manufacturer's instructions. After transfer to
nitrocellulose membranes, immunoblotting was performed with
indicated primary antibodies overnight at 4C and secondary
antibodies for 1 hour at room temperature. Stained proteins
were visualized using the Advansta WesternBright ECL reagent
and the VilberLourmat Fusion Solo S imaging system.
Pull-down assays
For peptide pull-downs, 30 mL streptavidin-coupled Dyna-
beads (Life Technologies) were incubated with 5 mg (2.7 nmol)
of biotinylated BRC4 peptides or biotin analogue d-desthio-
biotin (Sigma-Aldrich) in 1 mL PBS-T (0.1% Triton X-100) for
1 hour at 4C. Beads were washed three times with PBS-T
and blocked for 30 minutes with 0.3% BSA in PBS at 4C. A
total of 50 ng (1.35 pmol) recombinant RAD51 together with
2 mmol/L ATP was added to the beads and incubated for 2 hours
in 700 mL PBS-T. The beads were washed four times with
NTEN300 (20 mmol/L Tris pH 7.4, 0.1 mmol/L EDTA,
300 mmol/L NaCl, 0.5% NP-40) and once with TEN100
(20 mmol/L Tris pH 7.4, 0.1 mmol/L EDTA, 100 mmol/L
NaCl) before complexes were boiled in 2 SDS sample buffer
(10 mmol/L Tris pH 6.8, 20% glycerol, 3% SDS, 200 mmol/L
DTT, 0.04% bromophenol blue) and subjected to immuno-
blotting. For GST pull-down assays, glutathione sepharose
beads (GE Healthcare) were incubated for 1 hour at 4C with
equalized amounts of BL21 E. coli soluble extracts expressing
one of the four GST-BRCA2 fusion constructs in TEN100.
Beads were washed three times with NTEN300 buffer and once
with TEN100 before adding either 1 mg HeLa nuclear extracts
(CilBiotech) or 50 ng puriﬁed RAD51 supplemented with vary-
ing amounts of BRC4wt or BRC4mut peptides ﬁlled up to 1 mL
with TEN100. After 2 hours of incubation, beads were washed
twice with NTEN500 (20 mmol/L Tris pH 7.4, 0.1 mmol/L
EDTA, 500 mmol/L NaCl, 0.5% NP-40), twice with NTEN300,
and twice with TEN100 buffer before boiling in SDS sample
buffer and protein analysis by immunoblotting.
Coimmunoprecipitation
Cell extracts were prepared using NP-40 extraction buffer
[50 mmol/L Tris-HCl pH 7.5, 120 mmol/L NaCl, 1 mmol/L
EDTA, 6 mmol/L EGTA, 15 mmol/L sodium pyrophosphate
and 1% NP-40 supplemented with phosphatase inhibitors
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(20 mmol/L NaF, 1 mmol/L sodium orthovanadate), and pro-
tease inhibitors (1 mmol/L benzamidine and 0.1 mmol/L
PMSF)]. After benzonase (Novagen) digestion for 30 minutes
at 4C, cell extracts were cleared by centrifugation. Lysates
(2 mg) were supplemented with increasing amounts of peptides
ﬁlled up to 1 mL with NP-40 extraction buffer and incubated for
1 hour at 4C before adding 20 mL GFP-Trap agarose beads
(ChromoTek) for 1 hour at 4C. Beads were subsequently
washed three times with GFP-IP buffer (100 mmol/L NaCl,
0.2% NP-40, 1 mmol/L MgCl2, 10% glycerol, 5 mmol/L NaF,
50 mmol/L Tris-HCl pH 7.5) and boiled in SDS sample buffer
for analysis by immunoblotting.
Peptide transfection
Cells were seeded either into 8-well chamber imaging slides
(m-Slide 8 Well, ibidi), 24-well plates, 6-well plates, or 6-cm
culture dishes (Sarstedt) and grown to around 80% conﬂuence
at day of peptide transfection. Cells were washed at least once
with PBS to remove residual FCS and incubated with indicated
peptide concentrations in appropriate serum-free medium
for 1 hour at 37C. If not speciﬁed otherwise, the following
incubation volumes were used: 0.3 mL for 8-well chamber
imaging slides and 24-well plates, 0.5 mL for 12-well plates
and 2 mL for 6-well plates and 6-cm culture dishes.
Confocal microscopy
A total of 4  104 cells were seeded into 8-well chamber
imaging slides and grown overnight. After 30 minutes of staining
with 0.5 mg/mL Hoechst 33342 (Life Technologies), cells were
washed twice with PBS and incubated with indicated peptide
concentrations. Cells were washed twice with PBS and imaged in
Live Cell Imaging solution (Thermo Fisher Scientiﬁc). Images
were taken with CLSM SP5 Mid UV-VIS Leica with 63 objective
at 37C at ambient CO2 concentrations.
Flow cytometry
EdU incorporation was analyzed using the Click-it EdU
technology (Thermo Fisher Scientiﬁc) according to the man-
ufacturer's instructions. For peptide uptake studies, 1  105
cells were seeded into 12-well plates. The day after, peptide
transfection was performed and cells were harvested by tryp-
sinization to remove membrane-bound peptides. After one
wash with PBS, cells were resuspended in PBS and subjected to
ﬂow cytometry analysis. To quantify intracellular peptide
stability, same cells were released for indicated time points
in DMEM þ 10% FCS and ﬁxed with 4% formaldehyde (w/v)
in PBS for 15 minutes at room temperature. To measure the
TAMRA ﬂuorescence intensity, the LSR II Fortessa equipped
with a 561 nm laser line and a 586/15 band-pass ﬁlter was
used. Of note, the ﬂuorescence intensity of TAMRA-labeled
R9-BRC4mut peptides was corrected for quenching by multi-
plying measured TAMRA intensity with a quenching factor.
The quenching factor was calculated by loading 10 pmol of
freshly solubilized peptides on Tricine SDS-PAGE gel and
quantifying TAMRA intensity (see Fig. 2C, lane 5). Fluorescein
intensity was measured with Attune Nxt Flow Cytometer
equipped with 488 laser and 530/30 band-pass ﬁlter. For
each condition, 20,000 events were recorded. MACS Quant
Calibration Beads (MACS Miltenyi Biotec) were applied for
voltage standardization to exclude any machine-dependent
variations between measurements.
Tricine SDS-PAGE
To resolve low molecular weight peptides, Tricine SDS-
PAGE was performed as described previously (27). For peptide
separation, Laemmli lysates were loaded onto 16% Tricine
SDS-PAGE gel containing 6 mol/L urea. For peptide detection
via ﬂuorescence, gels were scanned using a Typhoon FLA
9500 FluorImager.
HR reporter assay
HR frequency was measured as described previously
(28, 29). Brieﬂy, following siRNA transfection, 1  105 HeLa
cells containing a stably integrated DR-GFP reporter con-
struct were seeded into 12-well plates. The day after, cells
were either mock-transfected or transfected with 0.6 mg I-SceI
expression plasmid (pCBASce) using jetPrime transfection
reagent (Polyplus transfection). Four hours later, medium was
exchanged and either a 1-hour peptide incubation or second
siRNA transfection was performed. Peptide incubations
were repeated 24 and 34 hours post–I-SceI transfection. After
each peptide incubation, 0.5 mL of DMEM þ 20% FCS was
directly added to the peptide/DMEM mix. Forty-eight hours
after I-SceI transfection, cells were harvested and directly ana-
lyzed for GFP expression by ﬂow cytometry using an Attune
Nxt Flow Cytometer.
Immunoﬂuorescence microscopy
Twenty-four hours after siRNA transfection, 8  104 cells were
seeded on coverslips in 24-well plates. The day after, cells were
treated either with 100 nmol/L camptothecin for 1 hour or
irradiated and incubated for another hour with the peptides,
before releasing them for 3 hours by directly adding 1 mL of
DMEM þ 14% FCS. Alternatively, cells were transfected with the
peptides, followed by 1-hour camptothecin treatment and direct
processing. Cells were preextracted for 5 minutes on ice
(25 mmol/L HEPES pH 7.4, 50 mmol/L NaCl, 1 mmol/L EDTA,
3mmol/LMgCl2, 300mmol/L sucrose, 0.5% Triton X-100), ﬁxed
with 4% formaldehyde (w/v) in PBS for 15 minutes at room
temperature, before incubating them with indicated primary and
appropriate secondary antibodies for 1 hour. Afterwards, cover-
slips were mounted with Vectashield (Vector Laboratories) con-
tainingDAPI and sealed. Imageswere acquired on LeicaDMI6000
wideﬁeld ﬂuorescence microscope with a 63 objective.
DNA ﬁber analysis
DNA ﬁber analyses were carried out as described previously
(30). In brief, U2OS cells were seeded into 6-well plates at a
conﬂuence of 40%. Twenty-four hours later, cells were pulse-
labeled with 33 mmol/L CIdU for 30 minutes, followed by
340 mmol/L IdU for 30 minutes prior to incubation with
2 mmol/L HU and peptides (10 mmol/L) for 4 hours in
serum-free medium. Cells were lysed (200 mmol/L Tris-HCl
pH 7.4, 50 mmol/L EDTA, 0.5% SDS) and DNA ﬁbers were
stretched onto glass slides before ﬁxation in methanol–acetic
acid (3:1, Merck) overnight. Rehydration in PBS was followed
by denaturation in 2.5 mol/L HCl for 1 hour, a PBS wash, and
blockage (2% BSA (w/v) PBS, 0.1% Tween 20) for 40 minutes.
CIdU and IdU staining was performed using anti-BrdU primary
and secondary antibodies for 2.5 hours. Coverslips were
mounted using Antifade Gold (Invitrogen). Images were acquir-
ed on Olympus microscope IX81 with 60 magniﬁcation, and
analysis was carried out using ImageJ software.
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Colony formation assay
Indicated cell lines were plated in poly-L-lysine (Sigma-Aldrich)
coated 24-well plates at low cell dilutions of 200 cells/well
in technical triplicates. PEO1 and PEO4 cells were seeded at
500 and 1,000 cells/well, respectively. Twenty-four hours later,
cells were washed once with PBS and incubated with olaparib
in presence or absence of peptides. After 1 hour, 1 mL of appro-
priate medium containing 14% FCS with indicated olaparib
concentrations was directly added to the cells without removing
the peptide solution. For MCF10A cells, FCS concentration of
culture medium was increased to 7%. Alternatively, HeLa cells
were treated for 1 hour with 1 mmol/L camptothecin, washed
twice with PBS, and peptide transfection was carried out for
1 hour before directly adding 1 mL of DMEM þ 14% FCS. Cells
were grown for 10 days before ﬁxation with crystal violet
solution [0.5 % crystal violet, 20% ethanol (w/v)]. For analysis,
plates were scanned and analyzed with the ImageJ Plugin
ColonyArea using the parameter colony intensity, integrating
the percentage of the covered area and staining intensity (31).
Statistical analysis
All results were conﬁrmed in at least two independent experi-
ments. Quantitative data are displayed as mean  SD, and
statistical analyses were performed using GraphPad Prism 7.
P values <0.05 were considered statistically signiﬁcant.
Results
BRC4 peptide inhibits BRCA2–RAD51 interaction
It is well established that BRCA2 binds RAD51 through its
BRC repeats composed of two highly conserved tetrameric
motifs (Supplementary Fig. S1A). Among the eight BRC repeats,
BRC4 was reported to display the highest afﬁnity for RAD51,
mainly using its FHTA sequence to bind the RAD51 oligomer-
ization motif. To speciﬁcally target the BRCA2–RAD51 protein
interaction interface, we therefore synthesized a 16-mer peptide
mimicking the N-terminal half of BRC4 comprising the FHTA
hydrophobic motif (Fig. 1A). In addition to the "wild type"
BRC4 peptide (BRC4wt), we included a "mutated" BRC4 pep-
tide (BRC4mut) harboring an inverted FHTA sequence (Fig. 1A).
Employing N-terminally biotinylated peptides, recombinant
RAD51 was efﬁciently pulled down by BRC4wt but to a much
lesser extent by BRC4mut (Fig. 1B). In agreement with previous
reports (32), we observed that GST-tagged BRCA2 fusion pro-
teins spanning BRC 1-2, BRC 3-5, or the C-terminal (C-term)
domain were able to interact with RAD51 (Supplementary
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Figure 1.
A short BRC4 peptide inhibits BRCA2–RAD51 interaction. A, Amino acid sequences of BRCA2-derived 16-mer peptides used in this study. In addition to
the wild-type BRC4 peptide (BRC4wt), a mutant version (BRC4mut) was included, characterized by an inverted FHTA tetrapeptide motif. B, Biotinylated
BRC4 peptides coupled to streptavidin beads were used to perform pull-down assays using bacterially expressed and puriﬁed human RAD51. Inputs
and pulled down protein complexes were analyzed by immunoblotting. SE and LE denote short and long exposure times of the same anti-RAD51
immunoblot. C, Different GST-BRCA2 fusion proteins coupled to glutathione–sepharose beads were used to perform pull-down assays using recombinant
RAD51. Inputs and pulled down protein complexes were analyzed by immunoblotting. D, GST-BRCA2 pull-down assays with recombinant RAD51 in the
absence or presence of increasing amounts of BRC4wt peptides. Inputs and pulled down protein complexes were analyzed by immunoblotting. E, Lysates
of U2OS cells inducibly expressing GFP-RAD51 were supplemented with 50 mg of the indicated BRC4 peptides and subjected to immunoprecipitation
(IP) using anti-GFP afﬁnity resin. Inputs and coimmunoprecipitated protein complexes were analyzed by immunoblotting.
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Fig. S1B; Fig. 1C). Remarkably, BRC4wt was able to out-
compete each of these individual interactions in a concentra-
tion-dependent manner (Fig. 1D). Interestingly, the BRC4
peptide was more effective in outcompeting RAD51 binding
to the BRCA2 C-term and BRC repeats 1-2 than to BRC repeats
3-5 (Fig. 1D), indicating that the BRC4 repeat of BRCA2
exhibits the highest binding afﬁnity for RAD51. Similar GST
pull-down results were obtained using HeLa nuclear extracts as
a source for RAD51 (Supplementary Fig. S1C). Given that the
BRCA2 C-terminal region exclusively binds to assembled
RAD51 oligomers, we reasoned that the BRC4 peptide is able
to disrupt RAD51 multimers present in solution, which is in
agreement with binding of the FHTA cluster to the RAD51
oligomerization motif (9, 10, 14). Most importantly, coimmu-
noprecipitation experiments in U2OS cells inducibly expres-
sing GFP-tagged RAD51 demonstrated that BRC4wt, but not
BRC4mut, is capable of interfering both with BRCA2 binding to
RAD51 and RAD51 oligomerization (Fig. 1E; Supplementary
Fig. S1D and S1E). Taken together, our results indicated that a
short, synthetic BRC4-derived peptide is proﬁcient in blocking
BRCA2–RAD51 protein–protein interaction.
The CPP R9 facilitates intracellular delivery of BRC4
Native peptides do not readily cross cell membranes. To
enhance cellular uptake, we decided to conjugate BRC4 pep-
tides with a nona-arginine (R9) CPP. In addition, a red ﬂuo-
rescent dye (TAMRA) was N-terminally attached to R9-BRC4
peptides to analyze cellular uptake. Using confocal microscopy,
we observed robust cytoplasmic and nuclear TAMRA signals in
HeLa and U2OS cells upon transfection with R9-fused peptides
(Fig. 2A). Moreover, we found that the concentration threshold
for efﬁcient R9-BRC4 cell penetration was above 10 mmol/L
(Supplementary Fig. S2A). Flow cytometry analyses further
conﬁrmed that BRC4 peptide delivery reached a transduction
efﬁciency of almost 100% when fused to R9 (Fig. 2B; Supple-
mentary Fig. S2B). Importantly, when replacing the TAMRA
label with a green ﬂuorescent dye (Fluorescein), we observed
very similar subcellular localization patterns and ﬂuorescent
intensities of the R9-BRC4 peptides (Supplementary Fig. S2C
and S2D). As peptides are prone to proteolytic degradation
upon cellular uptake, we next determined the amount of intact
peptides being delivered to the cells. To differentiate between
full-length and degraded peptides, whole-cell lysates of HeLa
and U2OS cells incubated with ﬂuorescently labeled peptides
were subjected to SDS-PAGE designed for resolving very low
molecular weight protein species (27). Using this approach, we
detected signiﬁcant amounts of intact TAMRA- and Fluorescein-
labeled R9-BRC4 peptides being effectively delivered to HeLa
and U2OS cells (Fig. 2C; Supplementary Fig. S2E). Comparing
the band intensity of TAMRA signals between 10 pmol of
freshly solubilized peptides directly loaded onto the gel and
those of peptide-transduced cell lysates, we calculated a deliv-
ery rate of approximately 107 peptides per cell, yielding an
estimated intracellular peptide concentration of around 1 to
10 mmol/L (Fig. 2C).
Next, to more precisely determine the intracellular residence
time and stability of our BRC4 CPPs, we modiﬁed a previously
established method (33) and monitored the Fluorescein signal
intensity in HeLa cells over a time course of 24 hours after
peptide incubation. SDS-PAGE analysis revealed that BRC4wt as
well as BRC4mut cargo peptides were gradually degraded with
an approximate half-life of 2 hours (Fig. 3A). Strikingly, using
the same experimental setup, ﬂow cytometry analysis of
Fluorescein-R9-BRC4wt indicated a rather heterogeneous deg-
radation pattern, which was most pronounced after 8 hours
with a large proportion of cells still showing moderate to high
ﬂuorescent intensities (Fig. 3B).
Collectively, we concluded that intracellular uptake of
R9-BRC4wt and R9-BRC4mut was efﬁcient and comparable
as determined by confocal microscopy, ﬂow cytometry, and
SDS-PAGE analysis, thus providing a solid basis for further
mechanistic investigations.
BRC4 peptide speciﬁcally inhibits RAD51-mediated HR
Conditional overexpression of full-length BRC4 was previ-
ously shown to inhibit DNA damage–induced RAD51 foci
formation in MCF7 (breast cancer) and chicken DT40 cells
(12, 34). Therefore, we wanted to investigate whether the
16-mer BRC4 peptide fused to R9 was able to mimic this
phenotype, indicative of effective disruption of RAD51 binding
to BRCA2. To this end, HeLa or U2OS cells were ﬁrst incubated
with our peptides and subsequently treated with the DNA
topoisomerase I poison camptothecin to induce replication-
dependent DSBs. Importantly, we did not detect any signiﬁcant
change in camptothecin-induced ATM and CHK2 phosphory-
lation as well as gH2AX foci formation upon peptide addition,
indicating regular activation of apical DNA damage response
kinases (Fig. 4A; Supplementary Fig. S3A and S3B). In contrast,
camptothecin-induced RAD51 foci formation in both cell lines
was speciﬁcally compromised in the presence of BRC4wt but
not BRC4mut CPPs (Fig. 4B and C; Supplementary Fig. S3C and
S3D). In line with this observation, BRC4wt signiﬁcantly sup-
pressed RAD51 foci formation following ionizing radiation
(Fig. 4D). Notably, intrinsic RAD51 protein stability was not
affected by BRC4wt cellular uptake (Supplementary Fig. S3E).
To directly examine the impact of BRC4 peptides on DSB repair
by HR, we performed repair reporter assays (DR-GFP) in HeLa
cells and observed a signiﬁcant decrease in HR frequency upon
repetitive BRC4wt transfections (Fig. 4E). Throughout all experi-
ments reported in this section, we observed that siRNA-medi-
ated BRCA2 depletion conferred much stronger phenotypes
compared with delivery of the BRC4wt peptide.
In summary, our ﬁndings suggested that delivery of a synthetic
BRC4 peptide potently inhibits RAD51 foci formation and HR,
most likely as a result of defective BRCA2-mediated RAD51
loading onto resected DSBs.
BRC4 peptide causes MRE11-dependent degradation of stalled
replication forks
BRCA2-dependent RAD51 loading is not only critical for HR,
but has also been established to protect stalled replication forks
from nucleolytic degradation by MRE11 (35, 36). Thus, we
examined a potential effect of the BRC4 peptide on replication
fork protection by performing dual-labeling DNA ﬁber assays
in the presence of HU, which stalls fork progression. Strikingly,
we found that the BRC4wt CPP resulted in shortening of nascent
DNA tracts, indicative of increased fork degradation (Fig. 5A).
BRC4 intracellular uptake did not interfere with global repli-
cation rates, as we could not observe any differences in EdU
incorporation (Supplementary Fig. S4). Similar to what has
been shown for BRCA2-deﬁcient cells, fork degradation in
BRC4 peptide–transduced cells was completely rescued both
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by mirin, an MRE11 SMI (Fig. 5B), and by siRNA-mediated
MRE11 depletion (Fig. 5C). Of note, BRC4 delivery did not
result in additive or synergistic effects when delivered into
BRCA2-depleted cells, indicating that peptide-mediated fork
degradation resulted most likely from speciﬁc targeting of the
BRCA2–RAD51 interaction (Fig. 5C).
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BRC4 peptide confers hypersensitivity to PARP inhibition in
cancer cell lines
On the basis of our molecular analyses providing robust
evidence of the inhibitory effect of the BRC4 peptide on BRCA2
functions in HR and fork protection, we next sought to deter-
mine whether it also sensitizes cells to DNA-damaging agents.
Profound hypersensitivity of BRCA2-mutant cells to PARP
inhibitors has become an emerging therapeutic paradigm
A
P
ep
tid
e 
st
ab
ili
ty
 (%
)
100
80
60
40
20
0
Fluorescein-R9-BRC4wt
Fluorescein-R9-BRC4mut
0 2 4 86 24
Release (hours)
B
0-10 4 10 4 10 5 10 6
0
200K
400K
600K
800K
1.0M
SS
C
-A
0 h 99.9%
0-10 4 10 4 10 5 10 6
0
200K
400K
600K
800K
1.0M
SS
C
-A
4 h 81.9%
0-10 4 10 4 10 5 10 6
0
200K
400K
600K
800K
1.0M
SS
C
-A
8 h 38.3%
HeLa + Fluorescein-R9-BRC4wt
0-10 4 10 4 10 5 10 6
0
200K
400K
600K
800K
1.0M
SS
C
-A
24 h 0.3%
Fluorescein
HeLa + Peptides
0 h 2 h 4 h 8 h 24 hP
ep
tid
e 
on
ly
M
ar
ke
r
1 2 3 4 5 6 7
25 kDa
25 kDa
Fluorescein-
R9-BRC4wt
Fluorescein-
R9-BRC4mut
Intact peptides
Degraded
peptides
Intact peptides
Degraded
peptides
(3.5 kDa)
(3.5 kDa) 0-10 4 10 4 10 5 10 6
0
200K
400K
600K
800K
1.0M
SS
C
-A
2 h 97.9%
Figure 3.
R9-BRC4 peptides have an approximate half-life of 2 to 4 hours upon cell entry. A, HeLa cells were transfected with 10 mmol/L of the indicated
Fluorescein-labeled peptides in serum-free DMEM for 1 hour, followed by a release in serum-containing medium for the indicated time points. Top, 10 pmol
of freshly solubilized peptides (lane 2) and whole-cell lysates of peptide-transduced cells (lanes 3–7) were loaded onto Tricine SDS-PAGE gel, and
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known as synthetic lethality (37). Therefore, we performed
clonogenic survival assays in peptide-transfected HeLa cells
treated with the PARP inhibitor olaparib (38). Indeed, targeting
of the BRCA2–RAD51 interaction by BRC4wt CPPs resulted in a
signiﬁcant reduction in cellular viability in response to chronic
PARP inhibition (Fig. 6A and B). Consistent with impaired
RAD51 foci formation, delivery of BRC4wt CPPs also sensitized
HeLa cells to camptothecin (Supplementary Fig. S5A). Upon
treatment with olaparib, we estimated the IC50 value of BRC4
to be around 10 mmol/L for HeLa cells (Fig. 6C). Importantly,
R9-BRC4wt alone did not decrease cell survival in otherwise
undamaged cells (Fig. 6C). Moreover, despite its relatively short
half-life, the efﬁcacy of BRC4 CPPs in sensitizing HeLa cells to
PARP inhibition was comparable with that of the B02 small-
molecule compound, which speciﬁcally inhibits RAD51 bind-
ing to DNA (Fig. 6D; refs. 23, 39). To further exclude potential
off-target effects of the BRC4 CPP in stimulating olaparib-
induced cytotoxicity, we employed PEO1 (BRCA2 null) and
PEO4 (BRCA2 revertant to wild type) isogenic ovarian cancer
cell lines (40). Notably, we observed a strong synergy between
PARP inhibition and R9-BRC4 peptides in PEO4 cells, whereas
PEO1 cells did not exhibit BRC4-mediated sensitivity toward
olaparib (Supplementary Fig. S5B). Differential peptide uptake
could be excluded as both cell lines displayed comparable
uptake efﬁciency and intracellular peptide localization (Sup-
plementary Fig. S5B). Finally, in addition to HeLa cells, we
observed that BRC4 CPPs elicited olaparib-induced cell death
of U2OS human osteosarcoma cells but not of noncancerous
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BRC4 peptide inhibits RAD51 foci formation and HR. A, HeLa cells were either transfected with control (CNTL) or BRCA2 siRNA oligos for 48 hours, or
incubated with 10 mmol/L of the indicated CPPs for 1 hour before treatment with 100 nmol/L camptothecin (CPT) for 1 hour. Whole-cell lysates were
analyzed by immunoblotting using the indicated antibodies. B and C, Same cells as in A were treated with 100 nmol/L camptothecin for 1 hour
before transfecting them with the depicted peptides (10 mmol/L) for 1 hour and releasing them for 3 hours in serum-containing medium. Cells were
preextracted, ﬁxed, and immunostained for RAD51. B, Scale bars, 10 and 5 mm (Zoom). C, The graph illustrates the percentage of cells displaying more
than 10 RAD51 foci/nucleus. For each condition, at least 100 cells were scored. D, Same cells as in A were irradiated with increasing doses of IR,
peptide-transfected (10 mmol/L), and released for 3 hours in serum-containing medium prior to preextraction, ﬁxation, and immunostaining for RAD51.
The graph illustrates the percentage of cells displaying more than 10 RAD51 foci/nucleus. For each condition, at least 100 cells were scored. E, HeLa DR-GFP
cells were transfected with the I-SceI expression plasmid 48 hours post-siRNA transfection. Alternatively, 1-hour incubation periods with 10 mmol/L
peptides took place 4, 24, and 34 hours post–I-SceI transfection of HeLa DR-GFP cells. A second siRNA transfection was performed 24 hours after I-SceI
transfection. Cells were harvested 48 hours post–I-SceI transfection, and GFP-positive cells were scored by ﬂow cytometry. A total of 20,000 events
were recorded. The graph illustrates the percentage of GFP-positive cells as a readout for HR efﬁciency. Data in C–E display the mean  SD (n  3).
Statistical signiﬁcance ( , P  0.001; ns, nonsigniﬁcant) was calculated with Tukey multiple comparison test using two-way ANOVA (C and D) and one-way
ANOVA (E).
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cell lines, including hTERT-immortalized human retinal pig-
ment epithelial cells (hTERT-RPE1), SV40-immortalized
human fetal lung ﬁbroblasts (MRC5) and human breast epi-
thelial cells (MCF10A; Fig. 6E; Supplementary Fig. S6A). This
ﬁnding could at least in part be explained by an overall low
cellular uptake efﬁciency and predominant endosome trapping
of BRC4 peptides in RPE1, MRC5, and MCF10A nontumori-
genic cell lines (Supplementary Fig. S6B and S6C).
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Figure 5.
BRC4 peptide provokes MRE11-dependent degradation of stalled DNA replication forks. A, U2OS cells were transfected with indicated siRNA oligos for
48 hours or left untransfected. Subsequently, cells were labeled with CIdU and IdU before adding hydroxyurea (HU) together with indicated peptides
(10 mmol/L) in serum-free medium for 4 hours followed by DNA ﬁber spreading. Top, experimental setup, representative DNA ﬁber images, and
their corresponding IdU/CIdU ratios, respectively; bottom, IdU/CIdU ratios for each condition illustrated by a dot plot with mean ratios denoted as a red line.
B, Same cells as in A were additionally treated with the MRE11 inhibitor mirin. C, U2OS cells were transfected with the indicated siRNA oligos for
48 hours before dual labeling and HU treatment in combination with 10 mmol/L R9 or R9-BRC4wt peptides. Representative immunblot is shown to
indicate individual knockdown efﬁciencies. Approximately 250 DNA replication tracks were scored, and numbers indicate the mean  SD (n ¼ 2).
Statistical differences ( , P  0.0001; ns, nonsigniﬁcant) were determined by Mann–Whitney U test.
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Figure 6.
BRC4 peptide sensitizes cancer cells to PARP inhibition. A, HeLa cells were transfected with the indicated siRNAs or left untransfected for standard peptide
transduction. Twenty-four hours later, cells were plated at low cell density into 24-well plates. Another 24 hours later, non-siRNA transfected cells
were incubated for 1 hour with 10 mmol/L of peptides in serum-free medium supplemented with 1 mmol/L olaparib. Finally, serum-containing medium
supplemented with 1 mmol/L olaparib was added, cells were grown for 10 days, and colonies were stained using crystal violet. Representative images of
a colony formation assay are shown. Clonogenic survival was determined by quantifying the colony intensity of olaparib-treated relative to untreated
and is depicted as bar graph. Data, mean  SD (n ¼ 4). Statistical signiﬁcance ( , P  0.001; ns, nonsigniﬁcant) was calculated with Tukey multiple
comparison test using one-way ANOVA. B, Peptide-transfected HeLa cells as in A were treated with increasing concentrations of olaparib, and survival
was determined by colony formation assay. C, Same cells as in A were treated with 1 mmol/L olaparib in combination with increasing concentrations of
BRC4 peptides, and survival was determined by colony formation assay. D, Same cells as in B were treated with 10 mmol/L of the RAD51 inhibitor BO2 under
identical experimental conditions as used for the BRC4 peptide, and survival was determined by colony formation assay. Data in B–D are represented as mean
 SD (n  3). E, HeLa, U2OS, RPE1, MRC5, and MCF10A were identically treated as in A, and survival was determined by colony formation assay.
Bottom, knockdown efﬁciencies were analyzed by immunoblotting of whole-cell lysates of indicated cell lines; Top, relative clonogenic survival is depicted
as mean  SD (n ¼ 4). Statistical signiﬁcance ( , P  0.0001;  , P  0.01; ns, nonsigniﬁcant) was calculated with Tukey multiple comparison test
using one-way ANOVA.
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Discussion
PPIs represent attractive but at the same time challenging
targets for pharmacologic intervention in cancer therapy. The
emergence of successful peptide-based PPI inhibitors seemed
promising, yet drug development was faced with the low mem-
brane translocation ability of native peptides. The identiﬁcation
of awide range of carriermolecules, commonly termed as CPPs or
protein transduction domains, provided a possible solution for
this major limitation (19).
Here, we designed a 16-amino acid short peptide derived
from the N-terminal half of the human BRCA2 BRC4 repeat
able to occupy the RAD51 oligomerization interface and there-
by potently inhibiting the interaction between BRCA2 and
RAD51. Covalent fusion of the BRC4 peptide with the cationic
polyarginine R9 CPP resulted in efﬁcient uptake into both
cytoplasm and nucleus, causing defects in HR repair, increased
fork degradation, and, ultimately, hypersensitivity to DNA-
damaging agents.
Detailed biochemical studies have demonstrated that the
full-length BRC4 repeat covering both FHTA and LFDE tetra-
meric cluster motifs selectively interacts with RAD51 and inhi-
bits RAD51–DNA complex formation (15, 41). To increase the
likelihood of intracellular peptide uptake (42), we reduced the
length of the native BRC4 peptide sequence from 35 to 16
amino acids, including only the ﬁrst FHTA module, which was
shown to mimic the RAD51 oligomerization motif (14). In line
with our ﬁndings, a similar 17-mer N-terminal BRC4 peptide
was reported to compete with full-length BRC4 for RAD51
binding, albeit with modest potency (15). We further corrob-
orated the importance of the FHTA sequence by showing that
BRC4 16-mer peptides harboring a mirrored ATHF sequence
display greatly reduced RAD51 binding afﬁnity.
Importantly, intracellular BRC4 peptide uptake in the low
micromolar range was sufﬁcient to impair BRCA2–RAD51 com-
plex formation. A high uptake efﬁciency was likely achieved
through a combination of the potent CPP R9 with the beneﬁcial
biochemical properties of the BRC4 peptide, including its positive
net charge, hydrophobicity, and three-dimensional conformation
(18). CPP internalization involves both endocytosis and direct
translocation, whereby direct cell penetration is preferred because
endocytosis can lead to the trapping of peptides in endosomes
and their ultimate degradation (18). Multiple factors, including
the CPP, cargo identity, concentration, cell type, and differenti-
ation status, inﬂuence the balance between both uptake mechan-
isms (18). We primarily observed a diffuse ﬂuorescent staining
and only minor punctuate patterns, indicative of direct translo-
cation as the preferred uptake mechanism. The substantial num-
ber of peptide molecules reaching the intracellular space might
compensate for the short half-life. Even though only 5% of intact
peptides are present 24 hours after transfection, the absolute
peptide number per cell at this stage still adds up to 106 functional
peptides. According to a recent proteomics study in the U2OS
cell line, most proteins involved in DSB repair processes, includ-
ing BRCA2, were shown to be of low to moderate abundance
(102–104 copies/cell; ref. 43). On the basis of these numbers,
we speculated that BRC4 peptides are present in high molar
excess over their endogenous BRCA2 target protein even 24 hours
after uptake.
RAD51 and its property to self-assemble are under dynamic
control to enable faithful homology-directed DSB repair. Yu
and colleagues proposed the presence of three RAD51 fractions
in the cell: a mobile fraction of RAD51 monomers, an immo-
bile oligomerized fraction, and an immobile BRCA2-bound
fraction (44). Strikingly, they found the BRCA2-bound fraction
to be selectively mobilized upon DNA damage and suggested a
dual BRCA2 function of RAD51 sequestration and mobiliza-
tion. Importantly, the other fractions did not change, suggest-
ing that only the BRCA2-bound RAD51 fraction is involved
in DNA repair. Notably, R9-BRC4wt did not affect viability
under unstressed growth conditions of conventionally cultured
cancer cell lines. Thus, we hypothesize that under normal,
undamaged conditions, RAD51 is stably bound to BRCA2 and
the peptide's afﬁnity for RAD51 is not high enough to disas-
semble the protein complex. Accordingly, the BRC4 mimetic
peptide is only able to disassemble mobilized BRCA2–RAD51
complexes. We speculate that upon mobilization and ultimate
RAD51 loading onto ssDNA, the protein complex becomes
increasingly unstable due to an equilibrium change during
DNA loading. In this context, the peptide is potent enough to
sequester RAD51 transiently dissociated from BRCA2. We fur-
ther presume that at low levels of DNA damage, requiring only
a small fraction of BRCA2-bound RAD51, repair processes are
not signiﬁcantly disturbed by the BRC4 peptide. However,
upon increasing DNA damage load and replication stress, when
there is a high demand of functional BRCA2–RAD51 com-
plexes, a major pool of RAD51 is sequestered away from BRCA2
by the BRC4 peptide.
Despite its potentially rather high dissociation constant
compared with SMIs, BRC4 peptides provided an unexpectedly
high degree of speciﬁcity. CPPs have often been reported to
cause unspeciﬁc membrane disruption, which has led to false
conclusions regarding their speciﬁcity for a number of peptide
therapeutics. Because we do not observe a decrease in cell
viability upon BRC4 peptide uptake, we can exclude such
unspeciﬁc CPP-mediated toxicity (45). Furthermore, our ﬁnd-
ing that MRE11 depletion fully rescued the peptide-induced
replication fork degradation phenotype and the lack of synergy
between peptides and PARP inhibition in BRCA2-deﬁcient
cancer cells argue against potential off-target activity of the
BRC4 CPP. Nevertheless, when comparing the outcomes of
siRNA-mediated BRCA2 depletion versus R9-BRC4wt peptide
delivery, depletion is commonly yielding much more pro-
nounced phenotypes. A possible explanation for this relates
to the high susceptibility of peptides to extra- and intracellular
protease attacks (17). To improve their pharmacokinetic poten-
tial, possible peptide optimizations include various backbone
modiﬁcations and cyclization (17, 46). Moreover, the BRCA2–
RAD51 interaction might not be completely abolished by the
BRC4 peptide as it only comprises the ﬁrst FHTA but lacks the
second LFDE tetrameric cluster motif.
The lack of cell-type speciﬁcity is commonly reported to
present another major limitation of CPP-mediated drug delivery
(19, 20). Strikingly, we could not ﬁnd a synergistic relationship
between the PARP inhibitor olaparib and the R9-BRC4 peptide
in normal cell lines as compared with cancer cell lines. Inter-
estingly, our peptide uptake data suggest an overall decreased
intracellular BRC4 concentration. It is reasonable to speculate
that efﬁcient intracellular peptide delivery relies on speciﬁc
membrane components or lipid compositions that are more
uptake responsive in cancer versus noncancerous cell lines.
Numerous reports classify lipid metabolic reprogramming as
a major source of cell transformation (47). Speciﬁcally, the
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sphingolipid metabolism, which was suggested to inﬂuence R9-
mediated peptide uptake, was reported to signiﬁcantly alter
during transformation (48). In addition, cancer cells possess
a more negatively charged membrane than normal cells, which
is partly caused by a loss in membrane symmetry and the
exposure of anionic phosphatidylcholine on the outer leaﬂet
(49). This feature, in combination with higher membrane
ﬂuidity (50), might favor the uptake of the cationic R9-BRC4
peptide.
Ultimately, the BRC4 peptide could emerge as a potent radio-
and chemosensitizer. Speciﬁcally, BRC4 peptide–induced HR
deﬁciency could represent a promising strategy for expanding
the utility of PARP inhibitors, successfully applied in breast and
ovarian cancer patients with a germline BRCA1 or BRCA2
mutation (51, 52), to BRCA-proﬁcient cancers. Similarly, the
BRC4 peptide could resensitize BRCA1/2-mutated tumors that
acquired chemoresistance to PARP inhibitors by restoring HR
(53). Moreover, malignant cells are frequently compromised in
genome stability maintenance pathways that are synthetically
lethal with HR deﬁciency (54). Consequently, monotherapy
with the identiﬁed BRCA2 peptide inhibitor could provide a
promising option for the treatment of these tumors. The
BRCA2–BRC4 peptide described in this study could also be
applied in combination with proton irradiation, which was
shown to be highly advantageous over conventional photon
therapy. Notably, it was found that HR-deﬁcient tumor cells
exhibit an enhanced susceptibility toward proton versus pho-
ton irradiation (55). Drug-induced HR deﬁciency with the
BRC4 peptide inhibitor could make this advantageous effect
accessible for patients with HR-proﬁcient tumors. Finally, we
reveal a straightforward approach to study distinct PPIs in a
biological context without the need of elaborate mutagenesis
methodologies and provide a potent research tool to study
BRCA2-dependent RAD51 loading to ssDNA in different bio-
logical contexts.
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Supplementary Tables  
Table S1: Primary antibodies 
Antibody target Species Supplier/Reference Applications Dilution 
ATM-pS1981 rabbit Abcam (ab81292) IB 1:1000 
ATM (2C1) mouse GeneTex (GTX70103) IB 1:1000 
BRCA2 (OP95) mouse Calbiochem IB 1:1'000 
BrdU/IdU (B44) mouse BD Biosciences (347580) DNA Fibers 1:80 
BrdU/CIdU rat Abcam (ab6326) DNA Fibers 1:400 
CHK2-pT68 rabbit CellSignaling IB 1:1'000 
CHK2 rabbit Abcam (ab47433) IB 1:10'000 
Cyclin D1 rabbit NeoMarkers (MS-210) IB 1:1'000 
GFP (B-2) mouse Santa Cruz (sc-9996) IB 1:100 
GST mouse Genscript IB 1:1000 
γH2AX mouse Millipore IF 1:400 
MRE11 (12D7) mouse GeneTex IB 1:1000 
Rad50  mouse GeneTex (13D3) IB 1:400 
RAD51 rabbit Abcam IB 1:2000 
RAD51 rabbit (1) IF 1:500 
Tubulin mouse Sigma-Aldrich (T9026) IB 1:20'000 
 
Table S2: Secondary antibodies 
Antibody  Supplier/Reference Applications Dilution 
HRP-conjugated GE Healthcare IB 1:5000 
Alexa Fluor-488 Life Technologies IF/DNA Fibers 1:1'000/1:250 
Alexa Fluor-647 Life Technologies IF 1:1'000 
Cy3 anti-rat Immuno Research DNA Fibers 1:250 
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Table S3: siRNA oligos 
Name Sense Sequence (5'-3') Reference/Cat. No. Supplier 
CNTL Negative Control No. 2 siRNA 4390846 Ambion 
BRCA2 CAGUUGAAAUUAAACGGAA s2083 Ambion 
MRE11 CGACUGCGAGUGGGACUAUA s8961 Ambion 
 
 
 
Supplementary Figure Legends 
 
Figure S1. BRC4 peptide inhibits RAD51 binding to BRCA2 and RAD51 self-
oligomerization. 
A, Multiple sequence alignment of all 8 BRC repeats in human BRCA2. The two te-
trameric RAD51 interaction motifs are highlighted in boxes. B, Schematic view of the 
full-length human BRCA2 protein depicting BRC repeats 1-8 and a C-terminal region 
implicated in RAD51 interaction. GST-tagged BRCA2 fragments spanning all 8 BRC 
repeats and the C-term of BRCA2 are shown below. C, Indicated GST-BRCA2 fusion 
proteins were immobilized on GSH beads and added to HeLa nuclear extracts in the 
absence (-) or presence of the indicated amounts of BRC4wt and BRC4mut. D and E, 
Lysates of U2OS cells inducibly expressing GFP-RAD51 were supplemented with 
increasing amounts of the indicated BRC4 peptides and subjected to immunoprecipi-
tation (IP) using anti-GFP affinity resin. Inputs and co-immunoprecipitated protein 
complexes were analyzed by immunoblotting. SE and LE denote short and long expo-
sure times of the same anti-RAD51 immunoblot. 
 
Figure S2. Efficient cellular uptake of TAMRA- and Fluorescein-labeled R9-
BRC4 peptides. 
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A, Hela and U2OS cells were pre-stained with Hoechst 33342 for 30 minutes to visu-
alize nuclei. After washing, cells were incubated with the indicated concentrations of 
the R9-BRC4wt peptide for 1 hour in serum-free medium and thoroughly washed. 
Peptide uptake was analyzed by live cell confocal microscopy. The scale bar repre-
sents 20 µm. B, Dot plots illustrate representative flow cytometry profiles after incu-
bation of HeLa cells with no peptides or 10 µM of R9-BRC4wt. The intensity of the 
TAMRA signal is plotted against the side-scatter area (SSC-A). Gate depicts percent-
age of TAMRA-positive cells. C, HeLa and U2OS cells were stained for 30 minutes 
with Hoechst 33342 to visualize nuclei and washed with PBS before adding 10 µM of 
Fluorescein-labeled R9-BRC4wt and R9-BRC4mut peptides. After 1-hour incubation in 
serum-free medium, cells were washed extensively and live cells were directly im-
aged on a confocal microscope. The scale bar represents 20 µm. D, HeLa and U2OS 
cells were washed with PBS before incubation with 10 µM of the Fluorescein-labeled 
R9-BRC4 peptides in serum-free medium for 1 hour. Cells were harvested by tryp-
sinization and Fluorescein signal intensities were recorded on a flow cytometer by 
scoring 20'000 events. Bar graph depicts median Fluorescein fluorescence intensity. 
a.u. = arbitrary units. Data are presented as the mean ± s.d. (n = 3). E, 10 pmol of 
freshly solubilized peptides (lanes 2 and 3) and whole-cell lysates of 70'000 peptide-
transfected cells as described in (D) were loaded onto Tricine-SDS-PAGE gel and 
Fluorescein signals were analyzed using a FluoroImager.  
 
Figure S3. BRC4 peptide suppresses DNA damage-induced RAD51 foci for-
mation in U2OS cells. 
A, U2OS cells were either transfected with control (CNTL) or BRCA2 siRNA oligos 
for 48 hours or incubated with 10 µM of the indicated cell-penetrating peptides 
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(CPPs) for 1 hour before treatment with 100 nM camptothecin (CPT) for 1 hour. 
Whole-cell lysates were analyzed by immunoblotting using the indicated antibodies. 
B, Cells treated as in (A) were pre-extracted, fixed and immunostained for γH2AX. 
Depicted are representative fluorescent microscopy images. Scale bar represents 10 
µM. C and D, Same cells as in (A) were treated with 100 nM CPT for 1 hour before 
transfecting them with the depicted peptides (10 µM) and releasing them for 3 hours 
in serum-containing medium. Cells were pre-extracted, fixed, and immunostained for 
RAD51. (C) Scale bars represent 10 µm and 5 µm (Zoom). (D) The graph illustrates 
the percentage of cells displaying more than 10 RAD51 foci/nucleus. For each condi-
tion at least 100 cells were scored. Data are presented as the mean ± s.d. (n = 4). Sta-
tistical significance (**, p-value ≤ 0.01; ns, non significant) was calculated with Tuk-
ey's multiple comparison test using two-way ANOVA. E, HeLa cells were incubated 
for 1 hour with 10 µM R9-BRC4wt. Cells were washed and released for the indicated 
time points in presence of 50 µg/ml cycloheximide (CHX). Whole-cell lysates were 
analyzed by immunoblotting using the indicated antibodies. 
 
Figure S4. BRC4 peptide does not affect bulk DNA replication. 
U2OS cells were incubated with 10 µM of R9, R9-BRC4wt, or R9-BRC4mut in serum-
free medium for 1 hour, washed with PBS and allowed to incorporate EdU (10 µM) 
for 30 minutes. Cells were harvested, permeabilized, fixed, and immunostained with 
anti-EdU antibody and DAPI before analysis by flow cytometry. Dot plots represent 
the intensity of the EdU signals (y-axis) against the DNA content (DAPI) (x-axis). 
Gates to quantify replicating cells were set with mock-treated sample (no peptide) and 
the percentage of cells within each gate is indicated. a.u. = arbitrary units. 
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Figure S5. BRC4 peptide confers DNA damage hypersensitivity. 
A, HeLa cells were transfected with the indicated siRNAs or left untransfected for 
standard peptide transduction. 24 hours later, cells were plated at low cell density into 
24-well plates. Another 24 hours later, cells were treated with 1 µM CPT, washed ex-
tensively, and subsequently incubated for 1 hour with 10 µM of the indicated pep-
tides. Immediately after, serum-containing medium was added, cells were grown for 
10 days and colonies were stained using crystal violet. Left panel, representative im-
ages of a colony formation assay are shown. Right panel, relative clonogenic survival 
is depicted as bar graph. B, PEO1 and PEO4 were transfected with indicated siRNAs 
or left untransfected for subsequent peptide incubation. One day later, cells were 
seeded at low cell density and 24 hours post-seeding incubated for 1 hour with 10 µM 
of indicated peptides and 1 µM olaparib in a serum-free environment. Serum-
containing medium with 1 µM olaparib was added and cells were grown for 14 days 
before fixation. Left panel, representative immunoblot is shown. Central panel, bar 
graph illustrates clonogenic survival relative to untreated conditions. Right panel, 
PEO1 and PEO4 were stained with Hoechst and transfected with 10 µM R9-BRC4wt 
prior to confocal image acquisition. The scale bar represents 20 µm. A and B, Data 
are represented as mean ± s.d. (n = 3). Statistical significance (****, p-value ≤ 
0.0001; ***, p-value ≤ 0.001; ** p-value ≤ 0.01; ns, non significant) was calculated 
with Tukey's multiple comparison test using one-way ANOVA.  
 
Figure S6: BRC4 peptide confers olaparib hypersensitivity in cancer cell lines. 
A, Representative images of colony formation assay shown in Fig. 6E. B, HeLa, 
RPE1, MRC5 and MCF10A cells were stained for 30 minutes with Hoechst 33342 to 
visualize nuclei, transfected with 10 µM of TAMRA-labeled R9-BRC4wt and directly 
Appendix
171
	 7	
imaged on a confocal microscope. The scale bar represents 20 µm. C, Same cells as in 
(B) were harvested by trypsinization and TAMRA signal intensities were recorded on 
a flow cytometer. Bar graph illustrates median TAMRA intensities. Data are repre-
sented as mean  ± s.d. (n = 2). a.u. = arbitrary units. 	
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Supplementary Figure 1
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ASupplementary Figure 2
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Supplementary Figure 3
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Supplementary Figure 4
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Supplementary Figure 5
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Supplementary Figure 6
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